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Summary 
 
Mononuclear phagocytes play a key role in tissue homeostasis and in host defense 
against pathogen invasion. However, the phenotypic identities and functional 
properties of this heterogeneous population within the peritoneal cavity remains 
poorly elucidated. In the context of peritoneal dialysis, it is hypothesized that the 
modification of macrophage/dendritic cell biology by the dialysis process would alter 
tissue homeostasis, host susceptibility to infection and local immunity, compromising 
long-term outcomes of the patients. The research work carried out in this thesis has 
tested this hypothesis by examination of the immunobiology (mainly phenotype and 
function) of human and murine peritoneal macrophage and dendritic cell subsets. 
Moreover, the potential link between the altered immunobiology of peritoneal 
mononuclear phagocytes and clinical outcomes of the dialysis patients has been 
investigated. Several key findings were generated during these studies: 1) multiple 
discrete peritoneal macrophage and dendritic cell subsets have been phenotypically 
identified in humans (from different clinical settings of peritoneal dialysis) and in 
mice (from naïve and inflamed conditions); 2) in humans, the phenotypes and the 
activation/maturation status of peritoneal macrophages and dendritic cells are 
modified throughout the dialysis course and also during acute peritonitis; some 
characteristic alterations are associated with adverse patient outcomes; 3) in mice, the 
distinctive kinetics of the respective peritoneal macrophage and dendritic cell subsets 
in clinically relevant acute peritonitis models have been characterized; 4) individual 
peritoneal macrophage and dendritic cell subsets (human and mice) display 
differences in their phagocytic capacity and the ability to process and present antigen.  
  
v 
 
Publications and Presentations 
 
Publications 
Davies LC, Rosas M, Jenkins SJ, Liao CT, Scurr MJ, Brombacher F, Fraser DJ, Allen 
JE, Jones SA, Taylor PR. (2013) Distinct bone marrow-derived and tissue-resident 
macrophage lineages proliferate at key stages during inflammation. Nat Commun 
4:1886. 
 
Fielding CA, Jones GW, McLoughlin RM, McLeod L, Hammond VJ, Uceda J, 
Williams AS, Lambie M, Foster TL, Liao CT, Rice CM, Greenhill CJ, Colmont CS, 
Hams E, Coles B, Kift-Morgan A, Newton Z, Craig KJ, Williams JD, Williams GT, 
Davies SJ, Humphreys IR, O'Donnell VB, Taylor PR, Jenkins BJ, Topley N, Jones SA. 
(2014) Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 
40(1):40-50. 
 
Rosas M, Davies LC, Giles PJ, Liao CT, Kharfan B, Stone TC, O'Donnell VB, Fraser 
DJ, Jones SA, Taylor PR. (2014) The transcription factor Gata6 links tissue 
macrophage phenotype and proliferative renewal. Science 344(6184):645-648. 
 
 
Presentations 
Annual Congress of European Renal Association- European Dialysis Transplantation 
Association (EDTA-ERA), Paris, France, 24th -27th May, 2012 (poster presentation)  
Title: Immunophenotyping of Peritoneal Macrophages and Their Surface Markers in 
Peritoneal Dialysis Patients 
 
Institute of Infection and Immunity Annual Meeting, Cardiff, United Kingdom, 12th 
September, 2012 (poster presentation) 
Title: Characterisation of peritoneal dendritic cells in mouse and human 
 
MITReG Postgraduate Research Day, Cardiff, United Kingdom, 21 September, 2012 
(oral presentation) 
Title: Characterisation of peritoneal dendritic cells in mouse and human 
 
vi 
 
Institute of Infection and Immunity Research Seminar, Cardiff, United Kingdom, 18 
February, 2013 (oral presentation) 
Title: Heterogeneity of macrophage and dendritic cells in the peritoneal cavity 
 
EuTRiPD spring school, Cardiff, United Kingdom, 14 March, 2014 (oral 
presentation) 
Title: Characterisation of peritoneal dendritic cells in peritoneal dialysis patients and 
its potential clinical implications 
 
Institute of Infection and Immunity Research Seminar, Cardiff, United Kingdom, 20 
October, 2014 (oral presentation) 
Title: Characterisation of peritoneal macrophages and dendritic cells in mice and 
humans 
  
vii 
 
Abbreviations 
 
A (as in A405, A488, 647 etc.) – Alexa-Fluor  
APC – Allophycocyanin 
APCs – Antigen presenting cells 
APD – Automated peritoneal dialysis 
APF – 3’-(p-aminophenyl) fluorescein 
BATF3 – Basic leucine zipper transcription factor ATF-like 3 
BM – Bone marrow  
BSA – Bovine serum albumin  
CAPD – Continuous ambulatory peritoneal dialysis 
CBS – Centre Biotechnology Service 
CCPD – Continuous cyclic peritoneal dialysis 
CD – Cluster of differentiation  
cDC – Conventional dendritic cell 
CDP – Common dendritic cell precursor 
CKD – Chronic kidney disease 
CLR – C-type lectin receptor 
CR – Complement receptor 
CTL – Cytotoxic T lymphocytes 
Cy – Cyanine  
DAPI – 4’,6-diamino-2-phenylindole  
DC – Dendritic cell  
DDAO – 7-Hydroxy-9H-(1,3-Dichloro-9,9-Dimethylacridin-2-One) 
D/P – Ratio of dialysate to plasma 
dH2O – deionised H2O  
DNA – Deoxyribonucleic acid  
ds – double stranded  
EDTA – Ethylenediaminetetraacetic acid  
EGF-TM7 – Epidermal growth factor receptor 7 pass trans-membrane  
EPS – Encapsulating peritoneal sclerosis  
ER – Endoplasmic reticulum 
ESRD – End-stage renal disease 
FACS – Fluorescence-activated cell sorting 
FcR – Fc receptor 
FCS – Foetal calf serum 
FITC – Fluorescein isothiocyanate 
FLT3 (L) – FMS-like tyrosine kinase 3 (ligand) 
viii 
 
FSc – Forward scatter  
G (phase) – Gap  
GDP – Glucose degradation product 
GFR – Glomerular filtration rate 
GM-CSF – Granulocyte/macrophage colony stimulating factor  
GPCR – G-protein coupled receptor 
h – hours 
HD – Haemodialysis 
HLA – Human leukocyte antigen 
IFN – Interferon  
IL – Interleukin  
Inf MØ – Inflammation associated or inflammatory macrophage 
IRF4 – Interferon-regulatory factor 4 
LPS – Lipopolysaccharides 
M (phase) – Mitosis  
mAb – monoclonal antibody 
CAM – ‘Classically activated’ macrophage  
AAM – ‘Alternatively activated’ macrophage  
MCP-1 – Monocyte chemoattractant protein-1 
M-CSF – Macrophage colony stimulating factor  
MDP – Macrophage and dendritic cell precursor  
MFI – median fluorescent intensity  
MHC – Major histocompatibility complex 
min – minutes 
MoP – Monocyte precursor 
MPS – mononuclear phagocyte system 
MØ – Macrophage  
NIPD –Night intermittent peritoneal dialysis 
PAMPs – Pathogen associated molecular patterns  
PBMC – Peripheral blood mononuclear cells 
PBS – Phosphate buffered saline  
PD – Peritoneal dialysis 
pDC – Plasmacytoid dendritic cell 
PE – Phycoerythrin 
PerCP – Peridinin chlorophyll  
PET – Peritoneal equilibration test 
phH3 – phospho-histone H3  
PRP – Pathogen recognition receptor 
ix 
 
RES – Reticuloendothelial system 
Res MØ – Resident macrophage 
RKF – Residual kidney function 
RPMI – Roswell Park Memorial Institute medium  
ROS – Reactive oxygen species 
ROX – 6-carboxyl-x-rhodamine  
rpm – revolutions per minute  
RT – Room temperature  
SEM – Standard error of mean  
SES – Staphylococcus epidermidis supernatant  
S (phase) – synthesis  
SR – Scavenger receptor 
SSc – Side scatter  
TGF- β – transforming growth factor β  
Th1 – type 1 helper T lymphocytes 
Th2 – type 2 helper T lymphocytes 
Th17 – type 17 helper T lymphocytes 
Tim-4 – T cell immunoglobulin and mucin domain-containing protein 4 
TipDC –Tumor necrosis factor (TNF) and inducible nitric oxide synthase (iNOS)-producing 
dendritic cell  
TLR – Toll-like receptors 
TNF – tumour necrosis factor  
Treg – Regulatory T cells 
  
x 
 
Contents 
 
 
Chapter 1 – General Introduction………………………………………………………. 1 
1.1 Overview…………………………………………………………………………. 2 
1.2 Peritoneal cavity and peritoneal membrane……………………………………… 3 
1.2.1   Anatomy of peritoneal cavity…………………………………...……… 3 
1.2.2   Peritoneal membrane physiology………………………………………. 4 
1.3 Peritoneal dialysis………………………………………………………...……… 6 
1.3.1 Background…………………………………………………………….. 6 
1.3.2 Peritoneal dialysis technique…………………………………………… 7 
1.3.3 Peritoneal equilibration test (PET)……………………………….…….. 9 
1.3.4 Complications………………………………………….………………. 10  
1.4 Heterogeneity of monocytes, macrophages and dendritic cells………….….…… 12 
1.4.1 Historical background……………………………………………….…. 12 
1.4.2 Origins and developmental pathways…………………………….……. 14 
1.4.3 Surface receptors and molecules……………………………………..… 19 
1.4.4 Functional specialization……………………………………………..... 22 
1.4.5 Macrophage activation and polarization……………………………….. 24 
1.5 Macrophages and dendritic cells in the peritoneal cavity……………………...… 25 
1.5.1 Leukocyte compositions in human peritoneal cavity…………………... 25 
1.5.2 The role of peritoneal macrophages in PD patients……………………..27 
1.5.3 The role of peritoneal dendritic cells in PD patients…………………… 30 
1.5.4 Mononuclear phagocytes in mouse peritoneal cavity………………….. 31 
1.6 Scope of the thesis………………………………………………………………...34 
xi 
 
Chapter 2 – Materials and methods……………………………………………………. 35 
2.1  Human study………………………………………………………………….… 36 
2.1.1   Ethical approval…………………………………………………………36 
2.1.2   Study populations………………………………………………………. 36 
2.1.3   Isolation of human peritoneal cells from PD effluent fluids…………… 39 
2.1.4   Isolation of human mononuclear cells from peripheral bloods of PD 
patients and healthy individuals………………………………….…….. 39 
2.1.5   Cell counting………………………………………………………….…40 
2.1.6   Flow cytometry……………………………………………………….…40 
            2.1.6.1   General staining procedures………………………………....40 
            2.1.6.2   Standarisation, calibration and quality control………………42 
2.1.7   Cell cycle analysis and proliferation assay………………………….…..43 
2.1.8   Ex vivo microbial product stimulation and cytokine production assay.....43 
2.1.9   Ex vivo phagocytosis and respiratory burst assay……………………….44 
2.1.10  Fluorescence-activated cell sorting of human peritoneal monocytic 
cells……………………………………….…......................................... 45 
2.1.11  Morphological analysis………………………………………….………45 
2.1.12  Antigen processing and presentation assay…………………………….. 46 
2.2  Mouse study…………………………………………………………………….... 47 
2.2.1   Animals……………………………………………………………….... 47 
2.2.2   Experimental peritonitis models……………………………………...…47 
2.2.3   Adoptive transfer experiments…………………………………………. 48 
2.2.4   Flow cytometry………………………………………………………… 48 
2.2.5   Cell cycle analysis and proliferation assay…………………………...…50 
2.2.6   Ex vivo microbial products stimulation and cytokine production assay... 50 
xii 
 
2.2.7  Apoptotic thymocyte clearance assay…………………………………….51 
            2.2.7.1   Generation of apoptotic thymocytes…………………………..51 
           2.2.7.2   Quantification of apoptotic thymocytes………………………51 
           2.2.7.3   In vivo apoptotic thymocyte clearance assay……………..…. 52 
2.2.8  Fluorescence-activated cell sorting of mouse peritoneal MØ/DC 
subsets………………………………………………………………….. 53 
2.3  Statistical analysis………………………………………………………………... 53 
 
Chapter 3 – Phenotypic and functional characterisation of peritoneal macrophages and 
dendritic cells in peritoneal dialysis patients…………………………...… 54 
3.1  Introduction…………………………………………………………………….....55 
3.2  Results………………………………………………………………………….....57 
3.2.1   Flow-cytometric analysis of human peritoneal cells– basic principles… 57 
3.2.2   Identification of peritoneal myeloid cells from PD effluent fluids based 
on CD116 (GM-CSF receptor alpha) expression………………………. 59 
3.2.3   Phenotypic identification of two major peritoneal monocytic subsets 
(CD14+CD1c– and CD14low/–CD1c+) from PD effluent fluids…………..61 
3.2.4   Phenotypic comparisons between peritoneal CD14+ MØ and CD1c+ 
DC from PD patients………………………………………………….. 64 
3.2.5   Heterogeneous activation and maturation of peritoneal MØ and DC...... 68 
3.2.6   Phenotypic comparisons between human blood monocytic subsets and 
peritoneal monocytic subsets from PD patients……………………...… 71 
3.2.7   Cytokine response to ex vivo stimulation with microbial products…….. 75 
3.2.8   Phagocytosis and respiratory burst response after ex vivo challenges 
with fluorescence-conjugated zymosan particles or bacteria………...… 77 
xiii 
 
3.2.9   Flow-cytometric cell sorting of human peritoneal MØ and DC 
subsets………………………………………………………………….. 80 
3.2.10  Antigen processing and presenting assay………………………………. 81 
3.3  Discussion………………………………………………………………………... 82 
 
Chapter 4 – Kinetics and distributions of peritoneal myelomonocytic cells during the 
course of peritoneal dialysis therapy……………………………………....85 
4.1  Introduction……………………………………………………………………….86 
4.2  Results…………………………………………………………………………….88 
4.2.1 Clinical outcomes of new-starter PD patients with 1-year follow-up….. 88 
4.2.2 Kinetic changes of major peritoneal myeloid cells during the 1st year of 
PD therapy……………………………………………………………… 90 
4.2.3 Kinetic changes of peritoneal MØ and DC subsets during the 1st year of 
PD therapy……………………………………………………………… 93 
4.2.4 Minimal local proliferation of peritoneal MØs and DCs alongside 
post-surgery inflammatory recruitment………………………………… 96 
4.2.5 Is the catheter-induced peritoneal inflammatory response associated 
with early non-peritonitis technique failure in new-starter PD 
patients?....................................................................................................98 
4.2.6 Association between peritoneal immune characteristics and the risk for 
developing first episode of peritonitis during the 1st year of PD therapy  
………………………………………………………………………… 102 
4.2.7 Differential distributions of peritoneal myeloid cells and MØ/DC 
subsets between infected PD effluents from acute peritonitis patients 
xiv 
 
and uninfected fluids from stable dialysis patients………......................104 
4.2.8 Differential distributions of peritoneal myeloid cells and MØ/DC 
subsets between patients with and without treatment failure upon acute 
bacterial peritonitis……………………………………………………...107 
4.2.9 Pathogen-specific distributions of peritoneal myeloid cells and MØ/DC 
subsets during acute bacterial peritonitis……………………………..…110 
4.2.10 Impact of peritonitis history on the distributions of peritoneal myeloid 
cells and MØ/DC in patients under stable dialysis………………..…….115 
4.3 Discussion…………………………………………………………………….…..118 
 
Chapter 5 – Characterisation of “dendritic cell-like” subsets in the murine peritoneal 
cavity……………………………………………………………….……...121 
5.1 Introduction………………………………………………………………….…....122 
5.2 Results………………………………………………………………………….....124 
5.2.1 Phenotypic identification of murine peritoneal ‘DC-like’ subsets under 
steady state……………………………………………………………....124 
5.2.2 Phenotypic discrimination between murine peritoneal ‘DC-like’ subsets 
and recruited monocyte-derived macrophages during inflammation…...129 
5.2.3 Cellular kinetics of different peritoneal macrophage and ‘DC-like’ 
subsets during acute experimental peritonitis…………………………...132 
5.2.4 Peritoneal ‘DC-like’ subsets are recruited from the periphery during 
acute experimental peritonitis…………………………………………...135 
5.2.5 Limited evidence of local proliferation of peritoneal ‘DC-like’ subsets 
during acute experimental peritonitis…………………………………...138 
5.2.6 CCR2-dependent homeostasis and inflammatory recruitment of 
xv 
 
peritoneal DC-like subsets………………………………………………141 
5.2.7 The role of IL-10 on the inflammatory recruitment of peritoneal 
‘DC-like’ subsets and MØs……………………………………………...146 
5.2.8 Differential cytokine responses among distinct peritoneal MØ/DC 
subsets upon ex vivo microbial product stimulation…………………….149 
5.2.9 Differential capacity for in vivo apoptotic thymocyte clearance among 
distinct peritoneal MØ/DC subsets……………………………………...153 
5.2.10 Fluorescence activated cell sorting and morphological analysis of 
murine peritoneal MØ/DC subsets……………………………………...157 
5.3 Discussion………………………………………………………….……………..159 
 
Chapter 6 – General discussion…………………………………………………………162 
6.1  The identities of peritoneal MØ/DC subsets……………………………………...163 
6.1.1   Peritoneal MØs: “resident” versus “recruited”……………………….....163 
6.1.2   Peritoneal DC population…………………………………………….…166 
6.1.3   Comparisons between human and murine peritoneal MØ/DC subsets....169 
6.1.4   Future directions………………………………………………………...170 
6.2  Alterations of peritoneal MØ/DC phenotypes and activation/maturation status 
during PD therapy………………………………………………………………...172 
6.2.1   Altered distribution of peritoneal MØ/DC during PD therapy………….172 
6.2.2   Altered activation/maturation status of peritoneal MØ during PD 
therapy…………………………………………………………………..174 
6.2.3   Future directions………………………………………………………...176 
6.3  From peritonitis to peritoneal fibrosis: defining the roles of peritoneal MØ and 
DC in PD patients………………………………………………………………...178 
xvi 
 
 
Bibliography…………………………………………………………………………….181 
 
Appendix  
1.  Clinical characteristics of the study patients………………….……………………200 
2.  Antigen processing and presentation assay in mice………………………………..201     
xvii 
 
Lists of figures 
 
Figure 1.1   Renal replacement therapy (RRT) modality in incident patients………... 6 
Figure 1.2   Different modes of peritoneal dialysis…………………………………... 8 
Figure 1.3   Origins and renewal of tissue-resident macrophages……..……..…….....15 
Figure 1.4   Hematopoietic origins of tissue macrophages and dendritic cells……….17 
Figure 2.1   PD patient recruitment and the timescale of PD fluid sampling…………38  
Figure 3.1   Flow-cytometric strategies to exclude doublets, cellular debris and dead   
cells during data analysis………………………………………………..58 
Figure 3.2   Flow-cytometric gating strategies to identify different peritoneal 
myeloid subsets from PD effluent fluids……………………………….. 60 
Figure 3.3   Phenotypic identification of two major mononuclear phagocyte subsets 
in the peritoneal effluent fluids from PD patients……………………… 62 
Figure 3.4   HLA-DR+CD14low/– cells are potentially peritoneal dendritic cells…….. 63 
Figure 3.5   Phenotypic comparisons between human peritoneal CD14+ MØ and 
CD1c+ DC……………………………………………………………….65 
Figure 3.6   Quantitative comparisons of receptor expression between human 
peritoneal CD14+ MØ and CD1c+ DC under stable status and during 
acute bacterial peritonitis………………………………………………..66 
Figure 3.7   Human peritoneal MØ/DC could be subdivided into six cell subtypes 
based on the differential expression of CD16 and CD206……………... 69 
Figure 3.8   Differential marker expression on six distinct peritoneal monocytic 
subsets under stable status or during acute bacterial peritonitis………...70 
Figure 3.9   Phenotypic characterisation of three major monocytic subsets in 
peripheral bloods from PD patients…………………………………......72 
Figure 3.10  Major monocytic subsets (based on CD14 versus CD16 expression) in 
peripheral bloods and in the peritoneal cavity from PD patients………. 73 
Figure 3.11  Phenotypic identification of blood CD1c+ DC precursors……………… 73 
Figure 3.12  Cytokine production by peritoneal MØ and DC after ex vivo stimulation 
with SES or LPS………………………………………………………...75 
Figure 3.13  Quantification of intracellular cytokine production by peritoneal 
MØ/DC after ex vivo stimulation with SES or LPS……………………. 76 
Figure 3.14  Phagocytosis and respiratory burst responses following ex vivo 
challenges with zymosan particles……………………………………... 78 
Figure 3.15  Phagocytosis and respiratory burst responses following ex vivo 
challenges with staphylococcus epidermidis (S.E)…………………….. 79 
Figure 3.16  Cell sorting of human peritoneal MØ/DC and their morphology………. 80 
xviii 
 
Figure 3.17  Human antigen processing and presenting assay……………………….. 81 
Figure 4.1   Flow diagram of longitudinal outcomes of new-starter PD patients 
during 1-year follow-up………………………………………………... 89 
Figure 4.2   Changes in the numbers of major peritoneal myeloid cells during the 1st 
year of PD therapy………………………………………………………91 
Figure 4.3   Kinetic changes of major peritoneal myeloid subsets during the 1st year 
of PD therapy……………………………………………………………92 
Figure 4.4   Differential kinetic changes of CD14+ MØ sand CD1c+ DC during the 
1st year of PD therapy…………………………………………………... 94 
Figure 4.5   Individual kinetic changes of six peritoneal monocytic subsets during 
the 1st year of PD therapy………………………………………………. 95 
Figure 4.6   Minimal proliferative activity of peritoneal MØ/DC during   
post-surgery inflammation……………………………………………... 97 
Figure 4.7   Comparisons of peritoneal myeloid cells from the 1st flush PD effluents 
between new-starter PD patients without early technique failure versus 
those with catheter-related technique failure……………………………99 
Figure 4.8   Differential distributions of peritoneal MØ/DC subsets from the 1st 
flush PD effluents between new-starter PD patients with and without 
catheter failure……………………………………………………….…100 
Figure 4.9   Comparisons of kinetic changes of peritoneal myeloid cells during     
pre-dialysis period between new-starter PD patients with and without 
non-peritonitis technique failure……………………………….……….101 
Figure 4.10  Comparisons of major peritoneal myeloid cells between infected PD 
effluents from day 1 acute bacterial peritonitis and uninfected fluids 
from stable dialysis patients…………………………………………. ...105 
Figure 4.11  Differential distributions of peritoneal MØ/DC subsets between PD 
patients with bacterial peritonitis versus the stable dialysis patients…...106 
Figure 4.12  Comparisons of major peritoneal myeloid cells between bacterial 
peritonitis episodes with treatment success versus those with treatment 
failure……………………………………………………………….…..108 
Figure 4.13  Differential distributions of peritoneal MØ/DC subsets between 
bacterial peritonitis with treatment success versus treatment failure…..109 
Figure 4.14  Comparisons of major peritoneal myeloid cells between 
culture-negative versus culture-positive peritonitis…………………….111 
Figure 4.15  Differential distributions of peritoneal MØ/DC subsets between 
culture-negative and culture-positive bacterial peritonitis……………...112 
Figure 4.16  Comparisons of major peritoneal myeloid cells between gram-positive, 
gram-negative and mixed type bacterial peritonitis…………………….113 
xix 
 
Figure 4.17  Differential distributions of peritoneal MØ/DC subsets between gram- 
positive, gram-negative and mixed type bacterial peritonitis…………..114 
Figure 4.18  Comparisons of major peritoneal myeloid cells and MØ/DC subsets 
between stable dialysis patients without history of peritonitis, with only 
one episode of peritonitis and with more than one episode of peritonitis 
            ………………………………………………………………………….116 
Figure 4.19  Differential distributions of peritoneal MØ/DC subsets between stable 
dialysis patients without history of peritonitis and those with history of 
peritonitis…………………………………………….………………….117 
Figure 5.1   Phenotypic identification of peritoneal ‘DC-like’ subsets in the naïve 
murine peritoneal cavity………………………………………………...126 
Figure 5.2   Phenotypic comparisons between peritoneal resident MØs and three 
‘DC-like’ subsets from naïve mice……………………….……………..128 
Figure 5.3   Phenotypic discrimination of ‘DC-like’ cells from monocyte-derived 
inflammatory MØs during peritoneal inflammation…………………....130 
Figure 5.4   Phenotypic comparisons between peritoneal resident MØs, 
inflammatory MØs and three ‘DC-like’ subsets from inflamed mice…..131 
Figure 5.5   Cellular kinetics of peritoneal myelomonocytic subsets during acute 
SES-induced peritoneal inflammation…………………………………..133 
Figure 5.6   Cellular kinetics of peritoneal myelomonocytic subsets during acute 
zymosan-induced peritoneal inflammation……………………………...134 
Figure 5.7   Peritoneal ‘DC-like’ cells are recruited from the periphery during acute 
SES-induced peritonitis…………………………………………………136 
Figure 5.8   Limited evidence of proliferation during peritonitis of murine peritoneal 
‘DC-like’ subsets………………………………………………………..139 
Figure 5.9   Myeloid cell compositions in the naïve peritoneal cavity of Ccr2‒/‒ mice, 
compared to wild-type Ccr2+/+ mice……………………………………142 
Figure 5.10  Myeloid cell compositions in the peritoneal cavity from 72h post-SES 
challenge Ccr2‒/‒ mice and wild-type Ccr2+/+ mice…………………….144 
Figure 5.11  IL-10 limits inflammatory response in acute SES-induced peritonitis 
model……………………………………………………………………147 
Figure 5.12  Peritoneal MØ/DC subsets exhibit differential pro-inflammatory 
cytokine production following SES or LPS exposure…………………..150 
Figure 5.13  Peritoneal MØ/DC subsets exhibit differential IL-10 production 
following SES or LPS exposure………………………………………...152 
Figure 5.14  Glucocorticoid-induced thymocyte apoptosis ex vivo……………….…..154 
Figure 5.15  Peritoneal MØ/DC subsets from naïve status exhibit differential 
capability of apoptotic thymocyte clearance……………………………155 
xx 
 
Figure 5.16  Peritoneal MØ/DC subsets from 72h after SES-induced peritonitis 
exhibit differential capability of apoptotic thymocyte clearance……….156 
Figure 5.17  Flow-cytometric cell sorting and morphological analysis of individual 
peritoneal MØ/DC subset……………………………………………….158 
 
 
 
 
 
 
 
 
 
  
xxi 
 
Lists of tables 
 
Table 1.1   Description of ‘three pores’ of peritoneal capillary endothelium………… 5 
Table 1.2   Peritoneal membrane characteristics of different transport status………... 9 
Table 1.3   Summary of select surface receptors and molecules on mononuclear 
phagocytes in mice and humans……………………………………….….21 
Table 1.4   Phenotypic definition of peritoneal mononuclear phagocyte subsets 
(steady state and inflamed state) used in the current literature…………...33 
Table 2.1   Fluorochrome-conjugated anti-human monoclonal antibodies for surface 
antigen staining in this project…………………………………………… 41 
Table 2.2   Fluorochrome-conjugated anti-mouse monoclonal antibodies used in this 
project………………………………………………………………….….49 
Table 3.1   Phenotypic comparisons of select receptor expressions between major 
monocytic subset in peripheral blood and in the peritoneal cavity……….74 
Table 4.1   Comparisons of clinical and peritoneal immune characteristics at the 
start of PD between patients free from peritonitis and patients 
developing first peritonitis episode within the 1st year of PD therapy…. 103 
Table 5.1   Differentially expressed genes between peritoneal F4/80lowMHCII+ MØs 
and F4/80intMHCII+ MØs during thioglycollate peritonitis……………. 127 
 
 
 
 
  
 
 1 
 
 
 
 
 
 
 
 
 
Chapter One 
 
General introduction 
  
 2 
 
1.1 Overview 
 
The overall purpose of the work carried out during my PhD research project was to 
understand the heterogeneity of peritoneal mononuclear phagocytes (macrophages 
and dendritic cells) and to define their respective immune characteristics (phenotypes 
and functional properties) in peritoneal dialysis patients.  
In order to introduce this subject, I will first describe the anatomy of the peritoneal 
cavity and the physiology of the peritoneal membrane, before considering peritoneal 
dialysis (PD) as a therapy. The overview of PD will provide a broad insight of the 
historical background, basic techniques and most importantly, its complications. 
Subsequently, I will introduce the current understanding of monocyte/macrophage/DC 
biology, particularly focusing on their ontogeny/development as well as their roles in 
tissue homeostasis and the body’s defences against pathogens. Finally, I will review 
the state of knowledge about the immunobiology of this heterogeneous population in 
the peritoneal cavity, encompassing PD patients and mouse models. 
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1.2 Peritoneal cavity and peritoneal membrane 
 
1.2.1  Anatomy of peritoneal cavity 
 
The earliest description of the peritoneal cavity can be dated back to 3000 B.C., when 
the Egyptian morticians described it as a “definitive entity in which the viscera were 
somehow suspended” (Cunningham et al., 1926). The peritoneum is derived from 
mesenchyme and composed of a thin connective tissue layer covered by a monolayer 
of mesothelial cells. The largest serous membrane of human body, the peritoneum 
supports the abdominal viscera and serves as a conduit for the blood vessels, 
lymphatic vessels and nerves. The peritoneal membrane has a surface area ranging 
between 1-2 m2 in human adults (Esperanca et al., 1966; Pawlaczyk et al., 1996). 
About 80-90% of this total membrane area consists of visceral peritoneum (including 
that covering the liver, mesenteries and omentum), and 10-20% is parietal peritoneum 
(Pawlaczyk et al., 1996; Albanese et al., 2009). The space between parietal and 
visceral peritoneum is the peritoneal cavity, normally filled with a small amount (~50 
mL) of serous fluid that permits the two layers to slide freely over each other. 
The submesothelial connective tissue layer (interstitium) primarily comprises cells 
(fibroblasts, mast cells and macrophages) and collagen fibres embedded in an 
amorphous substance (Hruza et al., 1977). The peritoneal membrane has extensive 
blood vessel coverage, with the visceral peritoneum supplied by the mesenteric 
arteries and the parietal peritoneum supplied by epigastric, intercostal and lumbar 
arteries. Another substantial component of the peritoneum is the lymphatic system, 
which drains a wide range of materials including water, proteins, cells, from the 
interstitial compartment and the peritoneal cavity (Mactier et al., 1987).  
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1.2.2  Peritoneal membrane physiology  
 
In 1877, a German investigator, Georg Wegner, by working on animal models, first 
depicted the concept of “peritoneal ultrafiltration”. His observations revealed that 
injection of hypertonic fluids into the peritoneal cavity led to increased intraperitoneal 
volume while hypotonic solutions resulted in a reduced intraperitoneal volume 
(Wegner 1877). Two English researchers then specifically determined that fluid and 
solute transport across the peritoneal membrane could be ‘bi-directional’, noting that 
solute exchange was primarily between solutions in the peritoneal cavity and blood 
compartment (Starling and Tubby 1894). Subsequently, Putnam defined the 
peritoneum as a semi-permeable membrane that allowed water and solute transport 
based on the principles of osmosis and diffusion, in his published paper “The living 
peritoneum as a dialyzing membrane” in the American Journal of Physiology (Putnam 
1923).  
Structurally, the peritoneum constitutes three major components involved in the water 
and solute transport between the peritoneal space and the plasma: 
1. Mesothelial cell monolayer 
2. Interstitial space 
3. Capillary endothelium 
Notably, it is the capillary wall (endothelium) that appears to be the primary filter 
determining the solute transport, as both mesothelial layer and interstitial space only 
provide minor resistance to the flow of solutes. Several theoretical models have been 
proposed to determine the transport of solutes across the peritoneal capillary bed. Of 
them, the “three pore model” is the most commonly described clinical model (Rippe 
1993). In this model, the capillary endothelial cells are postulated as having three 
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kinds of “pores” that allow for the movement of solute and water across the capillary. 
These three pores are the large pores, small pores and ultra small (transcellular) pores. 
Their characteristics are summarised in Table 1.1 as below. 
 
Table 1.1  Description of ‘three pores’ of peritoneal capillary endothelium  
 Large pores Small pores  Ultra small pores 
Size Up to 250 angstroms 40-55 angstroms 2.3-15 angstroms 
Density 
(% surface area) 
Few in number 
(<1%) 
Most numerous 
(>95%) 
Many in numbers 
(~ 2%) 
Molecules 
transported 
Macromolecules 
(ex. Proteins) 
Small solutes (ex. 
sodium) and water 
Water only 
Localization Inter-endothelial 
clefts 
Inter-endothelial 
clefts (?) 
Aquaporins (AQP1) 
on endothelium 
Modified from Rippe B. Perit Dial Int.13:S35-8, 1993 
 
The movement of water and solutes of varying sizes occurs due to two physiological 
processes that happen simultaneously:  
1. Diffusion- occurs when solutes move down a concentration gradient between two 
compartments 
2. Convection- occurs when dissolved solutes are small enough to move through the 
pores as water is moving across the capillary, in response to an osmotic force.  
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1.3 Peritoneal dialysis 
 
1.3.1  Background 
 
End-stage renal disease (ESRD), is the point at which kidney function has 
permanently declined to a level which no longer supports the body’s needs. This may 
be as a final consequence of progressive loss of function in a patient with Chronic 
Kidney Disease, or following irreversible Acute Kidney Injury. Patients with ESRD 
require replacement therapy (RRT) to maintain their lives. Currently, diabetic renal 
disease remains the single most common cause of ESRD in the UK (UK Renal 
Registry 2013). The distribution of the modality choices for newly initiated RRT is 
shown in Fig 1.1 A. About 20% of new adult ESRD patients are treated with 
peritoneal dialysis (PD) and about 70 % with haemodialysis (HD). The number of the 
incident adult patients treated with each dialysis modality (HD versus PD) in 2012 by 
age group is shown in Figure 1.1 B. [data recruited from UK Renal Registry (2013):  
https://www.renalreg.org/reports/2013-the-sixteenth-annual-report/] 
 
 
Figure 1.1  Renal replacement therapy (RRT) modality in incident patients   
(A)  Pie chart showing the RRT modality at 90 days from incident patient cohort in 
UK (1/10/2011–30/09/2012) (B) Number of incident dialysis patients in 2012, by age 
group and initial dialysis modality. [Adapted from UK Renal Registry 2013] 
A B 
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PD has several advantages over HD such as greater patient independence, no need for 
vascular access and needles, fewer dietary restrictions, relatively stable 
haemodynamics during continuous ultrafiltration (suitable for cardiac failure patients), 
and better preservation of residual kidney function (RKF) (Tokgoz 2009). The latter 
has been suggested to confer some survival benefits over HD in the short term (first 
2-3 years) (Chaudhary et al., 2011). However, long-term PD is limited with less than 
one-third able to maintain PD beyond 3 years due to a significant dropout rate. The 
main reasons for dropout, according to UK Renal Registry 2013, include: receiving 
kidney transplantation (~30%), deaths from any cause (~20%) and non-death 
technique failures resulting in modality shifting to HD (~20%). The one absolute 
contraindication to chronic PD is an unsuitable peritoneum owing to the presence of 
malignancy, severe fibrosis or extensive adhesions. Other situations not recommended 
for PD include abdominal hernias, presence of colostomy, ileostomy or nephrostomy, 
recurrent severe backache with pre-existing disc disease. 
 
1.3.2 Peritoneal dialysis technique 
 
PD has been a widely accepted RRT for treating ESRD patients since late 1970s 
(Teitelabaum et al., 2003). It involves using the peritoneum as a filter membrane. 
Before the commencement of PD, a small flexible catheter is surgically inserted in the 
abdomen. Maintenance dialysis ensued after catheter wound healed and appropriate 
training. During PD therapy, sterile “dialysis fluid” is filled by gravity into the 
peritoneal cavity. During the dwell, blood circulates through the peritoneum, so waste 
products and excess fluid are moved from the blood into the dialysis fluid. After 
variable dwell time, the dialysis fluid is then drained out into the “effluent bag”. 
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PD has two basic modes of choice (Fig. 1.2). Continuous ambulatory peritoneal 
dialysis (CAPD), which is done manually, normally consists of three fluid exchanges 
during daytime and one long dwell overnight. The alternative approach is to use a 
machine with settings for cyclic exchanges in the night time (automated peritoneal 
dialysis, APD), either with a long dwell during the daytime as Continuous Cycling 
Peritoneal Dialysis (CCPD) or free from dialysis in the daytime as Nocturnal 
Intermittent Peritoneal Dialysis (NIPD). The dose and the frequency of dialysis 
exchanges primarily depend on the adequacy of the patient’s dialysis.  
Figure 1.2  Different modes of peritoneal dialysis 
 
CAPD: continuous ambulatory peritoneal dialysis, CCPD: continuous cyclic peritoneal dialysis, 
NIPD: nocturnal intermittent peritoneal dialysis (Modified from Chiu et al., 2002) 
 
The most common form of PD solutions are traditional dextrose-based solutions with 
varying concentrations of glucose (1.5-4.25%) used to create osmotic gradients to 
drive ultrafiltration and convection. Other types of PD fluid include solutions 
containing lower glucose degradation products (GDPs) and/or neutral pH, and 
non-dextrose solutions (icodextrin) using polymers to create a colloidal osmotic 
pressure (García-López et al., 2012). 
 9 
 
1.3.3  Peritoneal equilibration test (PET) 
 
A patient's peritoneal membrane transport status can be assessed by measuring the 
creatinine equilibration curve and the glucose absorption curve during a standardized 
peritoneal equilibration test (Twardowski et al., 1987). The standardized 4-hour PET 
involves a 2-liter 2.5% dextrose dwell. During the dwell, dialysate samples are taken 
at 0, 2, and 4 hours and a plasma sample at 2 hours. The dialysate to plasma (D/P) 
ratios for creatinine and glucose are measured. Based on 4-hour dialysate and plasma 
creatinine level (D/P creatinine), patients can be classified into one of four transport 
categories: high (fast), high-average, low-average, and low (slow) transporter. The 
characteristics of different transporters are summarised below (Twardowski 1990): 
 
Table 1.2  Peritoneal membrane characteristics of different transport status 
Transport status D/P creatinine Solute clearance Ultrafiltration 
High (fast)      > 0.80 Excellent Poor 
High average 0.65-0.80 Adequate Adequate 
Low average 0.55-0.64 Borderline Good 
Low (slow) < 0.55 Inadequate Excellent 
 
Based on PET, clinicians can prescribe a suitable regimen for individual patient. For 
example, high transporters should be better on regimens with frequent, short-dwell 
exchanges (CCPD/NIPD), whereas low transporters are suitable for long-dwell 
exchange (CAPD). It has been recommended that an evaluation of peritoneal 
membrane characteristics should routinely be repeated at least once per year or when 
new clinical problems (overhydration, malnutrition, metabolic disturbance) are 
noticed (van Biesen et al., 2010).  
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1.3.4  Complications 
 
In general, the complications of PD therapy can be categorised into “catheter-related” 
and “dialysis-related” conditions.  
Catheter-related complications  
Catheter-related complications include catheter dysfunction, external cuff extrusion, 
pericatheter leak, exit site or pericatheter infection and early peritonitis (Kathuria et 
al., 2009). The following conditions would lead to catheter dysfunction: 1) 
intra-luminal obstruction with blood/fibrin clot, 2) catheter tip migration or kinking, 3) 
omental tissue encasement (‘omental wrapping’). Most of them can be reversed 
through medical or surgical interventions (Diaz-Buxo et al., 1998), however, in cases 
of severe irreversible occlusion, catheter removal is necessary. In fact, catheter 
dysfunction is one of the major reasons for early technique failure.  
Dialysis-related complications  
(1) Non-infectious complications ‒ 
These include abdominal hernias (due to increased intraperitoneal pressure), 
hydrothorax, haemoperitoneum, and chyloperitoneum. Abdominal hernias and 
hydrothorax can be repaired and the patients can choose to return to PD after 
surgery. The underlying aetiologies of haemoperitoneum (‘bloody effluent’) and 
chyloperitoneum (‘milky effluent’) are complex, ranging from benign conditions 
(i.e., menstruation, lymphatic vessel trauma) to serious situations (i.e., cancer 
metastasis with intra-peritoneal seeding, intraperitoneal tumours resulting in 
extrinsic obstruction of lymphatic vessels). For malignant cases, withdrawal from 
PD therapy may be necessary (McCormick et al., 2007). 
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(2) Peritonitis ‒  
Despite treatment advance, peritonitis remains a major cause for morbidity and 
mortality in PD patients. The diagnosis of acute peritonitis is based on the 
presence of abdominal pain and cloudy peritoneal effluent with >100 WBC/mm3 
(Li et al., 2010). Generally, broad-spectrum antibiotics covering Gram-positive 
and Gram-negative bacteria are prescribed intraperitoneally after the sampling of 
PD fluid (“cloudy effluent”) for microbiological examination. The choice of 
antibiotics is subsequently refined to narrower-spectrum cover, according to the 
culture results. Normally, the entire treatment course takes 14 to 21 days (Li et al., 
2010). Refractory peritonitis, defined as failure of the effluent to clear after 5 days 
of appropriate antibiotics, should be managed by catheter removal (Choi et al., 
2004). In cases of recurrent/relapsing peritonitis, catheter removal may prove 
necessary (Szeto et al., 2009). 
(3) Peritoneal membrane fibrosis ‒ 
Peritoneal membrane fibrosis resulting in ultrafiltration failure is one of the major 
complications in long-term PD patients. Two forms of membrane fibrosis are 
often classified: a slowly progressive ‘simple fibrosis’ and a fulminant 
‘encapsulating peritoneal sclerosis (EPS)’ (Davies et al., 2011). The underlying 
mechanism appears to be complex (Kim et al., 2009), but it has been argued that 
severe or multiple peritonitis episodes and the usage of non-physiological PD 
solutions (prolonged exposure to glucose and glucose degradation products) could 
be the key contributing factors (Davies 2014). A recent study showed that local 
inflammatory status, measured as intraperitoneal IL-6 level, correlated with 
peritoneal membrane function over time and can be a surrogate biomarker to 
predict membrane outcome (Lambie et al., 2013). 
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1.4 Heterogeneity of monocytes, macrophages and dendritic cells 
 
1.4.1  Historical background 
 
It has been widely recognized that Russian biologist Élie Metchnikoff first introduced 
the term ‘macrophage (MØ)’ (which means “big eater”) in late 19th century to 
describe the large mononuclear phagocytes in tissues, which was distinguished from 
another phagocytosing cell type, called ‘microphage’ (“small eater”, now known as 
polymorphonuclear leukocytes or neutrophils) (Metchnikoff 1892). In 1924, Aschoff 
assigned MØs to the ‘reticuloendothelial system (RES)’; a system also comprising of 
reticular cells, endothelial cells, fibroblasts, which were considered to have a common 
tissue origin at that time (Aschoff 1924). Subsequently, Ebert and Florey (1939), using 
rabbit ear chamber experiments, demonstrated that mammalian blood monocytes 
actively migrating towards sites of injury and differentiating into MØs in vivo. With 
the aid of thymidine autoradiography, Volkman and Gowans (1965) showed that these 
tissue-infiltrating MØs actually originated from the bone marrow (BM). Because of 
the involvement of non-monocyte/ MØ cells leading to the argument that RES did not 
truly represent a cell lineage, a group of scientists including Ralph van Furth, James G. 
Hirsch and Zanvil A. Cohn, proposed the ‘mononuclear phagocyte system (MPS)’ to 
replace the ‘RES’, on the basis that MØs shared important functional characteristics 
in vivo and were derived from monocytes, whereas reticular cells, endothelial cells 
and fibroblasts were not (van Furth et al., 1972). The MPS represented a linear model 
in which committed bone marrow precursors give rise to circulating monocytes from 
which tissue MØs are derived. The MPS paradigm has been disputed due to the 
evidences of MØ proliferation and maintenance in the tissues (Sawyer et al., 1982; 
Parwaresch et al., 1984; Czernielewski et al., 1987; Melnicoff et al., 1988), and also 
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the presence of MØ populations in the yolk sac before primitive haematopoiesis 
(Naito et al., 1996). Very recently, mouse studies have demonstrated that most 
tissue-resident MØs can be of embryonic origins and primarily independent of 
haematopoietic supply (Chorro et al., 2009; Ginhoux et al., 2010; Hoeffel et al., 2012; 
Schulz et al., 2012).    
On the other hand, Ralph M. Steinman and Zanvil A. Cohn (1973) first identified a 
novel cell type from mouse peripheral lymphoid organs – dendritic cells (DCs). 
Functionally, these classical DCs were professional in processing and presenting 
antigen to naïve T lymphocytes, initiating the adaptive immune response (Steinman et 
al., 1978). Shortly after its discovery, DCs were incorporated into MPS by Ralph van 
Furth (1980) and widely accepted by other researchers. Of note, the original 
Steinman-Cohn’s DCs were restricted in lymphoid tissues, but subsequently DC 
networks were also recognised in non-lymphoid tissues in mice and humans (Schlitzer 
et al., 2014). The developmental origin and differentiation pathways of DC subsets 
will be discussed in the next section. 
Several breakthroughs in the past decade have advanced our understanding of 
monocyte/MØ/DC biology (Davies et al., 2013; Schlitzer et al., 2014; Ginhoux et al., 
2014; Guilliams et al., 2014). Firstly, the application of polychromatic flow cytometry 
has permitted the exploration of reliable surface markers on discrete cell populations, 
which enabled the clear discrimination between DCs and MØs in tissue compartments. 
Secondly, with the aids of novel cell lineage tracing strategies, the developmental 
pathways of distinct monocyte/MØ/DC subsets under homeostatic or inflamed 
conditions could now be mapped in mice. Thirdly, the potential corresponding cell 
subsets between mice and humans could be identified through detailed gene 
expression profiling and the cross-species mapping.  
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1.4.2  Origins and developmental pathways  
 
Mononuclear phagocytes are broadly segregated into two main populations based on 
their developmental sources: ‘embryonic origin’ and ‘haematopoietic origin’. Recent 
evidences unveiled that part of adult tissue-resident MØs are basically originated from 
yolk sac and/or fetal liver during embryonic period (Fig. 1.3) (Davies et al., 2013; 
Ginhoux et al., 2014). Initial fate-mapping works confirmed that adult microglia and 
Langerhans cells were established prenatally (Chorro et al., 2009; Ginhoux et al., 
2010). Subsequently, these findings were extended to a ‘Myb-independent’ population 
of characteristically F4/80high MØs in several tissues, such as spleen (red pulp MØ), 
liver (Kupffer cell), brain (microglia), skin (Langerhans cell), pancreas, lung and 
kidney (Schulz et al., 2012). Additional evidence revealed that these ‘prenatally 
seeded’ tissue MØs have substantial self-renewal ability (proliferative expansion) that 
enables them to maintain tissue homeostasis after birth (Davies et al., 2011; Yona et 
al., 2013; Hashimoto et al., 2013), and to recover from the ‘MØ disappearance’ 
reaction upon specific immune challenges (Davies et al., 2011; Jenkins et al., 2011). 
However, others also suggested that microglia and Langerhans cells can derive from 
blood monocyte under certain conditions after birth (Merad et al., 2002; Ajami et al., 
2007). Very recently, new evidence confirms that BM-derived precursors or 
circulating monocytes could constantly contribute to the steady-state tissue MØ pools, 
although this hematopoietic supply has been suggested with tissue-specific variation, 
for example, mostly tissue MØs in the steady-state intestine are hematopoietic in 
origin. (Zigmond et al., 2012; Bain et al., 2014). Additional evidence implies that the 
embryonic MØs in tissues are gradually replaced by BM-derived MØs under 
steady-state conditions after birth, such as cardiac tissues (Molawi et al., 2014). 
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Figure 1.3  Origins and renewal of tissue-resident macrophages.  
Recent fate-mapping studies and single-cell analyses in mice indicate that MØs 
derived early in embryogenesis from the yolk sac can contribute to adult pools of 
tissue MØs, such as Langerhans cells and microglia. Other tissues may be similarly 
seeded or established after definitive haematopoiesis in the fetal liver or bone marrow. 
Proliferative local expansion of tissue MØs in the neonatal period, followed by 
low-level self-renewal during adulthood appears sufficient to maintain many tissue 
resident populations. During the resolution of acute inflammation, local proliferation 
can be enhanced to help restore homeostatic tissue-resident MØs. In the context of the 
Th2 cell environment associated with parasite infection, substantial IL-4–dependent 
proliferation can expand numbers of tissue-resident MØs beyond that normally seen 
in the tissue (Jenkins et al., 2011). This post-inflammatory proliferative expansion of 
resident MØs can also be found in acute zymosan-induced peritonitis model (Davies 
et al., 2011), although this is IL-4 receptor-independent. The exact contribution of 
BM–derived inflammatory MØs to these tissue-resident pools is still unclear, but it 
appears likely to happen, although perhaps with tissue-specific variation. 
(Modified from Davies et al., Nat Immunol 14:987, 2013) 
 
 16 
 
The haematopoietic lineages of monocyte/MØ/DC have been elucidated in mice 
recently (Fig. 1.4) (Geissmann et al., 2010; Guilliams et al., 2014). In the BM, the 
haematopoietic stem cells (HSC) produce common lymphoid progenitors (CLP) and 
common myeloid progenitors (CMP). The latter gives rise to MØ and DC precursors 
(MDP). It has been suggested that monocyte-MØ lineage (Monocyte precursors, MoP) 
(Hettinger et al., 2013) and DC lineage (common DC precursors, CDP) (Liu et al., 
2009) are separated from MDP. MoP give rise to Ly-6C+ classical monocytes and 
Ly-6C‒ non-classical monocytes; both of them leave BM and enter into blood 
circulation. Ly-6C+ monocytes are the predominant subset in the blood and poised to 
migrate to the inflamed sites (Geissmann et al., 2003; Serbina et al., 2008), whereas 
Ly-6C‒ monocytes (also called ‘patrolling monocytes’) serve to clear endothelial cell 
debris as ‘intravascular housekeepers’(Geissmann et al., 2003; Auffray et al., 2007). 
Notably, Ly-6C+ monocytes might constitute the steady-state precursors of Ly-6C‒ 
monocytes (Yona et al., 2012). As previously mentioned, circulating monocytes could 
also contribute to the steady-state ‘tissue MØ pool’ with tissue-specific variation 
(Bain et al., 2013; Molawi et al., 2014). On the other hand, CDP give rise to 
plasmacytoid DCs precursors (pre-pDC) and conventional DC precursors (pre-cDC); 
both of them leave BM and enter into blood circulation (Diao et al., 2004; Naik et al., 
2007; Onai et al., 2007). Under homeostatic conditions, pre-pDC and pre-cDC locally 
differentiate into pDC and cDC, respectively, either reside in lymphoid tissues or 
enter into non-lymphoid tissues (Naik et al., 2006; Liu et al., 2009; Ginhoux et al., 
2009; Onai et al., 2013). Of note, some pDC might originate from a lymphoid 
precursor (Corcoran et al., 2003; Pelayo et al., 2005). During inflammation, Ly-6C+ 
monocytes are the major sources of recruited ‘inflammatory MØs’ in the tissues and 
could differentiate into ‘inflammatory DCs’ such as tumour necrosis factor (TNF) and 
inducible nitric oxide synthase (iNOS)–producing DCs (TipDCs) (Serbina et al., 
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2006). However, it has been suggested that monocytes do not give rise to cDC and 
pDC both at steady state and during inflammation (Fogg et al., 2006; Liu et al., 2009). 
 
Figure 1.4  Hematopoietic origins of tissue macrophages and dendritic cells 
Simplified model showing the hematopoietic development of monocyte (Mo)/MØ/DC. 
In the bone marrow (BM), the haematopoietic stem cells (HSC) produce common 
lymphoid progenitors (CLP) and common myeloid progenitors (CMP). The latter give 
rise to MØ/DC precursors (MDP). MDP give rise to common DC precursors (CDP) 
and monocyte precursors (MoP), respectively. Monocytes arise from MoP leave BM 
and enter into the blood circulation. Circulating monocytes (mostly Ly-6C+ classical 
monocytes) contribute to the steady-state ‘tissue MØ pool’ (monocyte-derived MØ, 
‘Mo-MØ’) with tissue-specific variation. On the other hand, CDP give rise to 
precursors of plasmacytoid DCs (pre-pDC) and conventional DCs (pre-cDC); both 
enter into the blood circulation. Under homeostatic condition, pre-pDC and pre-cDC 
locally differentiate into pDC and cDC, respectively, either reside in lymphoid tissues 
or enter into non-lymphoid tissues. During inflammation, Ly-6C+ monocytes are the 
major sources of recruited ‘inflammatory MØs’ and could also differentiate into 
‘inflammatory DCs’ or ‘monocyte-derived DC, Mo-DC’ in the inflamed tissues. 
 18 
 
The lineage commitment and differentiation of monocyte/MØ/DC are controlled by 
several key cytokines or growth factors (Geissmann et al., 2010; Ginhoux et al., 2014; 
Guilliams et al., 2014). Macrophage-colony-stimulating factor (M-CSF or CSF-1), 
interleukin-34 (IL-34) and their receptor, CSF1R (also known as c-fms, M-CSFR, 
CD115) are important in MØ development, proliferation and survival (Hamilton et al., 
2008; Pollard et al., 2009; Greter et al., 2012; Wang et al., 2012) as well as in DC 
development (Fancke et al., 2008). FMS-like tyrosine kinase 3 (FLT3) and its ligand 
(FLT3L) are critical for the pan-DC development (McKenna et al., 2000; Waskow et 
al., 2008). The differentiation into each DC subtype is regulated by distinct sets of 
transcription factors. For example, basic leucine zipper transcription factor ATF-like 3 
(BATF3) is important for the development of CD8α+/CD103+ cDC subset (Hildner et 
al., 2008), whereas CD8α‒/CD11b+ cDC subset is controlled by IFN-regulatory factor 
4 (IRF4) (Suzuki et al., 2004; Schlitzer et al., 2013). The development of pDCs is 
regulated by E2-2 (Cisse et al., 2008; Ghosh et al., 2010). Granulocyte/macrophage- 
colony-stimulating factor (GM-CSF or CSF-2) and its receptor CSF2R (also known as 
GM-CSFR or CD116) also play a key role in DC development under steady state, and 
more importantly during inflammation (Zhan et al., 2012; van de Laar et al., 2012).   
Recently, through the cross-species gene expression profiling, the corresponding 
monocyte/MØ/DC subsets between mice and humans could be mapped. For example, 
mouse Ly-6C+ monocytes may correspond to human CD14+CD16‒ “classical” 
monocytes, while Ly-6C‒ monocytes are similar to human CD14dimCD16+ 
“non-classical” monocytes. In terms of DC subsets, mouse CD8α+ (lymphoid)/ 
CD103+ (non-lymphoid) cDCs correspond to human CD141+ cDCs, whereas mouse 
CD8α‒ (lymphoid)/CD11b+ (non-lymphoid) cDCs are akin to human CD1c+ cDCs 
(Schlitzer et al., 2014).  
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1.4.3  Surface receptors and molecules 
 
Mononuclear phagocytes contain a broad repertoire of surface receptors and 
molecules, which determine a wide range of cellular activities such as growth, 
differentiation, activation, maturation, migration, endocytosis, phagocytosis, pathogen 
recognition, antigen presentation and cell-cell interaction. Some of these receptors or 
molecules are not only restricted to monocyte/MØ/DC subsets but also shared by 
other cell types. Here, a select of surface receptors/molecules relevant to this thesis 
are summarised below and in Table 1.3.  
(1) Fc receptors (FcRs) –  
Binding of the Fc portion of immunoglobulin molecules to the Fc receptors can 
trigger various functions such as endocytosis, phagocytosis, transmembrane signal 
generation and secretion of potent mediators (Guilliams et al., 2014).  
(2) Complement receptors (CRs) – 
These are involved in the binding complement components (either in free form or 
as part of an immune complex) and ingestion of opsonized particles (van 
Lookeren Campagne et al., 2007). 
(3) Pathogen recognition receptors (PRRs) – 
These receptors mediate binding and endocytosis/phagocytosis of pathogens. They 
also act as sensors to recognize pathogen associated molecular patterns (PAMPs) 
and induce a pro-inflammatory cascade which leads to many anti-microbial 
effector responses (Gordon et al., 2002). PRRs include toll-like receptors (TLRs), 
C-type lectin receptors (CLRs), and scavenger receptors (SRs). 
(4) Cytokine receptors – 
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The receptor-ligand (cytokine) interactions mediate a variety of cellular activities 
such as growth and differentiation, proliferation, migration, activation and 
anti-microbial effector responses (Miyajima et al., 1992). 
(5) Chemokine receptors – 
Following interaction with their specific ligands (chemokines), these receptors 
trigger a process known as chemotaxis that traffics the cell to a desired location 
within the organism (Mantovani et al., 2004).  
(6) Cell adhesion molecules – 
These molecules involve in cell-cell interaction (NK/T/B cell activation), 
cell-matrix interaction, and leukocyte trafficking 
(7) Molecules involved in antigen presentation – 
These consists of MHC class I and II molecules and costimulatory molecules. 
Some surface markers have been adopted for phenotypic purpose due to their unique 
expressions on distinct cellular subsets (Gordon and Taylor, 2005). For example, 
F4/80 is the best known phenotypic marker for mouse tissue MØs (Austyn and 
Gordon, 1981). However, EGF-like module-containing mucin-like hormone 
receptor-like 1 (EMR1), the human homolog of F4/80, is an eosinophil-specific 
marker, not for human MØs (Hamann et al., 2007) and mouse F4/80 is not so specific 
to human MØs. Instead, CD14, a co-receptor for LPS, has long been used as a 
surrogate marker for human monocyte/MØs, though CD14dim monocyte subset has 
been characterised recently (Ziegler-Heitbrock et al., 1993). In mice, DCs are 
traditionally defined as CD11chighMHCII+ cells (Metlay et al., 1990), however, CD11c 
expression is also noted on activated monocytes/MØs, NK cells and other 
granulocytes, arguing its specificity for DC recognition. 
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Table 1.3  Summary of select surface receptors and molecules on mononuclear 
phagocytes in mice and humans 
Fc receptor 
   FcγRI (CD64), FcγRII (CD32), FcγRIII (CD16), FcγRIV*, FcɛRI, FcɛRII (CD23) 
Complement receptors 
   CR1 (CD35), CR3 (Mac-1, CD11b/CD18), CR4 (gp150/95, CD11c/CD18) 
Pattern recognition receptors 
   Toll-like receptors: TLR-1, TLR-2, TLR-4 (with CD14 as co-receptor for LPS-binding protein), 
TLR-5, TLR-6, TLR-10, TLR-11*,TLR-12* 
   C-type lectin receptors: DC-SIGN (CD209), Langerin (CD207), MGL (CD301, CLEC10A), 
                      MDL1 (CLEC5A), Dectin-1 (CLEC7A), MICL (DCAL2, CLEC12A), 
                      DNGR1 (CLEC9A), DCIR (CLEC4A), DCAR (CLEC4B), BDCA-2  
(CD303, CLEC4C) #, Mincle (CLEC4E), Dectin-2 (CLEC6A), 
Mannose receptor (CD206), DEC205 (LY75, CD205),  
Thrombomodulin (CD141, BDCA-3)#  
   Scavenger receptors: SR-AI/II, MARCO, CD36, SR-BI, CD68 (Macrosialin), CD163, LOX-1 
Cytokine receptors 
   IL-2R, IL-3R, IL-4R, IL-6R, IL-7R, IL-10R, IL-13R, IL-16R, IL-17R, IL-23R, leptin receptor, 
HGF receptor, TNF-αR, TGF-βR, IFN-α, β, γ receptors, M-CSFR (c-fms, CSF1R, CD115),  
GM-CSF (CSF2R, CD116) 
Chemokine receptors 
   CCR1, CCR2, CCR5, CCR8, CCR9, CXCR1, CXCR2, CXCR4, CX3CR1 
Cell adhesion molecules 
   L-selectin (CD62L), ICAM-1 (CD54), LFA-1 (CD11a/CD18), VLA-4 (CD49d/CD29) 
Molecules involved in antigen presentation 
   MHC class I, MHC class II, CD1 family (a/b/c/d/e, CD1c = BDCA-1)#, CD40, CD80, CD86 
Surface antigens important for monocyte/MØ subset identification 
   EGF-TM7 family (F4/80 or EMR1), Ly-6 family (Ly-6B or 7/4 antigen, Ly-6C) * 
Others  
   hormone receptors (binding to insulin, glucocorticoids), fibronectin receptors, laminin receptors, 
transferrin and lactoferrin receptors, advanced glycation endproduct (AGE) receptors, 
lipoprotein lipid receptors, receptors for peptides and small molecules (i.e., 1,2,5-Dihydroxy 
vitamin D3) and receptors for coagulants/anti-coagulants (i.e., fibrinogen/fibrin, 
α1-antithrombin, heparin) 
* Receptors/molecules only expressed in mice 
# Receptors/molecules only expressed in humans 
(modified from Ross JA and Auger MJ. The biology of the macrophage. In Burke B, Lewis CE: The 
Macrophage. 2nd edition, p12, 2002, Oxford University Press) 
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1.4.4  Functional specialisation 
 
To date, diverse functional properties of mononuclear phagocytes have been 
elucidated. From a simplified viewpoint, MØs are the powerful phagocytes efficiently 
engulfing and killing the encountered microorganisms, while DCs are the professional 
antigen-presenting cells which could activate naïve T lymphocytes to initiate the 
adaptive immune response. However, it should be noted that these two cell types do 
share lots of biological functions, which could be explained by their phenotypic 
similarity as well as plasticity (Geissmann et al., 2010). Below are the principal 
functions of MØ and DC: 
(1) Phagocytosis and killing of microorganisms 
The phagocytic and microbicidal activities begin with the recognition and 
opsonisation of the pathogens. The opsonins (IgG or C3 fragments) coated on the 
organisms bind to the related Fc receptors or complement receptors on MØs, 
initiating the subsequent microbicidal activity such as release of reactive oxygen 
intermediates (respiratory burst) and arachidonic acid metabolites (Rouzer et al., 
1980). On the other hand, particle ingestion is followed by the fusion of the 
phagosomes (containing ingested materials) with primary lysosomes (containing a 
variety of enzymes), forming secondary lysosomes or phagolysosomes necessary 
for the degradation of ingested pathogens (Myers et al., 1985).  
(2) Apoptotic cell clearance 
In many tissues, apoptosis of cells is an integral component of cell turnover. 
Proper clearance of apoptotic cells ensures tissue homeostasis being maintained 
appropriately in multicellular organisms. The process of apoptotic cell clearance is 
complex, generally involving several steps: sensing and recognition of the 
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apoptotic cells, engulfment and degradation (Poon et al., 2014). Unlike microbial 
phagocytosis, the phagocytosis of apoptotic cells is typically considered 
nonphlogistic. The defects in this process are thought to be the aetiology of a 
variety of diseases, such as autoimmune diseases, cancers (Elliott et al., 2010).     
(3) Antigen processing and presentation 
Antigen processing and presentation is a fundamental step to bridging innate and 
adaptive immunity. Most endogenous antigens are degraded by non-lysosomal 
proteolytic mechanisms. The processed peptides are associated with MHC class I 
molecules in endoplasmic reticulum (ER), transported to cell surfaces and 
presented to CD8+ T cells (Nuchtern et al., 1989). For exogenous proteins, the 
ingested antigens are degraded in endosomes (containing protease) and the 
processed peptides are transported into ER, associated with MHC class II 
molecules and presented on to CD4+ T cells (Cresswell et al., 1985). A third route 
called “cross-presentation”, in which APCs (especially DCs) uptake, process and 
present extracellular antigens with MHC class I molecules to CD8+ T cells, is 
important for induction of cytotoxic immunity against most tumours and against 
viruses that do not readily infect APCs (Heath et al., 2001; Joffre et al., 2012). 
Recent evidence shows that distinct DC subsets exhibit preferential antigen 
processing and presentation in vivo (Dudziak et al., 2007; Merad et al., 2013). 
Furthermore, MØ/DCs play important roles in mediating tissue inflammation through 
producing distinct inflammatory cytokine profiles to drive specific T cell polarisation 
(i.e., IL-12 for Th1; TGF-β/IL-6/IL-23 for Th17) (Damsker et al., 2010). Additionally, 
distinct MØ subsets have been postulated to participate in the resolution of tissue 
inflammation or tissue repair/wound healing process (Lucas et al., 2010; Duffield et 
al., 2013) 
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1.4.5  Macrophage activation and polarisation  
 
MØ activation or polarization has been a key area of immunological research in the 
past two decades, starting from in vitro experimental conditions then gradually 
translating into human diseases (Mantovani et al., 2005; Mosser et al., 2008; Gordon 
et al., 2010; Wynn et al., 2012; Martinez et al., 2014). MØs, as a frontline immune 
effector cells, display remarkable plasticity and can generate a diverse response to 
environmental signals or exogenous agents, as well as interact with different 
lymphocyte subsets (Stout et al., 2005; Biswas et al., 2010). In the early 1990s, the 
distinctive ‘alternative activation’ was described for the effect of interleukin-4 (IL-4) 
or interleukin-13 (IL-13) on MØs, compared to the interferon γ (IFN-γ) and/or 
lipopolysaccharide (LPS)- induced ‘classical activation’ (Stein et al., 1992; Doyle et 
al., 1994). Later on, Mills proposed the ‘M1/M2 dichotomy’, suggesting an intrinsic 
transition from pro-inflammatory M1 to wound-healing M2-MØs (Mills et al., 2000). 
Subsequent works by others have further extended this paradigm into a spectrum 
including further subdivisions, namely M1 (IFN-γ ± LPS), M2a (IL-4 or IL-13), M2b 
(immune complex), M2c (IL-10 or glucocorticoid ± TGF-β) (Stout et al., 2005; 
Mantovani et al., 2005; Edwards et al., 2006; Biswas et al., 2010; Martinez et al., 
2014). However, a lot of challenges have been faced when attempting to reconcile the 
biological properties and expression patterns derived from in vitro activated/polarized 
MØs with data from in vivo MØ activation/polarization. The main problems included 
the non-unified definitions, non-standardised experimental protocols and inconsistent 
biochemical or genetic markers used for characterization (Murray et al., 2014). The 
fact that M1 and M2 stimuli do not exist alone in tissues imply that the real situation 
of MØ activation/polarisation in vivo (mouse models or human diseases) could be far 
more complicated than the proposed scheme (Xue et al., 2014; Lavin et al., 2014). 
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1.5 Macrophages and dendritic cells in the peritoneal cavity 
 
1.5.1  Leukocyte composition in human peritoneal cavity 
 
The leukocyte composition in human peritoneal cavity was first described as early as 
1960s, when the cytologic examinations of pelvic cavity by peritoneal washings or 
aspiration through cul-de-sac were performed in women with benign and malignant 
diseases (Marcus 1962, McGowan et al., 1967 & 1969). Soon after the launch of PD 
therapy in 1970s, the peritoneal leukocyte biology became an important research topic 
in the PD field. Initially, researchers tried to identify different leukocyte 
subpopulations from the PD effluents and to determine how the dialysis process 
altered their distributions (Fakhri et al., 1978; Ganguly et al., 1980; Cichocki et al., 
1983; Goldstein et al., 1984). It has been revealed that the leukocyte populations 
within the PD effluents mainly consist of MØs, granulocytes (neutrophils and 
eosinophils) and lymphocytes (McGregor et al., 1989; Valle et al., 1989; Lewis et al., 
1991). Here, the characteristic features of each peritoneal immune cell type from PD 
effluents are depicted, except for MØs (detailed in the next section). 
Neutrophils 
When uninfected, the percentage of peritoneal neutrophils normally decreases to less 
than 5% of total peritoneal leukocytes after dialysis intervention for more than six 
months (McGregor et al., 1989). Upon acute peritonitis episodes, a substantial number 
of neutrophils rapidly accumulate in the peritoneal cavity and become the major 
effector immune cells executing the microbicidal activity (Hurst et al., 2002; Davey et 
al., 2011). In patients with good treatment response, neutrophils plummet back to 
normal status 5-7 days after antibiotics prescribed (Flanigan et al., 1985).  
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Eosinophils 
Increased peritoneal eosinophils in the PD effluents were initially noted in patients 
complicating with ‘sterile peritonitis’ (Lee et al., 1967). In most reported cases, 
‘peritoneal fluid eosinophilia’ appears to occur very soon after catheter insertion and 
initiation of PD (Gokal et al., 1981; Humayun et al., 1981), is relatively asymptomatic 
and does not require antibiotic therapy. It has been suggested that peritoneal fluid 
eosinophilia is related to intraperitoneal air (Daugirdas et al., 1987) or allergy to some 
constituents of the PD system, i.e., catheter tubing (Ejaz et al., 1998). Mostly, 
eosinophil counts spontaneously decrease to low level (<5%) after continued dialysis. 
However, recurrent eosinophilia did occur in some cases (Quinlan et al., 2010). 
 
Lymphocytes 
The majority of peritoneal lymphocytes within the PD effluents are T cells (Lewis et 
al., 1993). Recently, the differential role of T cell subsets such as T helper cells, 
cytotoxic T cells and γδ-T cells, during peritonitis have been explored (Wang et al., 
2003; Eberl et al., 2009; Roberts et al., 2010; Davey et al., 2011). Of note, 
PD-associated peritonitis is characterized with increased TNF-α, IL-1β, IL-12 and 
IL-18, followed by IFN-γ production, suggesting a predominant Th1-response (Wang 
et al., 2005). Furthermore, a progressive decrease of CD4/CD8 T cell ratio in serial 
PD effluents from peritonitis patients correlated with a persistent expression of TGF-β, 
linking to the deterioration of peritoneal membrane function (Wang et al., 2003). 
More recently, the role of γδ-T cell in the drive of inflammatory responses during 
acute peritonitis was noted (Eberl et al., 2009; Davey et al., 2011) and importantly, the 
increased frequency of peritoneal γδ-T cells on day 1 peritonitis is associated with 
poor outcomes in peritonitis patients (Davey et al., 2011; Lin et al., 2013). 
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1.5.2  The role of peritoneal macrophage in PD patients  
 
It has been revealed that MØs are the major cellular constituent within the uninfected 
PD effluents from maintenance PD patients (Fakhri et al., 1978; Ganguly et al., 1980). 
Due to its accessibility, PD fluids provide a major source of human peritoneal MØs, 
which has enabled the broad study of its immunobiology, including cytochemical 
(peroxidase, nonspecific esterase activity), biochemical (arachidonate metabolism) 
and functional properties (phagocytosis, hydrogen peroxidase generation and 
bactericidal activity) (Maddox et al., 1984; Goldstein et al., 1984; Adolfs et al., 1985; 
Peterson et al., 1985).  
Several groups investigated on the functional profiles of peritoneal MØs from 
uninfected PD effluents and also from healthy volunteers (mainly women receiving 
laparoscopic examination) (Goldstein et al., 1984; Peterson et al., 1985). They 
identified that these two cell types had similar capability of bacterial phagocytosis 
(Goldstein et al., 1984), however, peritoneal MØs from uninfected PD effluents posed 
superior respiratory burst response and intracellular bacterial killing than those from 
healthy volunteers (Peterson et al., 1985). Subsequently, it has been demonstrated that 
conventional glucose-based dialysates might have suppressive effect on the 
phagocytosis and respiratory burst activity of peritoneal MØs (Alobaidi et al., 1986; 
McGregor et al., 1987). In fact, this suppressive effect could be due to low pH, high 
osmolarity, high glucose concentration, and high sodium lactate in the conventional 
PD fluids (Alobaidi et al., 1986; Topley et al., 1988) or poor opsonizing activity (low 
IgG, complement and fibronectin) in the dialysates (Davies et al., 1990). Evidences 
also showed that the phagocytosis index, bactericidal activity, and TNF-α/IL-1β/IFN-γ 
production of peritoneal MØs were progressively decreased during the course of PD 
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therapy (Lin et al., 1990; McGregor et al., 1996), suggesting that long-term usage of 
conventional dialysates would compromise the host defence system in PD patients. 
Additionally, patients with history of peritonitis had significantly suppressed MØ 
function under uninfected status, compared to those free from peritonitis. Moreover, 
patients with ‘low occurrence of peritonitis’ had better peritoneal MØ function than 
those with ‘high occurrence of peritonitis’ (Lin et al., 1990).  
In 1990s, several new ‘biocompatible’ PD fluids were developed and were examined 
whether ‘new dialysis fluids’ are better than conventional fluids in terms of 
maintaining the peritoneal immunocompetence (Jörres et al., 1993; de Fijter et al., 
1993; Schenk et al., 1994; MacKenzie et al., 1998 & 2000, Jones et al., 2002). 
Notably, it has been shown in vitro as well as in vivo that new pH neutral, 
bicarbonate-buffered or bicarbonate/lactate-buffered PD solutions might provide 
better preservation of peritoneal MØ immune effector functions than conventional 
acidic, lactate-buffered solutions (MacKenzie et al., 1998 & 2000; Jones et al., 2002). 
In 1990s, researchers began to look at the immunophenotypes and activation status of 
peritoneal MØs in PD patients. Benefits from the application of contemporary flow 
cytometers in biomedical research, a variety of surface markers expressed on 
peritoneal MØs could be examined and differential expression patterns could be 
analysed from various clinical settings. The initial work revealed that peritoneal MØs 
from PD effluents expressed higher HLA-DR, RFD7 (mature phagocyte marker), 
IL-2R and surface IgG levels, compared to peripheral blood monocytes, suggesting 
peritoneal MØs have features of maturation and activation (Davies et al., 1989). 
Others reported that increased Fc and C5a receptor and CD14 expression (Lewis et al., 
1990) as well as transferrin receptors on peritoneal MØs (Moughal et al., 1991). 
During PD-related peritonitis, peritoneal MØs expressed higher ICAM-1 (CD54), Fc 
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gamma RI (CD64), Fc gamma RII (CDw32), Fc gamma RIII (CD16), transferrin 
receptors (CD71) and tissue factor, while lower levels of complement receptors such 
as CR1 (CD35), CR3 (CD11b/CD18), compared to blood monocytes (Hart et al., 
1992). On the other hand, longitudinal follow-up studies demonstrated that peritoneal 
MØs became increasingly immature with time on PD, represented by decreasing 
expression levels of CD11b, CD11c, CD14, CD16, CD64 (McGregor et al., 1996; 
Cárcamo et al., 1996). These findings highlighted the phenotypic plasticity of 
peritoneal MØs during the treatment course of PD and the status of MØ activation and 
maturation in the particular clinical scenario might reflect how tissue MØs respond to 
the local environmental changes.  
Recently, it has been suggested that peritoneal MØs from uninfected PD patients had 
features of M2 type MØs (in vitro polarised M-CSF–driven MØs), represented by 
positive CD163 expression but lack of CD16 expression. Functionally, like M2-MØs, 
they preferentially took up early apoptotic cells and could generate large amounts of 
IL-10 after LPS stimulation (Xu et al., 2007). However, there is some argument 
regarding M-CSF-driven M2-MØs (Murray et al., 2014). Another recent study 
showed that peritoneal MØs were phenotypically similar to IL-4–driven alternatively 
activated MØs (or pro-fibrotic M2-MØs), as they expressed surface markers such as 
CD206 and CD163. Of note, mRNA levels of TGF-β, MMP9 and CCL18 in 
peritoneal MØs were close to M2-MØs, and high dialysate CCL18 level was 
correlated with decreased peritoneal membrane function (high D/P Cre and poor 
ultrafiltration capacity), implying that peritoneal MØs might participate in the 
pathogenesis of peritoneal fibrosis (Bellon et al., 2009). 
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1.5.3  The role of peritoneal dendritic cells in PD patients 
 
In contrast to peritoneal MØs, the phenotypic and functional identity of dendritic cells 
in human peritoneal cavity is much less characterized. Traditionally, DCs are 
characterized by high MHCII expression, dendritic morphology and superior ability to 
induce a strong allogeneic T cell proliferation (mixed lymphocyte reaction). However, 
these features could be easily confused with MØs in the same tissue compartment. A 
serial of studies from Betjes and colleagues reported that distinctive intracellular 
staining patterns of CD68 could discriminate peritoneal DCs (‘juxtanuclear spot-like 
staining’) from peritoneal MØs (‘pan-cytoplasmic staining’) (Betjes et al., 1991 & 
1993). These newly identified DCs were superior APCs for allo-antigen, Candida 
albicans antigen or purified protein derivative (PPD) (Betjes et al., 1993). 
Subsequently, McCully and colleagues published another peritoneal DC population 
from uninfected PD effluents with characteristic CD14+CD4+ phenotype, arguing they 
were one of DC precursor subsets (McCully et al., 2005). They suggested that CD14+ 
monocytes could differentiate into CD14+CD4+ pre-DCs or CD14+CD4‒ MØs in the 
peritoneal cavity, and the former were more potent allo-stimulators than the latter. 
Interestingly, both Betjes et al., and McCully et al., observed the increased 
accumulation of peritoneal DC number during acute PD-related peritonitis, however, 
what they called ‘peritoneal DC’ may not be the same cell entity. These limited data 
point out that the immunobiology (particularly immunophenotype) of peritoneal DC 
in the context of PD remains unclear and its role in the human peritoneal pathologies 
such as peritonitis and peritoneal fibrosis needs to be further investigated.  
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1.5.4  Mononuclear phagocytes in mouse peritoneal cavity 
 
Murine peritoneal MØs are one of the best-studied non-lymphoid tissue MØs (Whitby 
et al., 1959; Jenkin et al., 1960). Substantial works done by Cohn and colleagues in 
1960s unveiled the unique monocyte-like peritoneal mononuclear phagocytes from 
either unstimulated animals or LPS-stimulated animals (Cohn et al., 1965). 
Importantly, they set up an in vitro culture system to comprehensively investigate the 
morphologic and biochemical changes during the differentiation process of peritoneal 
mononuclear phagocytes (Cohn et al., 1966). However, it should be kept in mind that 
these peritoneal mononuclear phagocytes are a mixed population. The tremendous 
breakthrough in murine tissue MØ biology is the discovery of F4/80 antigen as a 
marker for mature tissue MØs (Austyn and Gordon, 1981). This antigen is a G protein 
-coupled receptor (GPCR), a member of the epidermal growth factor-seven-pass 
transmembrane (EGF-TM7) family, which also includes EMR1 (human F4/80 
homolog) (McKnight et al., 1998). Using the application of anti-F4/80 monoclonal 
antibody has enabled the identification of resident MØ populations in the wide range 
of mouse tissues/organs such as kidney, liver, lung, endocrine organs, bone, red pulp 
of spleen and brain (Hume et al., 1983; Perry et al., 1985; Gordon et al., 1986).  
In the naïve peritoneal cavity, our group has shown via flow-cytometric analysis that 
two resident monocytic-like subsets coexist; the major population is F4/80high cells 
with CD11bhigh and MHCIIlow/‒ phenotype, while the minor subset is F4/80int-low cells 
with CD11b+ and MHCIIhigh phenotype (Rosas et al., 2007; Dioszeghy et al., 2008). 
The former was the classical ‘resident MØs’ whereas the latter was tentatively called 
‘DC-like’ cells as their superior ability of processing and presenting antigen 
(ovalbumin) and stimulating naïve T cell proliferation and IL-2 production 
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(Dioszeghy et al., 2008). However, these ‘DC-like’ cells seemed to be a 
heterogeneous population according to their non-uniform expression of CD11c 
(traditional DC marker). Additionally, our group was unable to discriminate “DC-like” 
cells from recruited monocyte-derived MØs during experimental peritonitis, due to 
the overlapping immunophenotypes (F4/80int-lowMHCIIhigh). Soon after this paper 
published, another group also identified two MØ subsets in naïve peritoneal cavity: 
‘large MØs’ (phenotypically identical to F4/80highMHCIIlow/‒ resident MØs) and 
‘small MØs’ with F4/80int-lowMHCIIhigh phenotype (Ghosn et al., 2010). Notably, these 
‘small MØs’ were gated after the exclusion of CD11c+MHCIIhigh cells (called “DCs” 
here). Functionally, ‘large MØs’ and ‘small MØs’ exerted differential nitric oxide (NO) 
production in response to LPS stimulation in vitro and in vivo. The group also 
suggested ‘small MØs’, which predominated in the peritoneal cavity after LPS or 
thioglycollate stimulation, were basically from circulating Ly-6C+ monocytes, not 
from ‘large MØs’, although there was no direct evidence supporting this statement. 
More recently, the transcriptional profiling of distinct murine tissue MØs published as 
part of Immunological Genome Project (ImmGen) provided substantial information 
regarding the molecular signatures of murine tissue MØ subsets such as splenic red 
pulp MØs, lung MØs, peritoneal MØs and microglia (Gautier et al., 2012). On the 
basis of identified 39 ‘core-MØ genes’, all peritoneal mononuclear phagocyte subsets, 
either from the steady state (F4/80highMHCIIlow/‒ and F4/80lowMHCIIhigh) or from day 
5 after thioglycollate stimulation (MHCII+ and MHCII‒), segregated together within 
the ‘MØ entity’, and none of them was close to the ‘DC entity’. Hence, the identity of 
peritoneal DC subsets in mice remains ambiguous, both at steady-state and during 
inflammation, and their exact role needs to be further elucidated (Gautier et al., 2012). 
Table 1.4 summaries the phenotypes of peritoneal MØ/DC subsets described in the 
literature (Dioszeghy et al., 2008; Ghosn et al., 2010; Gautier et al., 2012). 
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Table 1.4  Phenotypic definition of peritoneal mononuclear phagocyte subsets 
(steady state and inflamed state) used in the current literature 
 Dioszeghy et al (2008) Ghosn et al (2010) Gautier et al (2012) 
Steady state F4/80highMHCIIlow/‒ 
‘resident’ MØs 
CD11bhighF4/80highMHCIIlow/‒ 
‘large MØs’ 
F4/80highMHCIIlow/‒ 
MØs 
 
F4/80int/lowMHCII+ 
‘DC-like’ cells 
CD11b+F4/80+MHCII+ 
‘small MØs’ 
F4/80lowMHCII+ 
MØs 
 CD11bint/lowCD11c+MHCII+ 
classical DCs 
Inflamed state F4/80highMHCIIlow/‒ 
resident MØs 
CD11bhighF4/80highMHCIIlow/‒ 
‘large MØs’ 
F4/80highMHCIIlow/‒ 
MØs 
 F4/80int/lowMHCII+/‒ 
‘inflammatory’ MØ/DCs 
CD11b+F4/80+MHCII+/‒ 
‘Inflammatory’ MØs 
F4/80intMHCII+/‒ 
MØs 
  
 
(unable to discriminate 
between MØs and DCs) 
 
 
(unclear identity of DCs  
during inflammation) 
F4/80lowMHCII+ 
MØs 
(unclear identity of DCs  
during inflammation) 
Experimental peritonitis models used in each paper as follow: 
- Dioszeghy et al (2008): staphylococcus epidermidis supernatant-induced peritonitis (day 3) 
- Ghosn et al (2010): LPS-induced peritonitis (9 hours and day 2);  
thioglycollate-induced peritonitis (day 1 and day 4) 
- Gautier et al (2012): thioglycollate-induced peritonitis (day 5);  
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1.6  Scope of the thesis 
 
Despite general acceptance that the mononuclear phagocytes play key roles in tissue 
homeostasis and defence against pathogens, the immunobiology of this heterogeneous 
population in the peritoneal cavity remains poorly elucidated. In the context of PD, 
peritonitis and peritoneal fibrosis due to repeated infections remain major reasons for 
mortality and morbidity. It is hypothesized that the modification of MØ/DC biology 
by the dialysis process alters tissue homeostasis, host susceptibility to infection and 
local immunity, thus compromising long-term patient outcomes. The key objectives of 
the present study are to characterize human peritoneal MØ/DC, to investigate how 
these cells are modified by the dialysis treatment, and to delineate the specific roles of 
different MØ/DC subsets in peritoneal immunity, using clinically relevant mouse 
models. 
 
The specific aims of each chapter in this thesis are as follows:  
Chapter 3: To characterize the immunophenotypes and functional properties of 
peritoneal MØ/DC subsets in PD patients 
Chapter 4: To assess the cellular distribution/kinetics and phenotypic alterations of 
peritoneal MØ/DC subsets during the course of PD therapy, and examine 
their correlations with clinical outcomes 
Chapter 5: To identify the corresponding subsets between humans and mice, in order 
to clarify the differential roles of the respective MØ/DC subsets in the 
development of peritoneal immunity 
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Chapter Two 
 
Materials and methods 
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2.1  Human study 
 
2.1.1  Ethical approval 
 
This study was approved by the South East Wales Local Ethics Committee (COREC: 
04WSE04/27). All patients gave written, informed consent for the collection of PD 
fluids and peripheral bloods before the enrolment. The study was undertaken 
according to principles described in the Declaration of Helsinki and under the local 
ethic guidelines (Bro Taf Health Authority, Wales). 
 
2.1.2  Study populations 
 
Patients were recruited from the PD unit at University Hospital of Wales in Cardiff, 
United Kingdom between October 2010 and December 2014 and categorized into 
three cohorts defined by the clinical status of the patients at the time of enrollment. 
The definition of each patient category and the respective plan of PD fluids sampling 
are described below and summarised in Fig. 2.1: 
New starters 
Patients with end-stage renal disease (ESRD) who had chosen PD as renal 
replacement therapy (RRT) were recruited. These patients were followed from the 
time when PD catheter was surgically inserted to 1 year after PD treatment or until the 
discontinuation of dialysis due to any reason. Typically 1 week after catheter surgery 
the catheter was flushed (“1st Flush”) to check its patency. The catheter was checked 
again approximately 1 week before the start of dialysis (“2nd Flush”). The timing of 
the “2nd Flush” varied, but normally occurred after 3 weeks. When PD commenced, 
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an initial ‘training bag’ is used (“1st PD exchange-PD start”). Thereafter, PD effluent 
samples were collected at 3 months, 6 months and 1year after the start of PD therapy. 
A total of 50 new-starter PD patients were enrolled in this project. The reasons for 
discontinuation of PD therapy such as deaths, non-death technique failure (i.e., 
catheter dysfunction, ultrafiltration failure, peritonitis), kidney transplantation or 
transfer to other institutes were recorded. 
Stable patients  
Patients under maintenance PD therapy for more than one year with or without history 
of peritonitis were recruited. These patients were free from peritonitis for at least three 
months at the time of PD fluid sampling. A total of 37 uninfected PD effluent samples 
were collected from 37 stable patients in this project.  
Peritonitis patients 
Dialysis patients presenting with acute PD-related peritonitis were recruited. The 
diagnosis of acute peritonitis was based on the presence of abdominal pain and cloudy 
peritoneal effluent with >100 WBC/mm3 (Li et al., 2010). The day of the first 
appearance of cloudy effluent was defined as “day 1 peritonitis”. In this study, only 
PD effluents from day 1 peritonitis were collected for analysis. A total of 42 
peritonitis episodes from 37 patients (5 patients having two episodes of peritonitis) 
were analysed. Of them, 37 episodes were ‘culture-positive’ peritonitis with 
documented causative organisms and 5 episodes were ‘culture-negative’ peritonitis as 
no bacterial growth from cultures. The treatment of PD-related peritonitis followed 
the most updated ISPD Guidelines/Recommendations (Li et al., 2010). The outcome 
of each peritonitis episode was categorised into ‘treatment success’ or ‘treatment 
failure’ (defined as peritonitis-related mortality or technique failure). 
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Figure 2.1  PD patient recruitment and the timescale of PD fluid sampling 
Schematic plans of the recruitment of three categorised PD patients in this study. For 
new-starter PD patients (group 1), PD fluid samples were collected at specified time 
points during the course of PD therapy. For stable patients (group 2), non-infected 
overnight PD fluid samples were collected from patients under regular PD for at least 
1 year (free from peritonitis for at least 3 months). For peritonitis patients (group 3), 
PD fluid samples from day 1 peritonitis were collected.  
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2.1.3  Isolation of human peritoneal cells from PD effluent fluids 
 
PD effluent bags were collected from consented PD patients either at clinic or at the 
patients’ homes. Samples were kept in an ice box during transport to reduce cell 
adhesion to the PD bags and maintain cell quality. The dwell time and the type of 
dialysate of each collected PD bag were recorded. In the laboratory, the total volume 
of each PD effluent bag was measured, drained fluids were aliquoted into 500 ml 
centrifuge tube (Corning Inc., New York, USA) and centrifuged at 2000 rpm (863 g) 
at 4°C for 25 minutes (Sorvall Legend RT). The cell pellet was resuspended in 50 ml 
phosphate buffered saline (PBS) (Invitrogen), transferred to 50 ml Falcon tubes, and 
centrifuged at 1300 rpm (365 g) at 4°C for 8 minutes. The pellet was resuspended in 
PBS at 1-2×107 cells/ml, kept on ice prior to use. 
 
2.1.4  Isolation of human mononuclear cells from peripheral bloods of PD 
patients and healthy individuals 
 
Total 5-10 ml venous bloods were withdrawn from new-starter PD patients (at the 
time of ‘1st PD flush’) as well as healthy volunteers and collected in conventional 
EDTA tubes. PBMC were isolated by layering whole blood over 10-15 ml of 
LymphprepTM containing sodium diatrizoate 9.1% (w/v) and polysaccharide 5.7% 
(w/v) (Axis-Shield) and centrifuged at 1680 rpm (609 g), at 18°C for 20 minutes with 
minimal acceleration and deceleration. Granulocytes and erythrocytes have a higher 
density and sediment through the Lymphoprep™ layer during centrifugation. 
Mononuclear cells remained at the plasma:Lymphoprep™ interface and were 
aspirated to a 50 ml Falcon tube. After washing with PBS twice, the cell pellet was 
resuspended in PBS (~107/ml) and kept on ice prior to use. 
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2.1.5  Cell counting 
 
Cells were counted with a dual chamber Neubauer haemocytometer. The cells in four 
large squares at corners were counted and the number was divided by 4 to gain an 
average number of cells in 0.0001 cm3. This cell number was multiplied by 104 to 
give the number of cells per ml (1 cm3). Therefore, in each PD effluent sample: 
Total peritoneal cell counts = number of cells per ml x total volume of the bag (ml) 
 
2.1.6  Flow cytometry 
 
2.1.6.1  General staining procedures 
 
The isolated cells were stained with LIVE/DEAD Fixable Aqua Stain kit (Life 
technologies) for 15 minutes at room temperature in the dark. After washing with 
FACS wash buffer (0.5% w/v BSA, 5 mM EDTA, 2 mM NaN3 in PBS), the cells were 
aliquoted to a v-bottom 96-well plate (1-1.5 x106 cells in 100 µl per well) and blocked 
for 15 minutes with normal mouse serum (1 % v/v) to prevent non-specific binding, 
before the addition of a variety of anti-human monoclonal antibodies; together with 
appropriate isotype controls (Table 2.1). The antibody mixtures were incubated for 30 
minutes on ice in the dark. If a biotin-conjugated antibody was used, then the cells 
were washed with FACS wash buffer and stained with a streptavidin conjugated with 
PerCP, APC or Alexa-Fluor 405 (BD Biosciences) for another 30 minutes. The cells 
were washed three times with FACS wash buffer and transfer into microtitre tubes. 
Finally, the samples were acquired on a 3-laser, 9-colour Cyan ADP flow cytometer, 
and data analyzed with Summit software (Beckman-Coulter, Fullerton, CA, USA).  
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Table 2.1. Fluorochrome-conjugated anti-human monoclonal antibodies for 
surface antigen staining in this project 
Antigen Fluorochrome Clone Isotype Company 
CD1a PerCP HI149 Mouse IgG1, k abcam 
CD1c Biotin or APC AD5-8E7 Mouse IgG2a, k Miltenyi Biotec 
CD3 FITC SK7 Mouse IgG1, k BD Biosciences 
CD4 APC-H7 SK3 Mouse IgG1, k BD Biosciences 
CD8 PE-Cy7 SK1 Mouse IgG1, k BD Biosciences 
CD11b V450 ICRF44 Mouse IgG1, k BD Biosciences 
CD11c V450 B-ly6 Mouse IgG1, k BD Biosciences 
CD14 ECD RMO52 Mouse IgG2a, k Beckman Coulter 
CD15 APC HI98 Mouse IgM, k BD Biosciences 
CD16 PE-Cy7 3GB Mouse IgG1, k BD Biosciences 
CD19 PerCP  HIB19 Mouse IgG1, k BD Biosciences 
CD36 APC 5-271 Mouse IgG2a, k BioLegend 
CD40 PE 5C3 Mouse IgG1, k BD Biosciences 
CD45 APC 2D1 Mouse IgG1, k eBioscience 
CD56 PE MY31 Mouse IgG1, k BD Biosciences 
CD62L V450 DREG-56 Mouse IgG1, k BD Biosciences 
CD64 APC 10.1 Mouse IgG1, k BioLegend 
CD66 PE B1.1 Mouse IgG2a, k BD Biosciences 
CD73 APC 606112 Mouse IgG2b, k R&D Systems 
CD80 PE 2D10 Mouse IgG1, k BioLegend 
CD83 PE HB15e Mouse IgG1, k BD Biosciences 
CD86 PE-Cy5 2331 Mouse IgG1, k BD Biosciences 
CD115 Biotin 12-3A3-1B10 Rat IgG1 eBioscience 
CD116 FITC 4H1 Mouse IgG1, k eBioscience 
CD141 APC AD5-14H12 Mouse IgG1, k Miltenyi Biotec 
CD163 Biotin GH1/61 Mouse IgG1, k BioLegend 
CD206 PE 3.29B1.10 Mouse IgG1, k Beckman Coulter 
CD209 PerCP 120507 Mouse IgG2b, k R&D Systems 
CD226 APC 11A8 Mouse IgG1, k BioLegend 
CD301 APC H037G3 Mouse IgG2a, k BioLegend 
CD303 APC AC144 Mouse IgG1, k Miltenyi Biotec 
CCR2 APC 48607 Mouse IgG2b, k R&D Systems 
CCR3 APC 5E 8 Mouse IgG2b, k BioLegend 
CCR7 PE 3D12 Rat IgG2a eBioscience 
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HLA-A2 APC BB7.2 Mouse IgG2b, k BD Biosciences 
HLA-DR APC-H7 L243 Mouse IgG2a, k BD Biosciences 
Dectin-1 PE 259931 Mouse IgG2b, k R&D Systems 
Dectin-2 Alexa-Fluor 647 IMG3D1 Mouse IgG3, k IMGENEX 
Siglec-8 PE 7C9 Mouse IgG1, k BioLegend 
Tim4 PE 9F4 Mouse IgG1, k BioLegend 
FceR1 APC AER-37 Mouse IgG2b, k eBioscience 
MerTK APC 125518 Mouse IgG1, k R&D Systems 
 
2.1.6.2  Standardisation, calibration and quality control of flow cytometry 
 
To ensure the data generated from flow cytometric analysis are as accurate and as 
reliable as possible, several steps have been undertaken: 
1. The performance of components of flow cytometer such as lasers, photomultiplier 
tubes (PMTs), optical filters and log and linear amplifiers is regularly checked by 
qualified service personnel. 
2. Internal quality control is implemented regularly (normally once a week) by our 
Centre Biotechnology Service (CBS) staffs. This includes routine calibration of 
the instrument’s response to fluorescence signals using reference microbeads 
(SPHEROTM Ultra Rainbow Fluorescent Particles, Spherotech Inc.) to determine 
that the performance parameters from each fluorescence channel are within the 
acceptable ranges.  
3. When running on flow cytometer, the concentration of the sample would normally 
keep in the ranges of 105-106 cells per 100 μl. The acquisition flow rate is 
maintained around 1000 to 3000 event per second. The total events acquired are 
normally at least 50,000 events per sample and increased when the rare cell 
populations (i.e., peritoneal DC subsets) needed to be identified. 
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2.1.7  Cell cycle analysis and proliferation assay 
 
After surface staining, human peritoneal cells were washed with FACS wash buffer, 
fixed in 1% formaldehyde (in PBS) for 20 minutes at room temperature in the dark 
and permeabilized with FACS wash buffer containing 0.5% (w/v) saponin (Sigma). 
Following fixation and permeabilisation, cells were stained with anti-human 
Ki-67-FITC (clone B56, BD Biosciences); together with isotype controls. The 
antibodies were left on ice for 1 hour in the dark. After washed three times with FACS 
wash buffer containing 0.5% (w/v) saponin, the cells were stained with DAPI solution 
(4',6-diamidino-2-phenylindole, a fluorescent stain that binds strongly to A-T rich 
regions in DNA; Life Technologies) on ice for 30 minutes in the dark. The samples 
were acquired on the Cyan ADP flow cytometer and analyzed as described above. 
 
2.1.8  Ex vivo microbial product stimulation and cytokine production assay 
 
Human peritoneal cells were washed three times with complete RPMI medium (RPMI 
1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 10 
U/ml penicillin and 10 μg/ml streptomycin). 2x105 cells in 100 μl complete RPMI 
medium were then aliquoted into 48 well flat-bottomed plates. For TNF-α, IL-1β, 
IL-6, IL-10 assay, 10% v/v SES (homemade, a cell free supernatant prepared from a 
clinical isolate of S. epidermidis, Hurst et al., 2001) or LPS (100 ng/ml final 
concentration; from Salmonella enterica serotype typhimurium, Sigma) was added in 
the presence of GolgiStop™ (2 μM final concentration; BD Bioscience) and 
incubated for 4 hours (TNF-α, IL-1β and IL-6) or 24 hours (IL-10) at 37 °C, 5% CO2. 
For IL-12p40/70 assay, cells were primed for 2 hours with recombinant human IFN-γ 
(10 ng/ml final concentration; PeproTech), then activated with IFN-γ (10 ng/ml final 
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concentration) and either SES (10% v/v) or LPS (100 ng/ml final concentration) in the 
presence of GolgiStop™ (2 μM final concentration; BD Bioscience) for an additional 
22 hours at 37 °C, 5% CO2. The cells were carefully recovered using plastic cell 
lifters, washed with PBS twice, blocked with normal mouse serum (1% v/v) and 
stained with surface anti-human antibodies. After that, the cells were fixed in 1% 
formaldehyde (in PBS) for 20 minutes in the dark, permeabilized with FACS wash 
buffer containing 0.5% (w/v) saponin (Sigma), and then stained with anti-human 
cytokine antibodies including anti-TNF-α-APC (clone: 6401.1111) from BD 
Biosciences, anti-IL-1β-APC (8516) from R&D Systems, anti-IL-6-APC (MQ2-13A5) 
from BD Biosciences, and anti-IL-12(p40/p70)-APC (C8.6) from Miltenyi Biotec; 
together with appropriate isotype controls. The antibodies were left on ice for 30 
minutes in the dark before washing the cells three times with FACS wash buffer. The 
samples were acquired on the Cyan ADP flow cytometer and data were analyzed as 
described above. 
 
2.1.9  Ex vivo phagocytosis and respiratory burst assay 
 
Human peritoneal cells were washed three times with complete RPMI medium. 
~5x105 cells in 100 μl complete RPMI medium were then aliquoted into 48 well 
flat-bottomed plates. 3’-(p-aminophenyl) fluorescein (APF), a fluorescent probe 
designed for the detection of free radicals such as hydroxyl radical (HO•), 
hypochlorite anion (–OCl), was freshly prepared in complete RPMI medium with the 
final concentration of 5μM. The cell pellets were resuspended either with 100μl 
complete RPMI medium containing APF (5μM) or with RPMI medium alone (as 
controls) and incubated for 30 minutes at 37 oC, 5% CO2 in the dark. Following APF 
staining, 100 μl Alexa-Fluor 405-conjugated zymosan particles (2x106 particles) or 
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7-Hydroxy-9H-(1,3-Dichloro-9,9-Dimethylacridin-2-One)(DDAO)-conjugated 
Staphylococcus epidermidis (~108 CFU) were added and incubated for 30 minutes at 
37 oC, 5% CO2 in the dark. Then the plates were placed on ice to stop the reaction. 
After washing with complete RPMI medium twice, the cell pellets were stained as 
described above (section 2.1.6.1). The samples were acquired on the Cyan ADP flow 
cytometer and data were analyzed as described above. 
 
2.1.10  Fluorescence-activated cell sorting of human peritoneal monocytic cells 
 
For cell sorting, the same staining protocol as shown in section 2.1.6.1 was 
undertaken except for using FACS wash buffer without NaN3. After final wash, the 
cells were resuspended to ~107 cells per ml in FACS wash buffer without NaN3 and 
transferred to 5 ml polystyrene round-bottom tubes (BD Falcon). The cells were 
sorted using FACSAria III according to the instruction. The cells were kept cold in 
the FACSAria III by using the inbuilt refrigeration system, and collected in 
pre-labeled 5 ml polypropylene tubes with pre-filled 0.5 ml FCS (Life Technologies) 
as cell cushion. After sorting, the isolated cell populations were checked for the purity 
by flow cytometry and immediately used in functional assays. 
 
2.1.11  Morphological analysis   
 
Cytospin preparations were made using ~104 purified cells, spun at 300 rpm for 5 
minutes (Cytospin 3, Shandon). Cytospun cells were air-dried, stained with 
Microscopy Hemacolour (Merck), visualized on a Leica DMLB microscope with 
DFC490 camera (Leica) and processed using QWin Software (Leica). 
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2.1.12  Antigen processing and presentation assay 
 
Stable PD patients were screened by flow cytometry for their HLA-A2 status 
(anti-HLA-A2-APC, clone: BB7.2, eBiosicences). Antigen cross-presentation assays 
were performed as previously described with modifications (Meuter et al., 2010). The 
purified peritoneal MØ or DC subsets were cultured in 96-well round-bottomed plates 
(5x104-2x105 cells/well). M1-specific CD8+ T cells were generated by stimulating 
PBMCs with 0.1 nM M1p58-66. Resting cells with >95% M1p58-66-specific cells 
were used for assays, as determined by PE-tetramer staining (made in-house, 
performed by Dr. Wajid Khan). Recombinant Influenza M1 protein (1 μM) was added 
to the APCs for 20 hours at 37°C, 5% CO2. APCs were washed extensively before 
co-culturing with responder T cells at a ratio of 1:1-2 (APCs: responder T cells). 
M1p58-66 peptide (0.1 μM) was added to the APCs for 1 hour at 37°C prior to 
co-cultured with responder T cells. Responder cells alone and with 10 µg/ml PMA 
and 1 µM ionomycin were used as negative and positive controls, respectively. The 
co-cultures were incubated for 5 hours at 37°C, 5% CO2 in the presence of 
Brefeldin-A (10 µg/ml; Sigma-Aldrich). In brief, the cells were then stained with 
LIVE/DEAD Fixable Aqua Stain kit (Life technologies), blocked for 15 minutes with 
normal human IgG (0.1 mg/ml, KIOVIG, Baxter) and then stained with surface 
antibodies for 30 minutes on ice. The cells were fixed and permeabilised (as above) 
for intracellular staining with anti-IFN-ɣ-FITC (B27, BD Biosciences) for 30 minutes 
on ice in the dark. The samples were acquired on either the FACSCanto II or CyAn 
ADP flow cytometers and analyzed with FlowJo (TreeStar) or Summit software. 
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2.2  Mouse study 
 
2.2.1  Animals 
 
Animals in this study were housed and maintained at Cardiff University. All 
experiments were aged and sex matched (mostly 6-12 week-old females), unless 
otherwise stated. C57BL/6 mice were obtained from Harlan Olac. C57BL/6.Il10–/–
were obtained from Jackson Laboratory. Ccr2–/– mice (B6.129S4-Ccr2tm1lfc/J, from 
Jackson Laboratory Stock: 004999) and C57BL/6.CD45.1 mice (from Jackson 
Laboratory) were bred from our own colonies. 129S6/SvEv and 129S6/SvEv.CD45.1 
(gift from Professor Fiona Powrie, Oxford University) congenic mouse strains were 
bred from our own colonies. All experiments were performed in accordance with 
institutional and United Kingdom Home Office guidelines under the project licenses 
30/2401 (2010-2012) and 30/2938 (2012-2014).  
 
2.2.2  Experimental peritonitis models 
 
Experimental peritonitis was induced by single intraperitoneal administration of 200 
μl of a cell free supernatant prepared from a clinical isolate of S. epidermidis (SES) 
(Hurst et al., 2001) or administration of zymosan particles (0.2-2x107, as indicated). 
Mice were sacrificed at scheduled time points, typically 4 hours or 72 hours after 
inflammatory insults. Total peritoneal cells were harvested by lavage using a 5 ml 
syringe (with 21 G hypodermic needle) containing 5 ml ice-cold 5mM EDTA in PBS. 
The recovered cells were collected in 15 ml labeled centrifuged tubes (Corning Inc., 
New York, USA), kept on ice await further experiments. 
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2.2.3  Adoptive transfer experiments 
 
9 to 11-week-old donor naïve 129S6/SvEv.CD45.1 congenic mice were humanely 
sacrificed and peritoneal cells were recovered by lavage with 1 ml ice-cold PBS. Cells 
were pooled from several donors and 400μl (1.8x106 cells) was immediately 
intraperitoneally injected into host 129S6/SvEv (CD45.2) mice. One day after 
adoptively transferred, mice were either injected with SES or were left unchallenged 
then sacrificed on day 3. Total peritoneal cells were harvested and analyzed by flow 
cytometry as indicated below. 
 
2.2.4  Flow cytometry 
 
Flow cytometry was performed broadly the same as for human cells. Murine 
peritoneal cells were incubated in blocking buffer (5% v/v heat-inactivated rabbit 
serum, 0.5% w/v BSA, 5 mM EDTA, 2 mM NaN3, 4 µg/ml rat anti-mouse 2.4G2 in 
PBS) for 30 minutes on ice. Fluorochrome-labeled or biotin-conjugated antibodies 
(Table 2.2) in FACS wash buffer (0.5% w/v BSA, 5 mM EDTA, 2 mM NaN3 in PBS) 
were added. After 30 minutes incubation on ice in the dark, the cells were washed 
three times with FACS wash buffer. When necessary, the cells were incubated for 
further 30 minutes on ice in the dark with fluorochrome-conjugated streptavidin. After 
final wash, the samples were acquired and analyzed as previously described.  
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Table 2.2. Fluorochrome-conjugated anti-mouse monoclonal antibodies used in 
this project 
Antigen Fluorochrome Clone Isotype Company 
F4/80 Biotin CI:A3-1 Rat IgG2b Homemade 
F4/80 PE-TxR BM8 Rat IgG2b Invitrogen 
CD11b FITC 5C6 Rat IgG2b Homemade 
CD11b APC-Cy7 M1/70 Rat IgG2b BioLegend 
CD11c PE-Cy7 HL3 Ar Hamster IgG1 BD Biosciences 
CD19 V450 1D3 Rat IgG2a BD Biosciences 
CD36 PE HM36 Armenian Hamster 
IgG 
BioLegend 
CD45.1 APC, A20 Mouse IgG2a eBiosciences 
CD45.2 APC-Cy7 104 Mouse IgG2a BioLegend 
CD64 PE X54-57.1 Mouse IgG1 BD Biosciences 
CD73 eF450 TY/11.8 Rat IgG1 eBiosciences 
CD80 Biotin 16-10A1 Ar Hamster IgG2 BD Biosciences 
CD86 Biotin B7-2 Rat IgG2b BD Biosciences 
CD192/CCR2 PE, APC 475301 Rat IgG2b R&D Systems 
CD206 Biotin 5D3 Rat IgG2a Homemade 
CD209a Biotin 5H10/CIRE Rat IgG2a BD Biosciences 
CD226 PE, APC, 
Alexa-Fluor 647 
10E5 Rat IgG2b eBiosciences 
BioLegend 
CD301 Alexa-Fluor 647 ER-MP23 Rat IgG2a AbD Serotec 
Ly6C Brill.V421 HK1.4 Rat IgG2a BioLegend 
Ly6G APC-Cy7 1A8 Rat IgG2a BD Biosciences 
MHC-II I-A/I-E PerCP/PECy5.5 M5/114.15.2 Rat IgG2b BioLegend 
Tim4 PE RMT4-54 Rat IgG2a BioLegend 
MerTK APC 108928 Rat IgG2a R&D Systems 
TNF-α PE MP6-XT22 Rat IgG1 BD Biosciences 
IL-6 PE MP5-20F3 Rat IgG1 BD Biosciences 
IL-10 APC JES5-2A5 Rat IgG2b eBiosciences 
IL-12(p40/p70) PE C15.6 Rat IgG1 BD Biosciences 
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2.2.5  Cell cycle analysis and proliferation assay 
 
Peritoneal cells were harvested from 6-7 week-old female C57BL/6 mice at 72 hours 
after low dose zymosan (2x106 particles) challenge. The cells were fixed in 1% 
formaldehyde (in PBS) and permeabilized with FACS wash buffer containing 0.5% 
w/v saponin (Sigma). Following that, the cells were incubated in blocking buffer (5% 
v/v heat-inactivated rabbit serum, 0.5% w/v BSA, 5 mM EDTA, 2 mM NaN3, 0.5% 
w/v saponin, 4 µg/ml rat anti-mouse 2.4G2 in PBS) for 30 minutes on ice, then 
antibody cocktails including surface antigen staining and anti-human Ki-67-FITC 
(clone B56, BD Biosciences, cross-reacting with mouse species) antibodies were 
added; together with isotype controls. The antibody staining was left for 1 hour on ice 
in the dark. After washing three times with FACS wash buffer, the cells were stained 
with DAPI solution (Life Technologies) for 30 minutes on ice in the dark. The 
samples were acquired and analyzed as described above. 
 
2.2.6  Ex vivo microbial product stimulation and cytokine production assay 
 
Murine peritoneal cells were washed three times with complete RPMI medium. Cells 
were plated in 48 well flat-bottomed plates (2x105 in 200 μl per well) with 0.1% (v/v) 
Golgi-plug (BD Biosciences). SES (10% v/v) or LPS (100 ng/ml final concentration; 
from Salmonella enterica serotype typhimurium, Sigma) was added as stimulants and 
complete RPMI medium only controls were performed in parallel. After incubation at 
37°C, 5% CO2 for 6 hours, the cells were carefully recovered using plastic cell lifters 
and intracellular cytokines including TNF-α, IL-6, IL-10, IL-12(p40/p70) were 
assessed as previously described. 
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2.2.7  Apoptotic thymocyte clearance assay 
 
2.2.7.1  Generation of apoptotic thymocytes 
 
The thymus consists of two lobes and lies on the median line of vertebral column, just 
above the heart. In the young mice, the thymus is well-developed, while those in the 
adult or in the old age are atrophic and difficult to detect visually. After euthanasia, 
the rib cages are carefully opened to expose the thymus (“whitish pads”). After 
removal of thymus, thymocytes were obtained by mechanical dissociation with a 2-ml 
syringe plunger and the suspensions of cells in PBS were filtered through a sterile cell 
strainer (40 μm Nylon, BD Falcon) twice to remove residual fibrous tissue. The cells 
were washed with PBS, resuspended in 50 ml complete RPMI medium in the 
presence of 1 μM dexamethasone (Sigma-Aldrich) and transferred to Nunclon tissue 
culture flask, 175 cm2 (Thermo scientific) and incubated for 4 hours at 37°C, 5% CO2. 
The cells were washed and resuspended in PBS (~107 cells/100 μl). 
 
2.2.7.2  Quantification of apoptotic thymocytes  
 
A small aliquot of apoptotic thymocyte suspension was diluted with PBS (~104 cells/ 
100 μl) and cytospin preparations (Cytospin 3, Shandon) were made as previously 
described. Cytospun cells were air-dried, stained with Microscopy Hemacolour 
(Merck), visualized on a Leica DMLB microscope with DFC490 camera (Leica) and 
processed using QWin Software (Leica). Apoptosis was confirmed by characteristic 
morphological changes including nuclear fragmentation, chromatin condensation, cell 
shrinkage, and membrane blebbing. The percentage of induced apoptosis was 
assessed by flow cytometry through NIM-DAPI staining (containing nuclear isolation 
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medium, NIM-II and 4',6-diamidino-2-phenylindole, DAPI). Specifically, 200 µl cell 
suspensions (1-3x105 cells) were aliquoted to a 1.5ml Eppendorf tube, mixed with 200 
µl NIM-DAPI solution and left for 30 minutes in the dark. Following staining, the 
cells were centrifuged at 2,000 rpm (~700 g) at 4°C for 10 minutes. The supernatant 
was carefully discarded (not to disturb the nuclear pellet). The nuclear pellet was 
resuspended in ~200 µl PBS. The samples were acquired on the Cyan ADP flow 
cytometer and data were analysed by summit software. The proportion of ‘sub G0’ 
area on the flow-cytometric plots denoted the percentage of apoptotic thymocytes (see 
Fig. 5.14). Normally, ~50% of thymocytes become apoptotic after dexamethasone (1 
μM) treatment for 4 hours. 
 
2.2.7.3  In vivo apoptotic thymocyte clearance assay  
 
Apoptotic thymocytes (~2x107 cells in 200 μl PBS) from naive 129S6/SvEv.CD45.1 
congenic mice were intra-peritoneally transferred to 129S6/SvEv (CD45.2) mice, 
either naïve or 72 hours after SES challenge. After 30 minutes retention, mice were 
humanely sacrificed and peritoneal cells were recovered by lavage with 5 ml of ice 
cold PBS with 5 mM EDTA. The cells were washed twice with PBS followed by 
blocking and antibody staining for surface antigens (including anti-mouse 
CD45.1-V450). After that, the cells were washed, fixed in 1% formaldehyde (in PBS) 
and permeabilized with FACS wash buffer containing 0.5% (w/v) saponin (Sigma). 
Intracellular staining was undertaken with anti-mouse CD45.1-APC, together with 
IgG2a-APC controls, in order to identify the apoptotic thymocytes within the 
phagocytes, presumably CD45.1-APC+ (intracellular) CD45.1-V450– (surface). The 
samples were acquired on flow cytometer and analysed by summit software. The 
“percentage of phagocytosis” was measured by the subtraction plot (histogram) 
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between positive CD45.1-APC staining and IgG2a-APC isotype staining on 
individual MØ/DC subset, restricted to CD45.1-V450– and singlet cell gate to exclude 
the adhered but not ingested apoptotic cells (see Fig. 5.15 and 5.16). 
 
2.2.8  Fluorescence-activated cell sorting of mouse peritoneal MØ/DC subsets 
 
Subpopulations of peritoneal monocytic phagocytes were isolated from peritoneal 
lavages using a FACS AriaTM III (BD Bioscience). Typically, cells from 10 C57BL/6 
mice (6-7 week-old females), either naïve or 72 hours after SES challenge were 
pooled, centrifuged and resuspended in blocking buffer (without NaN3) at a 
concentration of 107 cells/ml for 30 minutes on ice. After that, anti-mouse antibodies 
were added and incubated for 30 minutes on ice in the dark. The cells were washed 
twice with FACS wash buffer (without NaN3) and resuspended in the same buffer at a 
concentration of 107 cells per ml for flow-sorting. The purified cells were collected 
and checked for the purity as previously described and immediately used in antigen 
processing and presentation assays (performed by Dr. Marcela Rosas, detailed in 
Appendix 2). Cytospin preparations were made, stained with Microscopy Hemacolour 
(Merck), visualized on a Leica DMLB microscope with DFC490 camera (Leica) and 
processed using QWin Software (Leica). 
 
2.3  Statistical analysis 
 
Statistical analyses were conducted using the GraphPad Prism. The statistical tests 
used are indicated as appropriate within the text. P-values are summarized as follows: 
*= P≤ 0.05, **= P≤ 0.01 and ***= P≤ 0.001. All analyses performed were two-tailed. 
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Chapter Three 
 
Phenotypic and functional characterisation of 
peritoneal macrophages and dendritic cells in 
peritoneal dialysis patients 
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3.1  Introduction 
 
The monocytic cell lineage (often called mononuclear phagocyte system) in lymphoid 
or non-lymphoid tissues comprises macrophages (MØs), dendritic cells (DCs) and 
other specialized cells, including microglia (brain), osteoclasts (bone), and Kupffer 
cells (liver) (Hume DA et al., 2002; Gordon and Taylor 2005). Recent progress in 
MØ/DC biology research has indicated that the heterogeneity of these cell phenotypes 
is related to different developmental origins, distinct differentiation pathway, and 
diverse compartmental status i.e., steady state or inflammation (Geissmann et al., 2010; 
Hashimoto et al., 2011; Satpathy et al., 2012; Merad et al., 2013). Also, studies on the 
phenotypic and functional attributes of different tissue MØ subsets in vivo have 
highlighted that distinct subset has specialised roles in tissue homeostasis and local 
innate or adaptive immunity (Villadango et al., 2007; Davies et al., 2013). In the context 
of peritoneal cavity, however, the immunobiology of human MØ/DCs remains poorly 
understood, which contrasts with the extensive knowledge derived from their murine 
counterparts. The requirement for invasive procedures to gain access to peritoneal cells 
for analysis has limited the biological investigation of human cells. Peritoneal dialysis 
(PD) as a renal replacement therapy for end-stage kidney failure patients provides a 
unique opportunity to study peritoneal cell biology in humans via an implanted PD 
catheter (Popovich et al., 1978; Maddox et al., 1984). In the field of PD research, studies 
in late 1970s/early 1980s began to examine the cellular composition of dialysis effluent 
fluids from non-infected PD patients, and revealed that the MØ is the predominant cell 
type within the PD fluids (Fakhri et al., 1978; Ganguly et al., 1980; Cichocki et al., 
1983; Goldstein et al., 1984). Based on ex vivo and in vitro functional analysis, these 
studies suggested peritoneal MØs are the frontline player of host peritoneal defence 
system in PD patients (Verbrugh et al., 1983; Peterson et al., 1985; McGregor et al., 
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1987; Lin et al., 1990). Recently, it has been suggested that peritoneal MØs from PD 
patients phenotypically and functionally resemble the in vitro polarised M-CSF–driven 
‘anti-inflammatory’ MØ (Xu et al., 2007) or IL-4–driven alternatively activated MØ 
(Bellon et al., 2009). However, these findings are relatively simplistic and contrast with 
recent studies in mice that highlight MØ heterogeneity during inflammation (Davies et 
al., 2013). Furthermore, the information regarding DC in the human peritoneal cavity 
is even less owing to the paucity of specific markers permitting the unambiguous 
identification of this cell type (McCully et al., 2006). Overall, the lack of detailed 
phenotypic and functional characterisation of human peritoneal MØ/DC has limited the 
investigation of their specialised roles in the process of initiation/resolution of 
peritonitis, which would be fundamental with regards to understand how PD therapy 
modifies the cellular distribution/kinetics and local immunity in patients. 
Hence, the specific aims of this chapter are: 
1. To establish a novel flow-cytometric gating strategy to specifically identify distinct 
peritoneal monocytic subsets in PD patients. 
2. To examine the expression of a broad range of surface receptors by distinct 
peritoneal monocytic subsets from PD patients under different clinical scenarios (i.e. 
new-starters, stable dialysis and during acute bacterial peritonitis).  
3. To explore the relationship between blood monocyte subsets and peritoneal 
monocytic subsets through surface phenotype comparisons. 
4. To investigate the specialised function of peritoneal MØ and DC, including: 
a) cytokine production after ex vivo microbial product stimulation. 
b) ex vivo phagocytic capacity and respiratory burst response. 
c) in vitro antigen processing and presentation. 
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3.2  Results 
 
3.2.1  Flow-cytometric analysis of human peritoneal cells—basic principles 
Cells within human peritoneal dialysate comprise mainly leukocytes, with a minority 
of non-leukocytes such as mesothelial cells. Following appropriate preparation of 
single cell suspensions and defined staining procedures (detailed in Materials and 
Methods), total peritoneal cells from PD effluents were run through a multi-colour flow 
cytometer. In order to accurately identify a target cell population and determine its 
specific receptor expression, three steps were employed during data analysis (Fig. 3.1). 
Firstly, the “singlet population” was gated in the density plot of Forward Scatter Linear 
(FS Lin) against Forward Scatter Area (FS Area). This “doublet discrimination” gating 
is to exclude aggregated cells and coincidental events, which could lead to false-
positive antibody staining. Secondly, the cellular debris, typically located at the extreme 
left lower corner in the density plot of FS Area against Side Scatter Area (SS Area), 
was excluded. Thirdly, only “live cells”, which were negative for Aqua Live/Dead stain 
(Life Technologies), were selectively gated to prevent from false-positive or false-
negative staining on the dead cells. Altogether, these strategies would ensure the 
phenotypic characterisation of target cell populations entirely based on single and live 
cells. These principles applied to all analysed human samples within the whole study. 
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Figure 3.1  Flow-cytometric strategies to exclude doublets, cellular debris and 
dead cells during data analysis 
After appropriate preparation of single cell suspensions and staining procedures, total 
peritoneal cells from PD effluent samples were examined by multi-colour flow 
cytometry. Representative density plots showed three-step flow-cytometric strategies 
including exclusion of doublets, cellular debris and dead cells, before going on 
phenotypic characterisation of leukocyte subpopulations. Data represent the analysis of 
peritoneal effluent cells from the first flush bag of a new-starter PD patient, and the 
same principles applied to all analysed human samples within the whole study. 
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3.2.2  Identification of peritoneal myeloid cells from PD effluent fluids based on 
CD116 (GM-CSF receptor alpha) expression 
Peritoneal leukocytes from PD effluents comprise mainly neutrophils, eosinophils, 
macrophages and lymphocytes. Traditionally, the identification of leukocyte 
composition within PD effluent cells is based on the morphologic features of each cell 
type demonstrated by cytochemical staining methods (Cichocki et al., 1983). Recently, 
techniques have become available utilising a wide range of fluorochrome-conjugated 
antibodies to recognize specific surface antigens, with which the cells of interest within 
a mixed cell population can be clearly identified through flow-cytometric analysis 
(Autissier et al., 2010). In this study, I employed a novel gating strategy based on 
CD116 (GM-CSF receptor alpha) expression, a pan-myeloid lineage cell marker (Fig. 
3.2), which has been used effectively in mice (Rosas et al., 2007). Together with HLA-
DR (MHC class II molecule) and CD14 (a co-receptor for LPS), CD116+ myeloid cells 
could be separated into two main subpopulations: mononuclear phagocytes (HLA-
DR+CD14+/low/–) and granulocytes (HLA-DR–CD14–). Major granulocytic subsets, such 
as neutrophils and eosinophils, could be further identified by their unique expression of 
surface markers, CD16+/CD15+/CD66b+ (Moulding et al., 1999; Schmidt et al., 2012) 
and CD16–/CCR3+/Siglec-8+ (Höchstetter et al., 2000; Floyd et al., 2000), respectively. 
Additionally, eosinophils could be identified simply by their characteristic FS/SS 
profile (Davies et al., 2011) after pre-gating on CD116+HLA-DR–CD14–CD16– cells. 
This flow-cytometric gating strategy provides a useful approach not only to identify 
and quantify major myeloid subsets, but also enables studies to include all the potential 
mononuclear phagocyte subsets in the human peritoneal cavity. 
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Figure 3.2  Flow-cytometric gating strategies to identify different peritoneal 
myeloid subsets from PD effluent fluids 
Density plots show myeloid cells were pre-gated on CD116+ populations after 
exclusion of doublets, cellular debris and dead cells. Within these cells, mononuclear 
phagocytes could be readily identified as HLA-DR+CD14+/low/–. Granulocytes were 
HLA-DR–CD14–. Other useful surface markers such as CD16, CD15, CD66(b), CCR3, 
siglec-8, are applied for confirmation of neutrophils (CD16+CD15+CD66b+) and 
eosinophils (CD16–CCR3+siglec-8+). Data represent the analysis of peritoneal effluent 
cells from the first flush bag of a new-starter PD patient. 
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3.2.3  Phenotypic identification of two major peritoneal mononuclear phagocyte 
subsets (CD14+CD1c– and CD14low/–CD1c+) from PD effluent fluids 
Heterogeneity of tissue mononuclear phagocytes has been widely studied in humans 
and in mice (Gordon and Taylor 2005; Satpathy et al., 2012; Davies et al., 2013). In the 
context of human peritoneal cavity, however, mononuclear phagocyte biology remains 
poorly described. Traditionally, CD14 is adopted as an identifying marker for peritoneal 
MØs (McCully et al., 2005; Xu et al., 2007). However, this is relatively simplistic as it 
has neglected the possibility of CD14low/– monocytic subsets, which have been found in 
peripheral bloods (Ziegler-Heitbrock et al., 1993; Geissmann et al., 2003) and other 
tissues such as liver (Liaskou et al., 2013), lung (Chana et al., 2013). On the other hand, 
the identity of peritoneal DCs in humans remains unclear due to lack of DC-specific 
markers and the highly overlapping marker expression on MØ and DC (McCully et al., 
2006). So far, there is no validated flow-cytometric strategy to clearly identify 
peritoneal MØ/DC subsets in PD effluents. Here, the proposed flow-cytometric gating 
strategy as shown in Fig. 3.2, has first defined the CD116+HLA-DR+CD14+/low/– 
mononuclear phagocytes in the PD effluents. These monocytic cells are negative for the 
following lineage markers: CD3 (T lymphocyte), CD19 (B lymphocyte), CD15 
(granulocyte) and CD56 (NK cell) (Fig. 3.3A). Within this population, two major 
subsets, CD14+ cells and CD14low/– cells, could be readily subdivided (Fig. 3.3B). 
Interestingly, the majority of CD14low/– cells were CD16low/–CD206high/+, and CD14+ 
cells were notably heterogeneous in the expression of CD16 and CD206. There were 
only subtle differences between these two cell types regarding the expression of 
myelomonocytic markers such as CD11b, CD11c, CD115 and CD116 (Fig. 3.3B). 
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Figure 3.3  Phenotypic identification of two major mononuclear phagocyte 
subsets in the peritoneal effluent fluids from PD patients 
(A) Flow-cytometric analysis of peritoneal effluent cells. Plots shown were pre-gated 
on CD116+HLA-DR+CD14+/low/– monocytic cells after exclusion of doublets, debris, 
dead cells and granulocytes. Histograms display CD3 (T cells), CD15 (granulocytes), 
CD19 (B cells) and CD56 (NK cells) lineage marker expression by the monocytic cells. 
Shaded histograms depict receptor specific staining and dotted lines denote isotype 
control staining. Data represent one of 5 stable PD patients. (B) Representative plots 
showing the separation of the two monocytic subsets, CD14+ (orange) and CD14low/– 
(blue). CD14low/– cells are mainly CD16low/–CD206high, and CD14+ cells were 
heterogeneous in the expression of CD16 and CD206 (upper panel). The expression of 
CD115, CD116, CD11c and CD11b is similar across both subsets (lower panel). Data 
are derived from one stable PD patient (representative of 37 in total). 
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Next, to determine whether these two discrete subsets could possibly represent the 
existence of MØ and DC within the dialysate, additional DC-associated markers, such 
as CD1c (BDCA-1, myeloid DC marker), CD141 (BDCA-3, myeloid DC marker), 
CD303 (BDCA-2, plasmacytoid DC marker), CD1a, CD83 and CD209 (DC-SIGN), 
were examined thoroughly. Interestingly, CD14low/– cells rather than CD14+ cells were 
distinctively found to be CD1c+ cells. Hence, phenotypically, CD14+CD1c– cells were 
suggested to be the contemporary “peritoneal MØs”, and CD14low/–CD1c+ cells could 
potentially be “peritoneal DCs”. 
 
 
 
 
 
 
 
 
Figure 3.4  HLA-DR+CD14low/– cells are potentially peritoneal dendritic cells 
Flow-cytometric plots showing positive CD1c+ expressions on CD14low/– cells (blue), 
but not on CD14+ cells (brown). All other relevant “DC-associated” markers were 
>98% negative across both cell types. The dotted lines denote the maximal level of the 
isotype control staining. Data are derived from one stable PD patient (representative of 
5 patients in total). 
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3.2.4  Phenotypic comparisons between peritoneal CD14+ MØ and CD1c+ DC 
from PD patients 
Following identification of CD14+ MØ and CD1c+ DC, a detailed phenotyping on these 
two monocytic subsets was performed, examining a wide range of surface markers, 
including receptors involving monocyte transmigration as well as MØ/DC 
activation/maturation (CD11b, CD11c, CD16, CD36, CD64, CD163, CD206, CD226, 
FcɛR1α), antigen presentation (CD40, CD80, CD86), pathogen recognition (CD301, 
Dectin-1, Dectin-2), apoptotic cell clearance (MerTK) and chemokine receptors 
involving MØ/DC recruitment and migration (CCR2, CCR7). In addition, Tim-4 (T cell 
immunoglobulin and mucin domain-containing protein 4) and CD73 (5’-nucleotidase) 
were evaluated, as both were found to be highly expressed on murine peritoneal resident 
MØs (Davies et al., 2011; Rosas et al., 2014). As shown in Fig. 3.5, these surface 
markers were differentially expressed on peritoneal CD14+ MØs and CD1c+ DCs. 
Select receptor expressions were quantitatively compared between these two subsets in 
PD patients under either uninfected status (“clear fluids”) or acute bacterial peritonitis 
(“cloudy fluids”) (Fig. 3.6). Notably, CD1c+ DCs were characterized by lower CD11b, 
CD16, CD36, CD64, CD163, MerTK, CCR2 expression, and higher CD11c, CD206, 
CD226, FcɛR1α, CD301 expression, compared to CD14+ MØs, under either uninfected 
stable conditions or during acute bacterial peritonitis (Fig. 3.6). In addition, very low 
expression of CD62L, CD80 and CCR7 were uniformly noted across two subsets in 
both circumstances. Other surface molecules such as Dectin-1, Dectin-2, Tim-4, and 
CD73 were similarly expressed by these cells. 
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Figure 3.5  Phenotypic comparisons between human peritoneal CD14+ MØ and 
CD1c+ DC 
Flow-cytometric analysis of select marker expression by peritoneal CD14+ MØ and 
CD1c+ DC. Representative histogram plots were pre-gated on CD116+HLA-DR+ cells 
after exclusion of doublets, debris, dead cells and granulocytes, then gated on the 
respective CD14+ MØ and CD1c+ DC subset. Shaded histograms depict receptor 
specific staining and bold lines denote isotype control staining. Data are representative 
of 4 stable PD patients. 
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Figure 3.6  Quantitative comparisons of receptor expression between human  
           peritoneal CD14+ MØ and CD1c+ DC under stable status and 
           during acute bacterial peritonitis 
Bar graphs shown were quantification of select receptor expression, measured as 
difference in medium fluorescence intensity (MFI) between receptor specific and 
isotype control staining. White bars denote CD14+ MØ and black bars are CD1c+ DC. 
Data are shown as mean ± SEM of the indicated number of patients (n) and was 
analysed using paired t-test. P-values are summarized as follows: *= P≤ 0.05, **= P≤ 
0.01 and ***= P≤ 0.001. 
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3.2.5  Heterogeneous activation and maturation of peritoneal MØ and DC 
Previous study has noticed that peritoneal MØs from infected or uninfected PD 
effluents express variable levels of CD16 (FcγRIIIa/IIIb) and CD206 (macrophage 
mannose receptor) (Bellon et al., 2009). Our data, consistent with these observations, 
also demonstrated heterogeneous expression levels of CD16 and CD206 on peritoneal 
mononuclear phagocytes (Fig. 3.3B). Both CD16 and CD206 have been adopted as 
markers indicative of monocyte-to-macrophage activation or maturation (Mokoena et 
al., 1985; Andreesen et al., 1990; Noorman et al, 1997). Notably, based on the 
expression levels (high/+ versus low/–) of CD16 and CD206, peritoneal MØ/DC could 
be sub-categorized into six cell subtypes (Fig. 3.7). Specifically, CD14+ MØs could be 
separated into CD16high/+ and CD16low/– cells, each with CD206+ and CD206–. CD1c+ 
DCs were basically CD16low/–, which consist of CD206+ (majority) and CD206– (rare). 
Interestingly, individual subtype displayed differential expression of HLA-DR, CD86 
and CD163 from PD patients under stable conditions (Fig. 3.8A) or during acute 
bacterial peritonitis (Fig. 3.8B). These differential expression profiles most likely 
reflect different stages of MØ/DC activation or maturation within the peritoneal cavity. 
Of note, peritoneal MØ with CD16+CD206+ (‘double positive’) subtype expresses the 
highest levels of HLA-DR, CD86 and CD163, among CD14+ MØs, whereas CD16–
CD206– (‘double negative’) subtype expresses the lowest levels of these surface 
antigens. 
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Figure 3.7  Human peritoneal MØ/DC could be subdivided into six cell subtypes 
based on the differential expression of CD16 and CD206  
Flow-density plots (upper left) and histogram plots (upper right) showing CD14+ MØs 
(orange) and CD1c+ DCs (blue) could be subdivided into six subtypes according to their 
differential CD16 and CD206 expression. Data represent one stable PD patient. The 
expression of these two markers have been studied in all patients’ effluent samples. 
Variations in the distribution of each subtype in the individual samples are analysed and 
discussed in Chapter 4. 
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Figure 3.8  Differential marker expression on six distinct peritoneal monocytic 
subsets under stable status or during acute bacterial peritonitis 
Bar graphs comparing select receptor expression (HLA-DR, CD86, CD163), measured 
as difference in medium fluorescence intensity (MFI) between receptor specific and 
isotype control staining, among individual six subsets from PD patients under stable 
status (n = 10, upper panel A) and during acute bacterial peritonitis (n = 10, lower panel 
B). Data is shown as mean ± SEM. 
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3.2.6  Phenotypic comparisons between human blood monocytic subsets and 
peritoneal monocytic subsets from PD patients 
To understand the potential lineage relationship between blood monocytic subsets and 
peritoneal mononuclear phagocyte subsets, it would be of interest to phenotypically 
compare the monocytic cells of two compartments. For this purpose, a similar flow-
cytometric gating approach was applied to peripheral blood mononuclear cells (PBMC) 
to identify CD116+HLA-DR+ cells and perform a detailed immunophenotyping of 
blood monocytic subsets in new-starter PD patients (Fig. 3.9). The results were in 
agreement with previous reports displaying three major cell types (stratified by CD14 
vs. CD16 expression) and their differential receptor expressions. By concomitantly 
analysing peritoneal mononuclear phagocytes from the same patients at the same time 
point (1st peritoneal flush), monocytic cells of different origins could be phenotypically 
compared. The most notable finding was minimal CD14low/–CD16+ cells in the 
peritoneal cavity, while the proportion of CD14low/–CD16low/– cells (CD1c+ DC) was 
much increased, compared to peripheral bloods (Fig. 3.10). Of note, CD14low/–
CD16low/– cells in blood comprise rare CD1c+ myeloid DC precursors (Fig. 3.11 and 
Cros J et al, 2010).  
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Figure 3.9  Phenotypic characterisation of three major monocytic subsets in 
peripheral bloods from PD patients 
(A) Representative density plots show blood monocytic cells. Cells were pre-gated on 
CD116+HLA-DR+ populations after exclusion of doublets, cellular debris and dead 
cells. These cells are readily subdivided into three major subsets (CD14+CD16low/–, 
CD14+CD16+, CD14low/–CD16+). CD14low/–CD16low/– cells comprise rare myeloid DC 
precursors (Cros J et al, 2010). (B) Plots depict differential receptor expressions by 
distinct monocytic subsets. Dashed lines denote the maximal level of isotype control 
staining. (C) Summary of the phenotypic comparison among three subsets. Data are 
derived from the analysis of PBMC from one new-starter PD patient (representative of 
10 patients in total). 
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Figure 3.10  Major monocytic subsets (based on CD14 versus CD16 expression) 
in peripheral bloods and in the peritoneal cavity from PD patients  
Representative density plots showing three major blood monocyte subsets (left) and 
peritoneal monocytic cells (right) according to the differential CD14/CD16 expression. 
Plots shown were pre-gated on CD116+HLA-DR+ cells after exclusion of doublets, 
debris, dead cells and granulocytes in both circumstances. Data are derived from the 
flow-cytometric analysis of PBMC and peritoneal cells from one PD patient at the time 
of 1st peritoneal flush (representative of 10 new-starter patients in total). 
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Figure 3.11 
Phenotypic identification of 
blood CD1c+ DC precursors 
Flow-cytometric density plots 
showing CD1c+ DC precursors 
(orange) in peripheral bloods are 
CD116+HLA-DRhighCD11c+ and 
CD14low/–CD16low/–. Data are 
derived from one healthy 
individual (representative of 4 in 
total). 
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Table 3.1 summarises the quantification of receptor expressions in blood and peritoneal 
monocytic subsets (stratified by CD14 vs CD16 expression). Remarkably, all subsets 
of blood monocytes have very low expression of CD206, a marker mainly expressed 
on mature MØs and DCs (Noorman et al., 1997). Within peritoneal monocytic cells, 
CD14+CD16– cells are phenotypically similar with their counterparts in peripheral 
blood (CD206low/–CCR2+CD86+CD163low) except for a very low CD62L expression, 
which might be due to shedding of CD62L when blood monocytes migrate into the 
peritoneal cavity (Smalley 2005). Peritoneal CD14+CD16+ subsets have broadly higher 
expression of CD11b, CD86 and CD163, while CD14low/–CD16–cells (basically CD1c+ 
DCs) have higher expression of CD11c, HLA-DR and CD206. 
 
 
Table 3.1  Phenotypic comparisons of select receptor expressions between major 
monocytic subset in peripheral blood and in the peritoneal cavity  
  Blood monocytes Peritoneal monocytic cells 
CD14+CD16– CD14+CD16+ CD14low/–CD16+ CD14+CD16– CD14+CD16+ CD14low/–CD16– 
CD11b 269.4 ± 46.28  265.2 ± 34.31  88.62 ± 10.62  307.8 ± 42.36 401.6 ± 53.79  195.9 ± 38.42 
CD11c 83.53 ± 6.579  161.2 ± 10.94  198.2 ± 13.81  178.2 ± 21.10 219.4 ± 27.44  401.3 ± 39.90 
CD62L 127.7 ± 29.56  20.13 ± 3.351  11.36 ± 2.066  4.742 ± 0.548 7.665 ± 1.669  4.994 ± 0.732 
CD86 38.34 ± 3.282  80.48 ± 6.400  94.08 ± 9.342  42.81 ± 4.399 103.0 ± 10.91  40.85 ± 4.389 
CD163 25.18 ± 3.148  36.38 ± 7.587  3.511 ± 1.140  33.51 ± 5.117 172.3 ± 31.22  16.35 ± 2.645 
CCR2 37.56 ± 4.941  26.31 ± 3.438  4.628 ± 0.416  36.39 ± 5.972 19.83 ± 2.398  17.65 ± 2.249 
HLA-DR 51.99 ± 11.92  299.0 ± 35.93  192.7 ± 25.32  197.2 ± 35.50 338.5 ± 45.30  461.8 ± 33.21 
CD206 0.683 ± 0.195   2.051 ± 0.275  1.568 ± 0.192  13.38 ± 2.751 63.91 ± 20.39  199.2 ± 24.69 
Data represent mean ± SEM of median fluorescence intensity (MFI), measured as difference between 
receptor specific and isotype control staining, and are derived from the analysis of PMBC and peritoneal 
effluent cells from 10 new-starter PD patients (at the time of 1st peritoneal flush). The monocytic cell 
type with the highest receptor expression in each compartment is denoted in red colour.  
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3.2.7  Cytokine response to ex vivo stimulation with microbial products 
To understand functional profiles of human peritoneal CD14+ MØ and CD1c+ DC in 
the dialysis effluents from PD patients, several assays were conducted. Firstly, to test 
the cellular responses to microbial stimuli, the production of the pro-inflammatory 
cytokines (TNF-α, IL-1β, IL-6, IL-12p40/p70) and anti-inflammatory cytokine (IL-10) 
were measured by intracellular flow cytometry after ex vivo stimulation with LPS or 
SES (See the details in section 2.1.8). Both CD14+ MØ and CD1c+ DC could generate 
significant amounts of TNF-α, IL-1β, IL-6, as well as small amounts of IL-10 and IL-
12p40/p70 after stimulation (Fig. 3.12). 
 
 
 
 
 
 
 
 
 
 
Figure 3.12  Cytokine production by peritoneal MØ and DC after ex vivo 
stimulation with SES or LPS 
Representative density plots illustrating the flow-cytometric determination of 
intracellular cytokine production by peritoneal MØ/DC from stable PD patients, after 
ex vivo stimulation with SES (1:10 dilution) or LPS for 4 hours (TNF-α, IL-1β, IL-6), 
24 hours (IL-10), or 22 hours (IL-12p40/p70, in addition to 2 hours IFN-γ priming), in 
parallel with medium only as unstimulated control. Data from one patient representative 
of 7 stable PD patients giving similar results. 
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There was no significant difference between CD14+ MØ and CD1c+ DC regarding the 
pro-inflammatory/anti-inflammatory cytokine productions at basal condition (medium 
only) (Fig. 3.13). Notably, upon either ex vivo SES or LPS stimulation, CD14+ MØs 
could generate higher TNF-α and IL-6 than CD1c+ DC. With regards to IL-1β, IL-10 
and IL-12p40/p70, no difference after stimulation between MØs and DCs was found. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13  Quantification of intracellular cytokine production by peritoneal 
MØ/DC after ex vivo stimulation with SES or LPS 
Bar graphs comparing the intracellular cytokine production between peritoneal CD14+ 
MØ (white bars) and CD1c+ DC (black bars). Cells were cultured in medium alone or 
stimulated ex vivo with SES or LPS for 4 hours (TNF-α, IL-1β, IL-6), 24 hours (IL-10), 
or 22 hours (IL-12p40/p70, in addition to 2 hours IFN-γ priming), . Positive 
intracellular cytokine production was determined by comparison with isotype controls 
(see Fig. 3.12). Data represent mean ± SEM and are derived from 7 stable PD patients. 
Statistical analysis was performed by paired t-tests. (*= P≤ 0.05, **= P≤ 0.01, ***= P≤ 
0.001, and ns= non-significant).  
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3.2.8  Phagocytosis and respiratory burst response after ex vivo challenges with 
fluorescence-conjugated zymosan particles or bacteria 
Phagocytosis of pathogens or microbial products is a major host defence function of 
peritoneal mononuclear phagocytes, a process leading to generation of various reactive 
oxygen species (ROS) for use in oxygen-dependent killing of microbes (Underhill and 
Ozinsky 2002). To examine their phagocytic capacity and their potential for generation 
of ROS, peritoneal cells were incubated with 3’-(p-aminophenyl) fluorescein (APF), a 
fluorescent probe designed for the detection of free radicals such as hydroxyl radical 
(HO•), hypochlorite anion (–OCl), then challenged with Alexa Fluor 405–conjugated 
zymosan particles or DDAO–conjugated Staphylococcus epidermidis (detailed in 
Materials and Methods). Zymosan is a cell wall extract from Saccharomyces cerevisiae 
(DiCarlo and Fiore 1958). It has been shown that it has ligands bind to TLR2/6 
(Underhill 2003) and C-type lectin receptors such as Dectin-1 (Brown et al., 2001 & 
2002) on monocytic cells. This assay was analysed by flow cytometry.  
As shown in Fig. 3.14, without zymosan particle loading (no phagocytosis), both 
CD14+ MØ and CD1c+ DC generated minimal ROS as low spontaneous activation (Fig. 
3.14A, upper second panel). Through the process of zymosan particle uptake, these 
monocytic cells produced significant amounts of ROS, detected by APF (Fig. 3.14A, 
lowest panel). The preliminary results revealed CD14+ MØ had a better phagocytic 
capacity for zymosan particles and that they generated a significantly higher respiratory 
burst response than CD1c+ DC (Fig. 3.14B).     
Similar results were observed when the same assay using DDAO–conjugated 
Staphylococcus epidermidis (DDAO-S.E) as inciting agents instead (Fig. 3.15). 
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Figure 3.14  Phagocytosis and respiratory burst responses following ex vivo 
challenges with zymosan particles 
(A) Representative flow-cytometric density plots showing the generation of reactive 
oxygen radicals from peritoneal MØ/DC, detected by 3’-(p-aminophenyl) fluorescein 
(APF), following challenges with Alexa Fluor 405-conjugated zymosan particles ex 
vivo or cultured in medium only. The percentages of cells found in each of specified 
gate are indicated. (B) Quantification of zymosan particles uptake by respective 
monocytic cells (upper graph) and positive APF staining (%) within the cells 
phagocytosing zymosan particles (lower graph). Data are representative of 4 new-
starter PD patients and were analysed by paired t-test.  
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Figure 3.15  Phagocytosis and respiratory burst responses following ex vivo 
challenges with Staphylococcus epidermidis (S.E) 
(A) Representative flow-cytometric density plots showing the generation of reactive 
oxygen species from peritoneal MØ/DC, detected by 3’-(p-aminophenyl) fluorescein 
(APF), following challenges with DDAO-conjugated S.E ex vivo or cultured in medium 
only. The percentages of cells found in each of specified gate are indicated. (B) 
Quantification of bacterial uptake by the respective MØ/DC subset (left graph) and 
positive APF staining (%) within the cells phagocytosing DDAO-S.E (right graph). 
Data are representative of 4 stable PD patients and were analysed by paired t-test.  
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3.2.9  Flow-cytometric cell sorting of human peritoneal MØ and DC subsets 
To purify the respective peritoneal CD14+ MØs and CD1c+ DCs, a flow-cytometric cell 
sorting approach was performed (Fig. 3.16A). The purity of each post-sorted subset was 
generally >95%. The cells were stained with Microscopy Hemacolor (Merck) and the 
morphology was shown in Fig. 3.16B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16  Cell sorting of human peritoneal MØ/DC and their morphology 
(A) Representative density plots depict the purification strategy of CD14+ MØs and 
CD1c+ DCs from peritoneal effluent cells by flow cytometry. Cells were gated on 
CD116+HLA-DR+, then separated into two. (B) Plots shown were the post-sorted cells 
(the purity >95%). Purified cells were cytospun, air-dried and stained with Microscopy 
Hemacolor. The morphology of cells was shown (scale bar denotes 30μm). Data 
represent one of 4 stable PD patients. 
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3.2.10  Antigen processing and presenting assay  
MØs and DCs are generally considered professional antigen-presenting cells (APCs). 
To test their ability to uptake, process and present specific antigen to responder T cells, 
a modified in vitro assay of cross presentation was conducted. The results suggested 
both cell types are effective antigen processing and presenting cells, albeit CD1c+ DCs 
are slightly more efficient than CD14+ MØs in this regard (Fig. 3.17).  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17  Human antigen processing and presenting assay 
(A) Representative density plots show flow-cytometric determination of intracellular 
IFN-γ production by responder CD8+ T cells specific for M1p58-66. Plots display 
responder T cells after co-culture with CD14+ MØ or CD1c+ DC (from HLA-A2+ stable 
PD patients), which were loaded with soluble Flu-M1 protein, or pulsed with Flu-
M1p58-66 peptide (at an APC: responder ratio of 1:1-2). PMA (10 µg/ml) + Ionomycin 
(1µM) was used as a positive control. Data are representative of 1 from 4 stable PD 
patients. (B) Quantification of intracellular IFN-γ expression from responder T cells 
derived from antigen processing and presentation assay based on loading Flu-M1 
protein antigen on the respective APCs (CD14+ MØ or CD1c+ DC). Data are 
representative of 4 stable PD patients and were analyzed by paired t-test.   
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3.3  Discussion 
 
In this chapter, the results shown demonstrate that human peritoneal mononuclear 
phagocytes within the PD effluents from PD patients are a highly heterogeneous 
population. Distinct peritoneal monocytic subsets might represent different 
developmental origins, differentiation pathways or activation/maturation status. 
Importantly, for the first time, we could identify human peritoneal DCs in PD effluents, 
which are morphologically, phenotypically and functionally distinct from traditional 
peritoneal MØs. 
The application of a wide range of cell-specific fluorochrome-conjugated antibodies 
and polychromatic flow cytometry enabled the analysis of the composition of leukocyte 
subpopulations within the PD effluents. In this project, I have established a novel flow-
cytometric gating strategy to successfully discriminate monocytic cells (CD116+HLA-
DR+CD14+/low/–) from other CD116+HLA-DR– myeloid subsets, such as CD16+CD66+ 
neutrophils and CCR3+Siglec-8+ eosinophils, within the PD effluents. From the 
peritoneal monocytic cells, two distinct subsets - CD14+CD1clow/– MØs and CD14low/–
CD1c+ DCs could be identified, for the first time in the context of PD. Interestingly, a 
very recent study also discovered these two monocytic subsets wihin tumor ascites from 
the advanced ovarian cancer patients, using a different flow-cytometric approach with 
direct gating on the CD11c+HLA-DR+ population and subsequent separation into 
CD14+ MØs and CD1c+ DCs (Segura et al., 2013). From my own comparison analysis, 
both methods generated the same results: specific identification of two discrete 
monocytic subsets. Based on the immunophenotyping in this study, CD1c+ DCs are 
CD11chighCD206highCD226+CD301highFcɛR1αhigh, whereas CD14+ MØs are CD11bhigh 
CD16+CD36highCD64highCD163highMerTK+. Notably, these unique surface marker 
profiles were seen both under uninfected and infected conditions, albeit with different 
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extents of expression levels. The comparisons of gene expression profiles between 
peritoneal CD14+ MØs and CD1c+ DCs derived from tumour ascites, as well as 
compared to different blood monocyte subsets and blood CD1c+ DC precursors, 
suggested that peritoneal CD14+ MØs and CD1c+ DCs are more likely monocyte-
derived (Segura et al., 2013). However, this inference should be validated on healthy 
individuals and patients under different clinical settings (i.e. uninfected and infected 
PD patients).  
Another noteworthy observation in PD patients is the heterogeneous status of peritoneal 
MØ activation or maturation. The flow-cytometric analysis has demonstrated the 
differential expression patterns of CD16 and CD206 on peritoneal MØs within the PD 
effluents. Sub-stratification based on these two surface markers has permitted further 
separation of peritoneal MØ/DCs into six subtypes. Interestingly, these subtypes 
displayed differential expression levels of HLA-DR, CD86 and CD163, which may 
reflect different stages of MØ/DC activation or maturation. For example, the 
CD14+CD16+CD206+ subtype has the highest HLA-DR/CD86/CD163 expression 
within CD14+ MØs, suggesting that this subtype is likely more mature peritoneal MØs. 
Conversely, the CD14+CD16low/–CD206– subtype with the lowest expression levels of 
HLA-DR/CD86/CD163, could be newly recruited monocyte-derived MØs as they are 
phenotypically close to ‘classical’ CD14+CD16low/– blood monocytes. Surprisingly, 
CD14lowCD16+ MØs were hardly found in the peritoneal cavity, in all PD effluent 
samples studied. The possible explanation is ‘non-classical’ CD14lowCD16+ blood 
monocytes either not being recruited into peritoneal cavity or differentiating into other 
phenotypes after migration. The fact that peritoneal CD14+ MØs from all PD effluents 
are mostly CCR2+ suggested that these cells might originate from CD14+CD16– blood 
monocytes (CCR2+), rather than CD14lowCD16+ blood monocytes (CCR2low/–). 
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Altogether, these data provided new insights into the heterogeneity of phenotypes and 
activation/maturation of peritoneal MØ/DCs within PD effluent. In the next chapter, the 
issue of how these phenotypes as well as activation/maturation status is influenced by 
the time on PD therapy, and by acute PD-related peritonitis, will be explored. 
Apart from phenotypic heterogeneity and plasticity, peritoneal monocytic subsets 
displayed distinct functional characteristics. Firstly, both CD14+ MØs and CD1c+ DCs 
could produce significant amounts of pro-inflammatory cytokines such as TNF-α, IL-
1β, IL-6 and IL-12p40/p70 in response to ex vivo stimulation with lipopolysaccaride 
(LPS) and Staphylococcus epidermidis supernatant (SES). These cytokines have 
recently been suggested to drive Th1 responses leading to chronic peritoneal 
injury/fibrosis as a consequence of repeat inflammation in a mouse peritonitis model 
(Fielding et al., 2014). Secondly, CD14+ MØs have superior phagocytic capability in 
response to ex vivo zymosan particles or Staphylococcus epidermidis challenges, 
compared to CD1c+ DCs. After uptake of zymosan particles or bacteria, CD14+ MØs 
could generate more respiratory burst response than CD1c+ DCs. Finally, in the assay 
of antigen cross-presentation, preliminary observations suggested CD1c+ DCs are more 
efficient than CD14+ MØs in influenza M1 protein uptake, processing and presentation 
of peptides to the responder CD8 T lymphocytes specific for M1p58-66.  
Collectively, through phenotypic and functional characterization, the results in this 
chapter have advanced our understanding of human peritoneal MØ/DC biology in the 
context of PD therapy.  
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Chapter Four 
 
Kinetics and distributions of peritoneal myeloid 
subsets during the course of peritoneal dialysis  
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4.1  Introduction 
 
Like any tissue, the homeostatic environment of the peritoneal cavity is tightly 
regulated. However, in the context of peritoneal dialysis (PD), the intraperitoneal 
immune system is perturbed. Initially, catheter insertion is anticipated to induce a 
surgical injury-related inflammatory response, followed by the resolution of this acute 
response. Meanwhile, the catheter tube component within the peritoneal cavity might 
induce a foreign-body response (Flessner et al., 2010), which would further 
complicate the inflammatory scenario during the post-surgery/pre-dialysis period. 
When the dialysis ensues (normally about one month after catheterization), patients 
begin daily exchange of dialysis fluid. Earlier evidence revealed that this continuous 
dialysis process altered the resident leukocyte compositions in the peritoneal cavity 
over time (McGregor et al., 1989). Based on a novel immunophenotyping approach 
(established in Chapter 3), in the work presented in this Chapter, the kinetics and 
distributions of peritoneal myeloid subsets as well as MØ/DC phenotypes have been 
monitored from one week after catheterization to PD commencement (“pre-dialysis 
period”), and then to the end of the first year of PD therapy (“post-dialysis period”). 
These data in combination with patient information have been used to address the 
following research questions: 
z What are the main features of the peritoneal inflammatory response induced 
by the catheter insertion surgery?  
z How do peritoneal myeloid subsets as well as the MØ/DC phenotypes change 
after dialysis intervention? 
z Do patients with different clinical outcomes during the course of PD therapy 
have distinct peritoneal immune characteristics? 
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In the second part of this chapter, two different clinical cohorts of PD patients have 
been investigated. These are, first, patients diagnosed with acute PD-related 
peritonitis and, second, stable dialysis patients (under dialysis for at least one year). 
Previous studies have shown that MØs are the predominant leukocytes within PD 
dialysate from stable patients (Goldstein et al., 1984). Upon PD-related peritonitis, a 
large number of neutrophils accumulate in the peritoneal cavity during the early time 
period following infection (Lin et al., 2013). However, the distribution of MØ/DC 
subsets during peritonitis has not been well characterised. Here, the compositions of 
myeloid cells as well as MØ/DC subsets have been analysed in “cloudy” effluents 
from the first day of peritonitis episodes, and compared with data from “clean” 
effluents from uninfected stable dialysis patients. Several research questions have 
been considered: 
z What are the key features of the inflammatory response upon acute PD-related 
peritonitis, in terms of peritoneal myeloid subsets as well as MØ/DC 
phenotype/activation, compared to uninfected status? 
z Do peritonitis patients with technique failure have distinct distributions of 
peritoneal myeloid subsets as well as MØ/DC phenotype/activation? 
z Is there any pathogen-specific distribution of peritoneal myeloid subsets and 
MØ/DC phenotype/activation upon acute PD-related peritonitis? 
z Do stable dialysis patients with or without a history of peritonitis have 
different peritoneal immune characteristics? 
Overall, the aim is to understand how the kinetics and distributions of peritoneal 
myeloid subsets and MØ/DC subsets change under different clinical scenarios during 
PD therapy, and to determine whether or not the alterations of peritoneal MØ/DC 
phenotype and activation have associations with patients’ clinical outcomes. 
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4.2  Results 
 
4.2.1  Clinical outcomes of new-starter PD patients with 1-year follow-up 
To investigate the cellular distribution of peritoneal MØ/DC subsets and their 
respective kinetic change during the course of PD therapy, 50 new-starter PD patients 
were enrolled and longitudinally followed for at least 1 year (summarized in Fig. 4.1). 
Discontinuation of PD therapy within the study period has been documented and is 
mainly attributed to receiving transplantation (n = 12), non-death technique failure 
from any aetiology (shifting to haemodialysis) (n = 19), or deaths from any reason (n 
= 3). Also, follow-up on one patient was lost due to his transfer to another institute 
(Fig. 4.1). Of 50 new-starters, 44 patients successfully commenced maintenance 
dialysis, while 5 patients could not start dialysis owing to catheter dysfunction 
refractory to treatment. One patient maintained a well preserved residual kidney 
function and no need for dialysis throughout the study period. After dialysis initiation, 
another 12 patients left PD within the initial 3-month period (3 receiving 
transplantation, 1 cancer death, 8 non-death technique failure). The reasons for 
technique failure included irreversible catheter dysfunction (n = 4), ultrafiltration 
failure (n = 2), unresolved peritonitis (n = 1) and abdominal hernia (n = 1). During the 
subsequent 3 months, 4 patients were transplanted, 1 patient moved to another 
institution, 1 patient died from unresolved peritonitis and 3 patients experienced 
non-death technique failure (1 peritonitis, 1 dialysis inadequacy, 1 abdominal hernia), 
leaving 23 patients remaining on PD after 6-month dialysis. From 6 month to the end 
of the first year, 9 patients left PD (5 transplantation, 1 cardiovascular death, 3 
peritonitis-related technique failure). By the end of the first year, 14 patients remained 
on PD therapy. 
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Figure 4.1  Flow diagram of longitudinal outcomes of new-starter PD patients 
during 1-year follow-up  
A total of 50 new-starter PD patients were enrolled in this study. The reasons for 
dropout from this cohort during 1-year follow-up period included receiving 
transplantation (n = 12), transferring to other institutions (n = 1), non-death technique 
failure (n = 19), death (n = 3). The number in each parenthesis denotes the number of 
patients under this defined category. 
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4.2.2  Kinetic changes of major peritoneal myeloid cells during the 1st year of 
PD therapy 
For new-starter PD patients, the compositions of myeloid subpopulations in peritoneal 
effluents have been analysed from one week after PD catheter implantation to the end 
of the first year of treatment. Each patient would have six time points of PD fluid 
sampling if he/she could maintain PD therapy for at least one year. In total, 171 PD 
effluent samples have been analysed: 50 samples from 1st flush, 37 samples from 2nd 
flush, 39 samples from PD start, 20 samples from PD for 3 months, 15 samples from 
PD for 6 months, and 10 samples from PD for 1 year. As shown in Fig 4.2, total 
peritoneal effluent cells as well as major peritoneal myeloid subsets (neutrophils: 
CD116+HLA-DR–CD16+; eosinophils: CD116+HLA-DR–CD16– with characteristic 
FSc/SSc profile; and monocytic cells: CD116+HLA-DR+CD14+/low/–, see Fig. 3.2) 
changed over time during the 1st year of PD therapy. Generally, the cell number of 
each subset declined during the post-surgery/pre-dialysis period, from 1st peritoneal 
flush to the start of PD. After dialysis initiation, peritoneal neutrophils and eosinophils 
were significantly depleted (Fig. 4.3). By contrast, monocytic cells gradually became 
the predominant cell type (40~ 70 % of total effluent cells) in the peritoneal cavity, as 
they decreased at a relatively slow rate. 
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Figure 4.2  Changes in the numbers of major peritoneal myeloid cells during 
the 1st year of PD therapy 
Numbers of total peritoneal cells, neutrophils, eosinophils, and monocytic cells 
changed during the 1-year follow-up period. Data are representative of 171 PD 
samples from 50 patients at different time points (50 samples from 1st flush, 37 
samples from 2nd flush, 39 samples from PD start, 20 samples from PD for 3 months, 
15 samples from PD for 6 months, and 10 samples from PD for 1 year). Horizontal 
bar in each group represents the mean.  
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Figure 4.3  Kinetic changes of major peritoneal myeloid subsets during the 1st 
year of PD therapy 
Graphs showing (A) the numbers and (B) the proportion of peritoneal neutrophils, 
eosinophils, and monocytic cells changed during the 1-year follow-up period. Data 
are representative of 171 PD samples from 50 patients at different time points (50 
samples from 1st flush, 37 samples from 2nd flush, 39 samples from PD start, 20 
samples from PD for 3 months, 15 samples from PD for 6 months, and 10 samples 
from PD for 1 year). Error bars in each group denote the standard error of mean.  
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4.2.3  Kinetic changes of peritoneal macrophage and dendritic cell subsets 
during the 1st year of PD therapy 
Peritoneal monocytic cells comprise CD14+ MØs and CD1c+ DCs, and could be 
further phenotypically stratified into six subtypes based on differential expressions of 
CD16 and CD206 (see Chapter 3, Fig. 3.7). Longitudinal analysis showed that CD14+ 
MØs decreased continuously along the course of PD therapy, while CD1c+ DCs 
maintained a stable number during the pre-dialysis as well as early dialysis period, 
then declined at a relatively slow rate as dialysis continued (Fig. 4.4A). This 
distinctive kinetic change resulted in a relative increase of the proportion of CD1c+ 
DCs and a decrease in the proportion of CD14+ MØ within the peritoneal monocytic 
cell population (Fig. 4.4B). This is easily visualised as an alteration in the ratio of 
CD14+ MØ to CD1c+ DC during pre-dialysis as well as early dialysis period, then 
reaching a relative stable figure after 6-month dialysis (Fig. 4.4C).  
Subsequent kinetic investigation of six peritoneal MØ/DC subsets revealed that all 
subsets decreased in number during the course of 1st-year PD therapy (Fig. 4.5A). In 
terms of the proportion of each subset, the most interesting finding was that 
CD14+CD16+CD206+ cells (blue, solid line), initially the major subset, gradually 
declined in number, while CD14+CD16+CD206— cells (orange, dashed line) increased 
after dialysis initiation, becoming the largest cell subtype (Fig. 4.5B).  
Altogether, these findings demonstrate that the dialysis process has altered the 
peritoneal immune system by changing the distributions of peritoneal myeloid subsets 
as well as MØ/DC phenotypes.  
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Figure 4.4  Differential kinetic changes of CD14+ MØ sand CD1c+ DC during 
the 1st year of PD therapy 
Graph showing (A) the numbers and (B) the proportion of CD14+ MØ sand CD1c+ 
DC within peritoneal monocytic population changed during the 1st year of PD therapy. 
(C) The ratio of CD14+ MØs over CD1c+ DC showed an initial decline and then 
gradually stabilised after 6-month therapy. Data are representative of 171 PD samples 
from 50 patients at six time points. Data are shown as mean ± SEM. Data are analysed 
by two-way ANOVA and interaction statistics P-values are indicated. 
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Figure 4.5  Individual kinetic changes of six peritoneal monocytic subsets 
during the 1st year of PD therapy 
Graphs showing (A) the cell number of each peritoneal monocytic subset changed 
during the 1st year of PD therapy. (B) The proportion of Individual subset changed 
during the study period illustrating distinctive kinetic distribution. Data are 
representative of 171 PD samples from 50 patients at six time points. 
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4.2.4  Minimal local proliferation of peritoneal MØs and DCs alongside 
post-surgery inflammatory recruitment 
Recently, our group showed in experimental peritonitis mouse models that peritoneal 
resident MØs as well as discrete recruited inflammatory MØs could display local 
proliferative activity during the early resolution phase of specific inflammation 
(Davies et al., 2011 and 2013), providing evidence of distinctive cellular kinetics 
during tissue inflammation. The observation of a kinetic change in peritoneal MØs 
during the catheter-induced inflammation/resolution process, raises a question as to 
whether these MØs are all recruited from the periphery, or whether to some extent, 
local proliferation also contributes to the peritoneal MØ pool. To answer this question, 
intracellular Ki67 expression (proliferation marker) and DNA content (Davies et al., 
2011) of peritoneal MØs and DCs were examined in PD effluents from 1st flush, 2nd 
flush and 1st exchange at PD start (Fig. 4.6). The results suggested that the majority of 
peritoneal MØs and DCs were within G0 phase of cell cycle. Very few proliferating 
cells (< 0.1% of cells, defined as cells within S-G2-M phase) were found in either 
subset (Fig. 4.6A & B). There was no significant difference in proliferative activity 
between the three time points (Fig 4.6C). These preliminary observations implied that 
the peritoneal MØ/DC pool during the post-surgery period originates principally via 
inflammatory recruitment from the periphery, with limited contribution from local 
proliferation. 
  
97 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6  Minimal proliferative activity of peritoneal MØ/DC during   
post-surgery inflammation 
(A) Flow-cytometric gating strategy used to serially exclude doublets before accurate 
analysis of DNA content and proliferation of specific subset (Davies et al., 2011). (B) 
Representative density plots of DAPI staining for DNA content and intracellular Ki67 
expression (proliferation marker) in CD14+ MØs and CD1c+ DCs, respectively. The 
majority of either MØs or DCs, were within G0 phase, while only very few cells under 
S-G2-M phase, suggesting that minimal proliferative activity had occurred. Data are 
derived from the 2nd PD flush of one new-starter patient. (C) Graph showing the 
percentage of respective MØs and DCs under S-G2-M phase at three time-point 
sample analysis. Data are derived from the analysis of 15 samples in total (n = 5 per 
time point). Data are shown as mean ± SEM.  
  
0 32 64 96 128
DNA Lin
10 0
10 1
10 2
10 3
10 4
ki
67
 L
og
0 32 64 96 128
DNA Lin
10 0
10 1
10 2
10 3
10 4
ki
67
 L
og
0 64 128 192 256
FS Lin
0
64
128
192
256
FS
 A
re
a
0 64 128 192 256
DNA Lin
0
64
128
192
256
D
N
A 
Ar
ea
0 64 128 192 256
DNA Lin
0
64
128
192
256
Pu
ls
e 
W
id
th
FS in DAPI Lin DAPI Lin 
G1 
G0 
SG2M 
FS
 A
re
a 
D
A
PI
 A
re
a 
 
D
A
PI
 A
re
a 
 
Polyploidy Polyploidy 
SG2M G1 
G0 
DAPI Lin DAPI Lin 
CD14+MØ CD1c
+DC 
Predialysis proliferation
1s
t F
lus
h
2n
d F
lus
h
1s
t E
xc
ha
ng
e
0.00
0.01
0.02
0.03
0.04
0.05
CD14+ M)
CD1c+ DC
%
 S
G
2M
A 
B C 
K
i6
7 
K
i6
7 
Predialysis proliferation
1s
t F
lus
h
2n
d F
lus
h
1s
t E
xc
ha
ng
e
0.00
0.01
0.02
0.03
0.04
0.05
CD14+ M)
CD1c+ DC
%
 S
G
2M
98 
 
4.2.5  Is the catheter-induced peritoneal inflammatory response associated with 
early non-peritonitis technique failure in new-starter PD patients? 
The fact that PD catheter insertion elicits a sterile inflammatory response, represents 
the patient’s immune system response to surgical injury as well as catheter tubing 
itself. During inflammation, peritoneal exudates containing fibrins accumulate in the 
peritoneal cavity, in severe cases, resulting in catheter occlusion. That is the reason 
why catheter dysfunction is one of the major causes for early technique failure in PD 
(Béchade et al., 2013; Kolesnyk et al., 2010; Quinn et al., 2010). In this cohort, 9 
patients suffered from catheter dysfunction-related technique failure (5 patients before 
dialysis and 4 patients soon after dialysis start). Compared to patients without early 
technique failure (n = 32), those with catheter failure (n = 9) had significantly higher 
peritoneal neutrophils and higher MØ to DC ratio at the 1st PD flush (Fig. 4.7). 
Notably, a higher percentage of CD16+ in CD14+ MØs was also observed in patients 
with catheter failure (Fig. 4.8A). In terms of MØ/DC subtypes, the most significant 
difference between two groups was a higher proportion and higher numbers of 
CD14+CD16+CD206‒ subtype (Fig. 4.8B & C) in patients with catheter failure than 
those without early technique failure. 
Additionally, compared to patients maintaining dialysis for 1 year (n = 14), those with 
post-dialysis non-peritonitis technique failure (n = 7, 4 for catheter dysfunction, 3 for 
membrane dysfunction including ultrafiltration failure and dialysis inadequacy) had 
distinct pre-dialysis inflammatory kinetics with a relatively slower rate of decline in 
the ratios of MØ to DC (Fig. 4.9).  
Collectively, these preliminary observations implied that severe or delayed resolution 
of catheter-induced inflammation may be associated with higher risk of developing 
early non-peritonitis technique failure in new-starter PD patients. 
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Figure 4.7  Comparisons of peritoneal myeloid cells from the 1st flush PD 
effluents between new-starter PD patients without early technique 
failure versus those with catheter-related technique failure 
Graphs showing the comparisons of total peritoneal cells, peritoneal neutrophils, 
eosinophils, macrophages and dendritic cells (in number) from 1st PD flush effluent 
samples between new-starter patients without early technique failure (n = 32) versus 
with catheter failure (n = 9). Horizontal bars represent the mean. The ratio of CD14+ 
MØ to CD1c+ DC was compared between two outcomes (right lower graph). Data are 
shown as mean ± SEM. Data are analysed by Student’s t-test (if parametric) or Mann 
Whitney U test (if nonparametric). (ns= P> 0.05, *= P≤ 0.05, **= P≤ 0.01 and ***= 
P≤ 0.001) 
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Figure 4.8  Differential distributions of peritoneal MØ/DC subsets from the 1st 
flush PD effluents between new-starter PD patients with and 
without catheter failure 
(A) Graphs showing the proportion of CD16+ (left) or CD206+ (right) expression on 
CD14+ MØ. (B) Pie charts demonstrating the proportion of four peritoneal MØ 
subsets. (C) Graph depicting actual number of each peritoneal monocytic subset from 
the 1st flush PD effluents of new-starter patients. Comparisons were performed 
between patients with catheter failure (n = 9) and those without technique failure (n = 
32). Data are shown as mean ± SEM. Data are analysed by Student’s t-test (if 
parametric) or Mann Whitney U test (if nonparametric). (ns= P> 0.05, *= P≤ 0.05, 
**= P≤ 0.01 and ***= P≤ 0.001) 
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Figure 4.9  Comparisons of kinetic changes of peritoneal myeloid cells during     
pre-dialysis period between new-starter PD patients with and 
without non-peritonitis technique failure 
Graphs showing the kinetic changes of the numbers of peritoneal neutrophils, 
eosinophils, MØs, DCs as well as MØ to DC ratio during the pre-dialysis period. 
Comparisons were made between new-starter PD patients with non-peritonitis 
technique failure (gray dots with solid line, n = 7) and those without failure (white 
dots with dashed line, n =14) within the first year of PD therapy. Error bars denote 
standard error of mean. Data are analysed by two-way ANOVA. (I: interaction, O: 
catheter outcomes, T: time factor; the numbers shown denote P-values)  
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4.2.6  Association between peritoneal immune characteristics and the risk for 
developing first episode of peritonitis during the 1st year PD therapy 
Peritonitis remains the most frequent cause of technique failure in PD despite the 
observed decline in incidence over the past decades (Davenport et al., 2009). Several 
epidemiological studies have looked for the risk factors or predictors for developing 
first peritonitis episode in incident PD patients (Chow et al., 2005; Nessim et al., 2009, 
Matin et al., 2011). These studies mainly focused on the demographic as well as 
clinical characteristics, i.e., age at PD start, gender, race/ethic, primary cause of ESRF, 
diabetic status, socioeconomic circumstance. However, little is known with regards to 
the association between peritoneal immune characteristics and the risk for developing 
PD-related peritonitis.     
In this cohort, of 44 successfully commenced PD patients, 8 patients developed first 
peritonitis episode during the 1st year of PD therapy. Only 12 patients maintained 
dialysis for more than one year without experiencing any peritonitis event. To 
investigate whether or not peritoneal immune characteristics at the start of PD could 
predict the risk for developing first peritonitis episode within the 1st year of PD 
therapy, the distributions of peritoneal myeloid cells as well as MØ/DC phenotypes at 
the start of PD were compared between patients who had first peritonitis episode (n = 
8) and those free from peritonitis for one year (n = 12). The results were shown in 
Table 4.1. There is no significant difference between two groups regarding the 
peritoneal immune characteristics presented in this study. 
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Table 4.1  Comparisons of clinical and peritoneal immune characteristics at the 
start of PD between patients free from peritonitis and patients 
developing first peritonitis episode within the 1st year of PD therapy 
Parameters 
Patients free from 
peritonitis (n =12) 
Patients having 
peritonitis (n = 8) 
P-value 
Clinical characteristics 
  Age at PD start (year-old) 56.33 ± 4.96 60.13 ± 5.96 0.6322 
  Gender (% female) 16.7 50 0.1110 
  Diabetes (%) 41.7 12.5 0.1632 
Peritoneal immune characteristics 
  Total peritoneal cells (x106) 55.93 ± 8.71 44.19 ± 7.00 0.3470 
  Neutrophils (x106) 13.53 ± 8.03 8.84 ± 5.01 0.6664 
  Eosinophils (x106) 9.56 ± 3.81 8.12 ± 4.04 0.8034 
  Macrophages (x106) 18.13 ± 2.67 16.38 ± 2.49 0.6561 
  Dendritic cells (x106) 1.60 ± 0.20 1.51 ± 0.15 0.7436 
  MØ to DC ratio 12.07 ± 1.23 10.83 ± 1.20 0.4991 
  % CD16+ in MØ 61.50 ± 3.43 61.47 ± 4.70 0.9962 
  % CD206+ in MØ 50.68 ± 5.00 45.57 ± 2.67 0.4449 
  % CD16+CD206+ in MØ 42.57 ± 5.52 36.25 ± 5.96 0.4581 
  % CD16+CD206‒ in MØ 27.72 ± 4.88 25.93 ± 3.58 0.7918 
  % CD16‒CD206+ in MØ 10.83 ± 2.18 15.25 ± 3.23 0.2530 
  % CD16‒CD206‒ in MØ 18.87 ± 2.67 22.56 ± 4.12 0.4398 
CD14+CD16+ MØ (x106) 10.85 ± 1.45 10.40 ± 1.94 0.8520 
CD14+CD206+ MØ (x106) 9.15 ± 1.19 7.35 ± 1.08 0.3068 
  CD14+CD16+CD206+ MØ (x106) 6.74 ± 0.01 5.24 ± 0.96 0.3191 
  CD14+CD16+CD206‒ MØ (x106) 4.30 ± 0.87 5.17 ± 1.03 0.5329 
  CD14+CD16‒CD206+ MØ (x106) 2.22 ± 0.33 2.11 ± 0.28 0.8229 
  CD14+CD16‒CD206‒ MØ (x106) 4.87 ± 1.28 3.86 ± 0.58 0.5495 
  CD1c+CD206+ DC (x106) 0.94 ± 0.11 0.97 ± 0.86 0.8528 
  CD1c+CD206‒ DC (x106) 0.66 ± 0.11 0.54 ± 0.08 0.427 
Data are expressed as mean ± standard error of mean. Group differences are assessed by Student’s t-test 
(if parametric) or Mann Whitney U test (if nonparametric) for continuous variables and chi-square test 
for categorical variables. 
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4.2.7  Differential distributions of peritoneal myeloid cells and MØ/DC subsets 
between infected PD effluents from acute peritonitis patients and 
uninfected PD fluids from stable dialysis patients 
In the second part of this chapter, a cohort of PD patients experiencing acute 
PD-related peritonitis was enrolled. A total of 37 acute bacterial peritonitis episodes 
were recorded during the study period. Microbiological data showed that 26 episodes 
were gram positive bacteria, 8 episodes were gram negative bacteria, and 3 episodes 
with mixed gram positive/negative bacteria. Notably, 30 episodes had been 
successfully treated, while 7 episodes had unresolved peritonitis leading to technique 
failure or peritonitis-related death. Meanwhile, a total of 37 uninfected PD fluid 
samples (overnight long-dwell bags) were collected from 37 patients under stable 
dialysis for more than one year. History of peritonitis and the number of peritonitis 
episodes were recorded. Of them, 17 patients had a history of peritonitis (9 patients 
with a single episode and 8 patients with more than one episode). 
The results shown in Fig 4.11 revealed that peritoneal neutrophils, eosinophils, MØs, 
DCs, significantly increased in the infected fluid samples from day 1 bacterial 
peritonitis, compared to uninfected fluid samples from stable dialysis patients. 
Interestingly, in patients with acute peritonitis, the increase in CD14+ MØs was much 
greater than CD1c+ DCs, and the ratio of MØ to DC also increased significantly, from 
6.6 ± 0.6 fold in uninfected samples to 110.1 ± 15.4 fold in peritonitis samples. 
Additionally, the percentage of CD16+ or CD206+ expression in CD14+ MØs was 
much lower in the presence of peritonitis (Fig. 4.11A). With regards to MØ subtypes, 
the proportion of CD14+CD16‒CD206‒ subset was significantly higher in the infected 
fluid samples compared to uninfected fluid samples (Fig. 4.11B). All six MØ/DC 
subtypes increased in number during acute bacterial peritonitis (Fig. 4.11C). 
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Figure 4.10  Comparisons of major peritoneal myeloid cells between infected 
PD effluents from day 1 acute bacterial peritonitis and uninfected 
fluids from stable dialysis patients 
Graphs showing the comparisons of total peritoneal cells, peritoneal neutrophils, 
eosinophils, MØs and DCs (in number) within infected PD fluids on day 1 acute 
bacterial peritonitis (n = 37) versus uninfected fluids from stable dialysis patients (n = 
37). The ratio of CD14+ MØ to CD1c+ DC was compared between two groups (right 
lower panel). Data are shown as mean ± SEM. Data are analysed by Student’s t-test 
(if parametric) or Mann Whitney U test (if nonparametric). (ns= P> 0.05, *= P≤ 0.05, 
**= P≤ 0.01 and ***= P≤ 0.001) 
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Figure 4.11  Differential distributions of peritoneal MØ/DC subsets between PD 
patients with bacterial peritonitis versus the stable dialysis patients 
(A) Graphs showing the proportion of CD16+ (left) or CD206+ (right) expression on 
CD14+ MØ. (B) Pie charts illustrating the distribution of individual MØ subset. (C) 
Graph depicting actual number of each MØ/DC subset within infected PD effluents 
on day 1 bacterial peritonitis (n = 37) versus uninfected fluids from stable dialysis 
patients (n = 37). Data are shown as mean ± SEM. Data are analysed by Student’s 
t-test (if parametric) or Mann Whitney U test (if nonparametric). (ns= P> 0.05, *= P≤ 
0.05, **= P≤ 0.01 and ***= P≤ 0.001) 
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4.2.8   Differential distributions of peritoneal myeloid cells and MØ/DC subsets 
between patients with and without treatment failure upon bacterial 
peritonitis 
The reasons for treatment failure upon PD-related bacterial peritonitis may be 
multi-factorial, including antibiotic efficacy, pathogen virulence, and host immunity. 
It is assumed that impaired or dysregulated host peritoneal immune response to 
invaded pathogens may play a contributive role. Here, the aim is to examine whether 
peritonitis patients with unresolved peritonitis leading to technique failure or 
infectious deaths, have distinctive recruitment of peritoneal myelomonocytic cells 
during bacterial peritonitis. To answer this question, the cellular constituents of PD 
effluent samples from the day 1 bacterial peritonitis were compared between episodes 
with treatment failure (n = 7) and those successfully treated (n = 30). As shown in Fig. 
4.12, unresolved/refractory peritonitis episodes were associated with significantly 
higher numbers of peritoneal neutrophils, eosinophils, MØs and DCs as well as higher 
ratio of MØ to DC than successfully treated ones. Although there was no significant 
difference of the percentage of CD16+ or CD206+ in CD14+ MØs between two groups 
(Fig. 4.12A), there were significant increase in the numbers of CD14+CD16– (CD206+ 
or –) MØs in peritonitis patients with poor outcomes, compared to successfully treated 
group (Fig. 4.13B & C). 
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Figure 4.12  Comparisons of major peritoneal myeloid cells between bacterial 
peritonitis episodes with treatment success versus those with 
treatment failure 
Graphs showing the comparisons of total peritoneal cells, peritoneal neutrophils, 
eosinophils, macrophages and dendritic cells (in number) within PD effluents from 
the 1st day of acute bacterial peritonitis episodes between “treatment success” group 
(n = 30) versus “treatment failure” group (n = 7). The ratio of CD14+ MØ to CD1c+ 
DC was also compared between two outcomes. Data are shown as mean ± SEM. Data 
are analysed by Student’s t-test (if parametric) or Mann Whitney U test (if 
nonparametric). (ns= P> 0.05, *= P≤ 0.05, **= P≤ 0.01 and ***= P≤ 0.001) 
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Figure 4.13  Differential distributions of peritoneal MØ/DC subsets between 
bacterial peritonitis with treatment success versus treatment failure 
(A) Graphs showing the proportion of CD16+ (left) or CD206+ (right) expression on 
CD14+MØ. (B) Pie charts demonstrating the distribution of individual MØ subset. (C) 
Graph depicting actual number of each peritoneal monocytic subset within PD 
effluents from the 1st day of acute bacterial peritonitis episodes. The comparisons 
were performed between “treatment success” group (n = 29) versus “treatment failure” 
group (n = 9). Data are shown as mean ± SEM. Data are analysed by Student’s t-test 
(if parametric) or Mann Whitney U test (if nonparametric). (ns= P> 0.05, *= P≤ 0.05, 
**= P≤ 0.01 and ***= P≤ 0.001) 
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4.2.9   Pathogen-specific distributions of peritoneal myeloid cells and MØ/DC 
subsets during acute bacterial peritonitis 
A recent study suggested that pathogen-specific inflammatory characteristics (an 
“immune fingerprint”) based on leukocyte subsets (particular T lymphocyte subsets) 
and cytokine profiles in PD effluent fluids could distinguish culture-positive from 
culture-negative peritonitis, as well as gram positive peritonitis from gram negative 
peritonitis (Lin et al., 2013). Here, the distribution of peritoneal myelomonocytic cells 
during peritonitis was compared between culture-positive peritonitis (n = 37) and 
culture-negative peritonitis (n = 5). As shown in Figure 4.14, PD effluents from 
culture-positive peritonitis had significantly higher numbers of total peritoneal cells 
and neutrophils, compared to those from culture-negative peritonitis. Additionally, 
culture-positive peritonitis had a trend to lower proportion of CD16+ or CD206+ in 
CD14+ MØs (Fig. 4.15A), and more specifically, a higher proportion of CD16–
CD206– (Fig. 4.15B), than those in culture-negative peritonitis. There was a general 
trend that culture-positive peritonitis had higher numbers of each MØ/DC subtype 
than culture-negative peritonitis (Fig. 4.15C). 
Next, the comparisons among gram positive peritonitis (n = 26) and gram negative 
peritonitis (n = 8) and mixed gram positive/negative bacterial peritonitis (n = 3) were 
conducted. The results showed a trend of higher numbers of each myeloid subset in 
the mixed gram positive/negative peritonitis, compared to either gram positive or 
negative peritonitis. No significant differences in numbers of peritoneal neutrophils, 
eosinophils, MØs and DCs between gram positive and gram negative peritonitis were 
found (Fig. 4.16). However, those with gram negative peritonitis had a trend for a 
lower proportion of CD16+ in CD14+ MØ and higher proportion of CD16–CD206– 
than those with gram negative peritonitis (Fig. 4.17). 
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Figure 4.14  Comparisons of major peritoneal myeloid cells between 
culture-negative versus culture-positive peritonitis 
Graphs showing the comparisons of total peritoneal cells, peritoneal neutrophils, 
eosinophils, macrophages and dendritic cells (in number) within PD effluents from 
the 1st day of PD-related peritonitis between culture-negative peritonitis (n = 5) and 
culture-positive peritonitis (n = 37). The ratio of CD14+ MØ to CD1c+ DC was 
compared between two groups (right lower panel). Data are shown as mean ± SEM. 
Data are analysed by Student’s t-test (if parametric) or Mann Whitney U test (if 
nonparametric). (ns= P> 0.05, *= P≤ 0.05, **= P≤ 0.01 and ***= P≤ 0.001) 
 
 
Mac: DC ratio
)
Cu
ltu
re 
(
Cu
ltu
re 
(+)
0
50
100
150
C
D
14
+ 
M
) 
: C
D
1c
+ 
D
C ns 
Total peritoneal cells
)
Cu
ltu
re 
(
Cu
ltu
re 
(+)
107
108
109
1010
1011
C
el
l c
ou
nt
s
* * 
Neutrophils
)
Cu
ltu
re 
(
Cu
ltu
re 
(+)
107
108
109
1010
1011
C
el
l c
ou
nt
s
Eosinophils
)
Cu
ltu
re 
(
Cu
ltu
re 
(+)
105
106
107
108
109
1010
C
el
l c
ou
nt
s
ns 
Macrophages
)
Cu
ltu
re 
(
Cu
ltu
re 
(+)
105
106
107
108
109
1010
C
el
l c
ou
nt
s
ns 
Dendritic cells
)
Cu
ltu
re 
(
Cu
ltu
re 
(+)
105
106
107
108
109
1010
C
el
l c
ou
nt
s ns 
112 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15  Differential distributions of peritoneal MØ/DC subsets between 
culture-negative and culture-positive bacterial peritonitis 
(A) Graphs showing the proportion of CD16+ (left) or CD206+ (right) expression on 
CD14+ MØ. Horizontal bars represent the mean. (B) Pie charts demonstrating the 
distribution of individual MØ subset. (C) Graph depicting actual number of each 
peritoneal monocytic subset within PD effluents from the 1st day of PD-related 
peritonitis. The comparisons were performed between culture-negative (n = 5) versus 
culture-positive peritonitis (n = 37). Data are shown as mean ± SEM. Data are 
analysed by Student’s t-test (if parametric) or Mann Whitney U test (if nonparametric). 
(ns= P> 0.05, *= P≤ 0.05, **= P≤ 0.01 and ***= P≤ 0.001) 
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Figure 4.16  Comparisons of major peritoneal myeloid cells among gram- 
positive, gram-negative and mixed bacterial peritonitis 
Graphs showing the comparisons of total peritoneal cells, peritoneal neutrophils, 
eosinophils, macrophages and dendritic cells (in number) within PD effluents from 
the 1st day of bacterial peritonitis among gram-positive (n = 8), gram-negative and 
mixed bacterial peritonitis (n = 20). The ratio of CD14+ MØ to CD1c+ DC was also 
compared. Horizontal bars denote the median. Data are analysed for statistical 
significance by Kruskal-Wallis (KW) test and Dunn’s multiple comparison post-tests 
(asterisks) are indicated where significant (ns= P> 0.05, *= P≤ 0.05, **= P≤ 0.01 and 
***= P≤ 0.001) 
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Figure 4.17  Differential distributions of peritoneal MØ/DC subsets between 
gram-positive and gram-negative bacterial peritonitis 
(A) Graphs showing the proportion of CD16+ (left) or CD206+ (right) expression on 
CD14+ MØ. (B) Pie charts demonstrating the distribution of individual MØ subset. (C) 
Graph depicting actual number of each peritoneal monocytic subset within PD 
effluents from the 1st day of bacterial peritonitis. The comparisons were performed 
between gram-negative (n = 5) versus gram-positive bacterial peritonitis (n = 24). 
Data are shown as mean ± SEM. Data are analysed by Student’s t-test (if parametric) 
or Mann Whitney U test (if nonparametric). (ns= P> 0.05, *= P≤ 0.05, **= P≤ 0.01 
and ***= P≤ 0.001) 
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4.2.10  Impact of peritonitis history on the distributions of peritoneal myeloid 
cells and MØ/DC subsets in patients under stable dialysis 
Clinically, some PD patients might experience one or more episodes of peritonitis 
during maintenance dialysis, while others could remain free from peritonitis for years. 
Earlier study revealed that stable PD patients who had a peritonitis history would have 
a distinct immunological profile of peritoneal MØ, compared to patients free from 
peritonitis (Lin et al., 1990). Whether or not the history of peritonitis would change 
the distribution of peritoneal myeloid cells and MØ/DC phenotypes is unclear. Here, a 
comparison of stable dialysis patients (defined as maintaining PD for at least one year) 
without history of peritonitis and those with only one episode or multiple episodes of 
peritonitis showed that there is a higher number of peritoneal MØs as well as higher 
MØ to DC ratio in patients with multiple episodes of peritonitis, compared to those 
without any history of peritonitis (Fig. 4.18). However, there is no difference between 
those with single peritonitis episode and those without any history of peritonitis in 
terms of each myeloid subset. Compared with no history of peritonitis, those with 
history of peritonitis (including single and multiple episodes) had a trend of increase 
in the proportion and also the number of CD14+CD16+CD206– subtype (Fig. 4.19).  
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Figure 4.18  Comparisons of major peritoneal myeloid cells and MØ/DC subsets 
between stable dialysis patients without history of peritonitis, with 
only one episode of peritonitis and with more than one episode of 
peritonitis 
Graphs showing the comparisons of peritoneal neutrophils, eosinophils, macrophages 
and dendritic cells (in number) within PD effluents from stable dialysis patients 
without history of peritonitis (n = 20), with only one episode of peritonitis (n = 9) and 
with more than one episode of peritonitis (n = 8). The ratio of CD14+ MØ to CD1c+ 
DC was also compared. Horizontal bars denote the median. Data are analysed for 
statistical significance by Kruskal-Wallis (KW) test and Dunn’s multiple comparison 
post-tests (asterisks) are indicated where significant (ns= P> 0.05, *= P≤ 0.05, **= P≤ 
0.01 and ***= P≤ 0.001) 
KW: P=0.1037 KW: P=0.7144 
KW: P=0.0402 KW: P=0.7127 KW: P=0.0301 
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Figure 4.19  Differential distributions of major peritoneal MØ/DC subsets 
between stable dialysis patients without history of peritonitis and 
those with history of peritonitis 
(A) Graphs showing the proportion of CD16+ (left) or CD206+ (right) expression on 
CD14+ MØ. (B) Pie charts demonstrating the distribution of individual MØ subset. (C) 
Graph depicting actual number of each peritoneal monocytic subset within PD 
effluents from stable dialysis patients without and with peritonitis. The comparisons 
were performed between those without peritonitis history (n = 20) versus those with 
peritonitis history (n = 17). Data are shown as mean ± SEM. Data are analysed by 
Student’s t-test (if parametric) or Mann Whitney U test (if nonparametric).  (ns= P> 
0.05, *= P≤ 0.05, **= P≤ 0.01 and ***= P≤ 0.001) 
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4.3  Discussion 
 
The results in this chapter have demonstrated that the intervention of PD therapy in 
ESRD patients has changed the peritoneal immune system and altered the 
composition of peritoneal myeloid subsets and the MØ/DC phenotypes as well as 
their activation/maturation status. Individual clinical circumstance, such as 
post-catheter implantation in new-starters, during acute PD-related peritonitis, or 
under long-term stable dialysis, displayed unique distributions of myeloid 
subpopulations and distinct MØ/DC phenotypic changes. These observations also 
suggested that the altered constituents of peritoneal myeloid cells as well as the 
variable MØ/DC phenotypes and activation/ maturation status might represent 
different situations of intraperitoneal inflammation, which in turn could be linked to 
different patients’ clinical outcomes. 
In new-starter patients, the compositions of peritoneal myeloid cells and MØ/DC 
phenotypes have been greatly altered by the commencement of PD. Mononuclear 
phagocytes become the predominant leukocytes in the peritoneal cavity after dialysis. 
Perhaps the most interesting finding is the distinctive kinetics of CD14+ MØs and 
CD1c+ DCs during the course of PD therapy. CD1c+ DCs maintained a relatively 
stable number in the pre-dialysis phase and appeared more resistant to the dialysis 
depletion, which was in contrast to CD14+ MØs, implying these two monocytic 
subsets might have distinctive recruitment and/or differentiation processes during 
homeostasis and inflammation. Indeed, a significantly greater number of CD14+ MØs 
were recruited during an episode of peritonitis, compared to CD1c+ DCs. In the future, 
it may be of interest to explore the underlying mechanisms controlling the trafficking 
of the respective cell types, or differentiation pathways, in a particular clinical setting. 
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Regarding the MØ subtypes, the results suggested that the mature CD16+CD206+ 
MØs considerably decreased after dialysis intervention, replaced by the relatively 
immature CD16+CD206‒ MØs. This phenomenon could be explained by the 
maturation process of newly recruited MØs being perturbed under continuous dialysis 
process, possibly due to dilution of the growth factors that stimulate MØ maturation. 
Upon peritonitis, CD16‒CD206‒ MØs became the major subtype. As these MØs were 
phenotypically close to circulating classical blood monocytes, it is suggested that the 
latter were heavily recruited into peritoneal cavity upon PD-related peritonitis. The 
fate of these recruited MØs, either becoming activated or differentiated into other 
subsets, is difficult to determine owing to the practice of continuous fluid exchanges 
in the context of PD.  
In the aspect of the associations between the peritoneal immune characteristics and 
patient outcomes, the relatively small size of this cohort did limit the interpretation of 
the results. However, some of the preliminary observations are noteworthy. For 
example, the ratio of MØ to DC could be a potential indicator of the severity of 
intraperitoneal inflammation. Higher MØ/DC ratio was associated with poor patient 
outcomes as demonstrated in new-starter patients (catheter failure versus no failure) 
and in peritonitis cases (treatment failure versus treatment success). The value of the 
differential expression of CD16 and CD206 in CD14+ MØs (or the distribution of MØ 
subtypes) in predicting patient outcomes is not prominent in the present study, 
although it is worth pointing out some alterations possibly correlating to clinical 
outcomes. For example, the increased proportion of CD16–CD206– MØs 
(“monocyte-like”) has been noted in peritonitis cases with culture-positive (versus 
culture-negative), gram-negative (versus gram-positive) as well as treatment failure 
(versus treatment success), suggesting the “skewed” pattern of peritoneal MØ 
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activation/maturation might reflect a unique inflammatory scenario. Larger size of 
patient cohorts would be needed to justify these complex relationships. As for stable 
dialysis patients, there seemed to be a trend that patients experiencing multiple 
peritonitis episodes may have a higher number of peritoneal MØs and a higher ratio of 
MØ to DC, compared to those without any history of peritonitis. This preliminary 
observation could be explained by the fact that patients have had multiple episodes of 
peritonitis would acquire a more inflamed peritoneum with more inflammatory 
monocyte/MØ infiltration and then release into the peritoneal cavity. Indeed, a recent 
observational study revealed that stable dialysis patients with past history of 
peritonitis had higher levels of dialysate MCP-1, a major inflammatory chemokine for 
monocyte migration, compared to those with no history of peritonitis (Malik et al., 
2007). Interestingly, both peritoneal macrophage infiltration (Sawai et al., 2011) and 
dialysate MCP-1 level (Malik et al., 2007) are positively correlated with higher 
peritoneal solute transport rate in new-starter PD patients and in stable dialysis 
patients, respectively. Hence, the increased MØ accumulation (and also the MØ to DC 
ratio) within PD effluents may reflect chronic inflammation of the patient’s peritoneal 
membranes as a sequela of repeated peritonitis. However, it has to be mentioned that 
even in patients without any history of peritonitis, there is a substantial variation of 
peritoneal MØ number accumulating within PD effluents, suggesting that other 
factors such as uraemic background, time and/or types of dialysis fluids use, may also 
contribute to local peritoneal inflammation in long-term PD patients.  
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Chapter Five 
 
Characterisation of ‘dendritic cell-like’ subsets in 
murine peritoneal cavity 
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5.1   Introduction 
 
Dendritic cells (DCs) are professional antigen-presenting cells (APCs), acting as central 
regulators between innate and adaptive immune system. Recently, subsets of 
heterogeneous DC populations in lymphoid and non-lymphoid tissues have been 
defined in mice and humans (Merad et al., 2013; Schlitzer and Ginhoux 2014), however, 
the DC phenotype in the mouse peritoneal cavity and its role in the clinically relevant 
experimental peritonitis models remains poorly understood. In parallel with the novel 
identification of human peritoneal DCs within the dialysate of PD patients (see Chapter 
3 and 4), it is important to investigate the immunobiology of mouse peritoneal DC 
subsets in order to understand possible variations between humans and mice in terms 
of cellular kinetics during peritonitis as well as their phenotypes and functions. 
Moreover, the interspecies comparisons will be useful in the future for defining the role 
of peritoneal DCs in pathological conditions including acute peritonitis and repeated 
peritonitis-related peritoneal fibrosis.  
In the peritoneal cavity of mice, the initial observations of Steinman’s group identified 
a relatively rare population with high MHCII expression and weak CD11c expression, 
but this was masked by the relative high autofluorescence of resident macrophages 
(‘ResMØs’) (Witmer-Pack et al., 1993). Recently, a 12/15-LOX– myeloid cell type in 
the naïve peritoneal cavity has been characterised by our group, with a distinct 
F4/80int/lowMHCII+ and high expression of CD116 (GM-CSF receptor alpha-chain) and 
CD206 (macrophage mannose receptor). These cells were able to mount effective 
inflammatory responses (Rosas et al., 2007; Dioszeghy et al., 2008) and present model 
antigens to naïve CD4+ T cells, which led to their tentative classification as ‘DC-like’ 
cells (Dioszeghy et al., 2008). However, we could not clearly identify these ‘DC-like’ 
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cells within the bulk population of infiltrating MØs in the inflammatory settings (named 
as inflammatory macrophages, ‘InfMØs’) due to their overlapping immunophenotypes 
(F4/80int/lowMHCII+). Subsequently, the presence and function of these cells has been 
ratified by other groups, however, the inability to discriminate these cells from 
monocyte-derived MHCII+ InfMØs, has led to the ambiguity and confusion of whether 
these cells represent a mix of ‘bona-fide’ DC and MHCII+ MØ populations during 
inflammation (Ghosn et al., 2010; Cassado Ados et al., 2011; Nguyen et al., 2012).  
Since these peritoneal DC subsets remain poorly defined, the functional roles and 
cellular kinetics of these particular cell types during tissue homeostasis as well as 
intraperitoneal inflammation-resolution process are also not well characterized. 
Hence, the specific aims of this chapter are:  
1. To validate a select panel of surface markers for phenotypic determination of 
peritoneal ‘DC-like’ subsets during homeostasis and inflammation.  
2. To investigate the respective cellular kinetics of distinct peritoneal MØ/DC 
subpopulations in relevant experimental peritonitis models, including acute SES-
induced peritonitis and acute zymosan-induced peritonitis.  
3. Finally, to assess each individual subset’s responsiveness to external microbial 
product stimulation, capacity to clear apoptotic cells and their capability of 
processing and presenting antigen to helper T cells.  
Together, these data will help to delineate the nature of the DC network in the murine 
peritoneal cavity and will inform as to whether mouse peritoneal DCs exhibit 
similarities with the newly identified human peritoneal DCs, and hence whether mice 
are a useful animal model for the study of human diseases. 
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5.2   Results 
 
5.2.1   Phenotypic identification of murine peritoneal ‘DC-like’ subsets under 
steady state 
Myelomonocytic cells in the mouse peritoneal cavity can be subdivided based on 
expression of CD11b and F4/80 (Rosas et al., 2007; Dioszeghy et al., 2008; Ghosn et 
al., 2010). In the steady state, apart from the large number of 
CD11bhighF4/80highMHCIIlow/‒ ResMØs, a minor population has been noted with a 
CD11bintF4/80int-lowMHCII+ phenotype (Fig. 5.1A). This rare population, considered to 
be ‘DC-like’ because of their ability to present antigen to naïve T cells (Dioszeghy et 
al., 2008), is phenotypically heterogeneous and not readily defined by CD11c, a 
traditional surface marker for DCs. More importantly, these cells could not be clearly 
discriminated from recruited InfMØs during inflammation in our previous studies 
(Rosas et al., 2007; Dioszeghy et al., 2008). By analysis of published microarray data 
comparing peritoneal ‘F4/80lowMHCII+’ cells (most likely a mixed population, 
containing InfMØs and ‘DC-like’ cells) with ‘F4/80intMHCII+’ cells (predominantly 
comprising InfMØs) 5 days after the induction of inflammation with thioglycollate 
broth, a series of differentially expressed genes were identified (Table 1, data analysis 
performed by Dr. Peter Giles). Notably, F4/80lowMHCII+ cells were associated with 
higher expression of Cd226 and Cd209a. Based on the differential surface expression 
of CD11c and CD226, three putative peritoneal ‘DC-like’ subsets could be separated: 
CD226+CD11c+, CD226+CD11clow and CD11c+CD226low (Fig. 5.1A). Interestingly, 
CD226+ cells were associated with higher CD11b, but heterogeneous CD209a and 
CD11c. Whilst CD11c+CD226low cells were primarily CD209+ and had lower CD11b 
than their CD226+ counterparts (Fig. 5.1B). Thus neither CD11c nor CD209a allowed 
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definitive identification of a discrete DC population, but CD11c+CD226low expression 
did appear to define one population of cells.  
Further immunophenotyping depicts that all three putative peritoneal ‘DC-like’ 
populations and ResMØs, express co-stimulatory molecules CD80 and CD86 (Fig. 5.2), 
however, only the ‘DC-like’ cells express CD206 (macrophage mannose receptor) (also 
shown by Dioszeghy et al., 2008), CD301 (macrophage galactose-type C-type lectin, 
MGL1/MGL2) and CCR2. Of the three subsets, CD11c+CD226low cells have more 
uniformly high CD209a (DC-SIGN) expression. By contrast, ResMØs express higher 
levels of MerTK, CD36, CD64 (FcγRI) and CD73 than all three ‘DC-like’ subsets, 
suggesting that these markers are more ‘MØ-associated’.  
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Figure 5.1  Phenotypic identification of peritoneal ‘DC-like’ subsets in the naïve 
murine peritoneal cavity  
(A) Flow-cytometric analysis of peritoneal cells from naïve mice. Density plots shown 
were gating strategies to identify ResMØs (CD11bhighF4/80highMHCIIlow/‒) and ‘DC-
like’ cells (CD11bintF4/80int-lowMHCII+). The latter were readily subdivided into three 
subsets: CD226+CD11clow, CD226+CD11c+and CD11c+CD226low. Histogram plots 
depicted expression level of CD11c and CD226 on ResMØs and ‘DC-like’ cells. Shaded 
histograms depict receptor specific staining and bold lines denote isotype control 
staining. (B) Multi-colour analysis highlighting heterogeneity of CD226 and CD209a 
expression. Data are representative of two independent experiments with C57BL/6 
mice. 
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Table 5.1  Differentially expressed genes between peritoneal F4/80lowMHCII+ 
MØs and F4/80intMHCII+ MØs during thioglycollate peritonitis 
(Gautier 2012). Only genes showing a >5-fold difference in 
expression are shown.  
  
Probe ID P-value Abs FC Symbol Description 
10576784 1.29E-08 19.56224 Cd209a CD209a antigen 
10483046 1.29E-08 18.37917 Dpp4 dipeptidylpeptidase 4 
10457168 2.14E-08 14.52031 Cd226 CD226 antigen 
10414262 2.07E-08 13.73705 Ear2 eosinophil-associated, ribonuclease A family, member 2 
10419154 1.26E-07 12.46663 Ear1 eosinophil-associated, ribonuclease A family, member 1 
10541581 5.55E-08 11.95879 Clec4b1 C-type lectin domain family 4, member b1 
10419156 2.14E-08 11.52477 Ear10 eosinophil-associated, ribonuclease A family, member 
10 10576829 1.25E-08 11.52477 Cd209c CD209c antigen 
10598175 1.31E-08 11.26155 Ear10 eosinophil-associated, ribonuclease A family, member 
10 10538791 1.13E-07 10.0329 Tnip3 TNFAIP3 interacting protein 3 
10415392 2.71E-08 9.781122 Ltb4r1 leukotriene B4 receptor 1 
10399691 8.32E-09 9.042155 Id2 inhibitor of DNA binding 2 
10497345 3.02E-08 8.574188 751864 predicted gene, 751864 
10351644 9.29E-07 7.835362 Cd244 CD244 natural killer cell receptor 2B4 
10548552 1.54E-07 7.799239 Klra2 killer cell lectin-like receptor, subfamily A, member 2 
10548314 2.69E-06 7.464264 Klrb1b killer cell lectin-like receptor subfamily B member 1B 
10352000 5.36E-07 7.143676 Kmo kynurenine 3-monooxygenase (kynurenine 3-
hydroxylase) 10538802 4.07E-08 6.868523 A930038C07Rik RIKEN cDNA A930038C07 gene 
10538356 2.07E-08 6.528116 Chn2 chimerin (chimaerin) 2 
10362896 1.54E-07 6.483023 Cd24a CD24a antigen 
10597743 3.13E-08 6.379014 Cx3cr1 chemokine (C-X3-C) receptor 1 
10548105 4.94E-07 6.276673 Ccnd2 cyclin D2 
10364038 4.73E-08 6.247735 Upb1 ureidopropionase, beta 
10499189 1.53E-08 6.218931 Fcrls Fc receptor-like S, scavenger receptor 
10548345 1.98E-06 6.090947 Klrk1 killer cell lectin-like receptor subfamily K, member 1 
10555297 2.48E-08 5.656854 Kcne3 potassium voltage-gated channel, Isk-related subfamily, 
gene 3 10530827 1.49E-07 5.451551 Spink2 serine peptidase inhibitor, Kazal type 2 
10538150 6.04E-07 5.36409 Tmem176a transmembrane protein 176A 
10439542 2.31E-06 5.278032 Zdhhc23 zinc finger, DHHC domain containing 23 
10470529 3.44E-07 5.074738 Olfm1 olfactomedin 1 
10569646 2.71E-08 5.063026 Ccnd1 cyclin D1 
10351792 1.89E-06 5.039684 Slamf9 SLAM family member 9 
Abs FC, absolute fold change 
Note: Microarray data analysis is performed by Dr. Peter Giles. CEL files were downloaded from GEO 
(GSE15907) before expression summarization using the RMA algorithm in R (Irizarry et al., 2003). 
Differentially expressed genes were identified using limma (Smyth GK 2005) with P-values corrected 
for multiple testing and false discovery (Benjamini Y and Hochberg Y 1995). 
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Figure 5.2  Phenotypic comparisons between peritoneal resident MØs and three 
‘DC-like’ subsets from naïve mice 
Flow-cytometric analysis of select marker expression by peritoneal ResMØs and three 
‘DC-like’ subsets. Representative histogram plots were pre-gated on the respective cells 
based on definitive phenotypic markers after exclusion of doublets, debris and CD19+ 
B cells (as shown in Fig. 5.1A). Shaded histograms depict receptor specific staining 
and bold lines denote isotype control staining. Data are representative of two 
independent experiments with a total of four C57BL/6 mice. 
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5.2.2   Phenotypic discrimination between murine peritoneal ‘DC-like’ subsets 
and recruited monocyte-derived macrophages during inflammation 
Previously, our group and others have characterized a CD11bintF4/80intMHC+ to low/‒ 
monocytic population during experimental peritonitis (Rosas et al., 2007; Ghosn et al., 
2010). We denoted them as ‘inflammatory MØs (InfMØs)’, to distinguish them from 
CD11bhighF4/80high ResMØs, and because of their large accumulation within the 
peritoneal cavity upon elicited peritonitis. Adoptive transfer experiments and bone 
marrow chimera studies suggested that these cells are peripherally recruited, with 
limited self-renewal ability (Davies et al., 2011 & 2013). However, a lack of definitive 
markers has led to ambiguity, and confusion of these cells with monocyte-derived 
InfMØs and potential ‘DC-like’ cells during inflammation (Ghosn et al., 2010; Nguyen 
et al., 2012). Here, using the combination of CD11c and CD226, this mixed MØ/DC 
population, defined as CD11bintF4/80int to lowTim4‒ (Tim4 is a useful marker for 
distinguishing the majority of ResMØs from InfMØ/DCs, Davies et al., 2011), could 
be separated into CD226‒CD11c‒ InfMØs as well as three ‘DC-like’ subsets 
(CD226+CD11c+/CD226+CD11clow/CD11c+CD226low) (Fig. 5.3). Further phenotyping 
depicts that the marker expression profiles of three peritoneal ‘DC-like’ populations 
and ResMØs under inflammation are similar with those under naïve status except for 
the decreased expression of CD73 on ResMØs (Fig. 5.4). Of note, InfMØs express 
CD206 and CCR2 like the ‘DC-like’ cells, while they express MerTK, CD36 and CD64, 
similar to ResMØs. 
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Figure 5.3  Phenotypic discrimination of ‘DC-like’ cells from monocyte-derived 
inflammatory MØs during peritoneal inflammation 
Flow-cytometric analysis of peritoneal cells from mice 3 days after intraperitoneal 
staphylococcus epidermidis supernatant (SES) challenge. Density plots show MØ/DC 
populations were pre-gated on CD11b+F4/80high/low cells (central plot) after exclusion 
of doublets, cellular debris, CD19+ B cells, Ly6G+ neutrophils and eosinophils (Davies 
et al., 2011). Within these cells, individual MØ/DC subset could be further separately 
identified: ResMØs (CD11bhighF4/80highTim4‒), InfMØs (CD11bintF4/80intTim4‒
MHCII+/‒CD11c‒CD226‒) and three ‘DC-like’ subsets (CD11bintF4/80int-lowTim4‒
MHCII+ with CD226+CD11clow, CD226+CD11c+ and CD11c+CD226low). Data are 
representative of two independent experiments with C57BL/6 mice. 
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Figure 5.4  Phenotypic comparisons between peritoneal resident MØs, 
inflammatory MØs and three ‘DC-like’ subsets from inflamed mice 
Flow-cytometric analysis of select marker expression by peritoneal ResMØs, InfMØs 
and three ‘DC-like’ subsets. Representative histogram plots were pre-gated on 
respective MØ/DC subsets based on definitive phenotypic markers after exclusion of 
doublets, debris, CD19+ B cells and Ly6G+ neutrophils (as shown in Fig. 5.3). Shaded 
histograms depict receptor specific staining and bold lines denote isotype control 
staining. Data are representative of two independent experiments with a total of four 
C57BL/6 mice. 
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5.2.3   Cellular kinetics of different peritoneal MØ/DC subsets during acute 
experimental peritonitis 
In an acute Staphylococcus epidermidis cell-free supernatant (SES)-induced sterile 
peritonitis model (Hurst et al., 2001), neutrophils (CD11b+F4/80–Ly6G+) are rapidly 
recruited into the peritoneal cavity during the first few hours, but numbers subside after 
24 hours (Hurst et al, 2001) (Fig. 5.5). In contrast, the numbers of ResMØs decline 
initially but gradually recover in a similar way to that seen in zymosan-peritonitis 
(Davies et al., 2011 & 2013). InfMØs, which were found to lack CD226 and CD11c 
expression in the SES-peritonitis model (CD11bintF4/80intCD11c–CD226–, Fig. 5.5A), 
accumulated in the peritoneal cavity after SES administration (Fig. 5.5B). All three 
putative ‘DC-like’ subsets noted in naïve peritoneal cavity could be identified during 
the inflammatory response (Fig. 5.5A), based on the same phenotypic strategy. During 
inflammation, numbers of CD11clowCD226+ and CD11c+CD226low cells initially 
decreased following SES administration (4 hours after inflammatory challenge) and 
then increased later on (72 hours after inflammatory challenge) (Fig. 5.5B). To test 
whether these cellular kinetics can be found in a different inflammatory setting, low 
dose (2x106 particles) and high dose (2x107 particles) zymosan-induced peritonitis 
models were examined, and similar results were obtained albeit with different 
magnitudes of the inflammatory recruitment. (Fig. 5.6A & B). 
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Figure 5.5  Cellular kinetics of peritoneal myeloid subsets during acute SES-
induced peritoneal inflammation 
(A) Representative flow-cytometric analysis showing the kinetic changes of InfMØs 
(F4/80intCD11bintCD11cCD226) and three ‘DC-like’ cells (CD226+CD11c+, 
CD226+CD11clow, CD11c+CD226low) during acute SES-induced peritoneal 
inflammation. (B) Graphs showing the absolute numbers of neutrophils (F4/80 Ly6G+), 
ResMØs (F4/80highCD11bhigh), InfMØs and three DC subsets (as defined above) 
observed during acute SES-induced peritoneal inflammation. Data (mean ± SEM) are 
derived from 5- to 6- week-old C57BL/6 mice (n = 4 per group) and are derived from 
one of two independent experiments. 
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Figure 5.6  Cellular kinetics of peritoneal myeloid subsets during acute 
zymosan-induced peritoneal inflammation 
(A) Graphs showing the absolute numbers of neutrophils, ResMØs, InfMØs and three 
DC subsets observed during acute high dose zymosan (2x107 particles)-induced 
peritoneal inflammation. Data (mean ± SEM) are derived from 5- to 6- week-old 
C57BL/6 mice (n = 4 per group) and from one experiment. (B) Similar results from 
another experiment with low dose zymosan (2x106 particles) challenge. Data (mean ± 
SEM) are derived from 5- to 6- week-old C57BL/6 mice (n = 3-5 per group).  
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5.2.4   Peritoneal DC-like subsets are recruited from the periphery during 
acute experimental peritonitis 
To determine whether the expansion of peritoneal ‘DC-like’ cells seen at later time 
points following acute experimental peritonitis is due to recruitment from the periphery, 
an intraperitoneal adoptive transfer experiment was performed (Fig. 5.7). Briefly, donor 
(CD45.1+) peritoneal cells were harvested and pooled, then transferred intraperitoneally 
into (CD45.2+) congenic mice one day before i.p. SES challenges. Recipient mice 
without SES challenges were treated as controls (Fig. 5.7A). The respective numbers 
of CD45.1+ (donor) and CD45.2+ (host) cells in each peritoneal MØ/DC subset were 
measured 4 days after intraperitoneal adoptive transfer (both SES-challenged and 
unchallenged mice) (Fig. 5.7B). The results showed that the proportion of donor ‘DC-
like’ cells dropped considerably after SES challenges, suggesting that these cells were 
either dead or lost to retrieval through increased adhesion or emigration, with less local 
expansion during the resolution phase of inflammation, compared to ResMØs (Davies 
et al., 2011) (Fig. 5.7C). Notably, all three donor ‘DC-like’ subsets showed similar 
reduction after SES challenges, while host ‘DC-like’ subsets after SES challenges have 
similar (or even higher) numbers, compared to those unchallenged (Fig. 5.7D) These 
findings are compatible with the kinetic studies of these MØ/DC subsets in previous 
experimental peritonitis models, demonstrating that these ‘DC-like’ cells are basically 
recruited from the periphery during inflammation. 
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Figure 5.7  Peritoneal ‘DC-like’ cells are recruited from the periphery during 
acute SES-induced peritonitis 
(A) Schematic representation of the adoptive transfer strategy used to study to 
determine the origin of peritoneal ‘DC-like’ cells during peritonitis. One day after 
adoptive transfer of naïve peritoneal cells between CD45 allotype-mismatched animals, 
mice were either injected intraperitoneally with SES or were left unchallenged, and 
were sacrificed on Day 3. (B) Representative flow-cytometric plots showing the relative 
contribution of donor and host cells to the ResMØs and ‘DC-like’ populations 4 days 
after adoptive transfer. ‘R2’ represents CD11bintF4/80int/low population, which further 
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subdivided into three subsets of DC and InfMØs based on CD11c and CD226 
expression. Data are derived from 1 of 4 individual 129S6/SvEv mice. (C) Bar graphs 
showing the relative proportion of CD45.1+ donor cells in the peritoneal cavity of 
unchallenged and SES-challenged CD45.2+ host mice 4 days after intraperitoneal 
adoptive transfer (normalized to unchallenged mice). Data represents the mean ± SEM 
and are derived from 8 individual 129S6/SvEv mice (n = 4 per group). (D) Graphs 
showing the number of recoverable donor (white symbols) and host (black symbols) 
ResMØs and ‘DC-like’ subsets in the peritoneal lavage of the mice shown in (C) above. 
Data represents mean ± SEM. Data was analyzed for statistical significance by two-
way ANOVA after log transformation and interaction statistics P-values and 
Bonfferoni post-tests (asterisks) are indicated where significant. 
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5.2.5   Limited evidence of local proliferation of peritoneal DC-like subsets 
during acute experimental peritonitis 
Previous mouse studies have demonstrated that tissue ResMØs, such as peritoneal 
ResMØs have distinct self-renewal ability during the resolution phase of certain 
inflammatory circumstances (Jenkins et al., 2011; Davies et al., 2011). Subsequent 
study also provided evidence that a discrete subset of peripherally recruited monocyte-
derived MØs, Ly-6B+ MØs, could proliferate at the recovery phase during tissue 
inflammation (Davies et al., 2013). Here, a similar flow-cytometric method was applied 
using DPAI (4',6-Diamidino-2-phenylindole) for measuring DNA content and 
intracellular Ki-67 staining for measuring active cell division, to investigate the 
proliferative potential of these peritoneal ‘DC-like’ cells, compared to ResMØs and 
InfMØs (MHCII+ and MHCII‒) (Davies et al., 2011; and Fig. 5.8). The data indicated 
that whilst ResMØs were experiencing substantial proliferation 3 days after low dose 
zymosan-induced peritonitis, there was only limited evidence of proliferation in the 
‘DC-like’ subsets and InfMØs, suggesting that recruitment from the periphery may be 
the major source of these cells during peritonitis.  
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Figure 5.8  Limited evidence of proliferation during peritonitis of murine 
peritoneal ‘DC-like’ subsets  
(A) Peritoneal cells from mice 3 days after low dose zymosan-induced peritonitis 
(2x106 particles) were analysed by flow cytometry for evidence of cell cycle. Peritoneal 
MØ/DCs were gated by exclusion of eosinophils (upper left panel) and CD19+ B cells 
(upper right panel), before selectively gating on F4/80high ResMØs (gate 1, lower left 
panel) and F4/80+/low InfMØ/DCs, which were further divided into MHCII– InfMØs 
(gate 2, lower middle panel) and MHCII+ cells. The MHCII+ cells (lower middle panel) 
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were further divided into MHCII+CD226–CD11c– InfMØs (gate 3, lower right panel), 
and the 3 previously described ‘DC-like’ populations (gates 4-6, lower right panel). (B) 
The cells were assessed for active cell division during peritonitis as previously 
described (Davies et al., 2011) by measuring Ki67 expression and DNA content. (C) 
Quantification of the data indicated that whilst ResMØs were experiencing substantial 
proliferation as previously observed, there was only limited evidence of proliferation 
in the ‘DC-like’ subsets indicating that recruitment from the periphery may be the major 
source of these cells during peritonitis. Data represents the mean ± SEM of three 
C57BL/6 mice from one of two similar experiments. 
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5.2.6   CCR2-dependent homeostasis and inflammatory recruitment of 
peritoneal ‘DC-like’ subsets 
As shown in Figure 5.2 & 5.4, peritoneal ‘DC-like’ subsets express the highest levels 
of the chemokine receptor CCR2 of all leukocytes, not only in the peritoneal cavity of 
naive, but also inflamed mice. Kinetic studies and adoptive transfer experiments 
indicate that ‘DC-like’ cells are relatively transient in the peritoneal cavity during 
inflammation and replenished predominantly from the periphery, and in contrast to 
ResMØs, do not largely arise through local proliferation (Section 5.2.3, 5.2.4 and 5.2.5). 
As CCR2 is a major chemokine receptor that regulates monocyte migration (Serbina 
and Pamer 2006), the expression of CCR2 suggests that CCR2 may be of importance 
for these cells to enter into peritoneal cavity under tissues homeostasis and during 
inflammation. To test this hypothesis, CCR2-deficient mice (Ccr2‒/‒) were compared 
to wild type controls (Ccr2+/+, C57BL/6 CD45.1 strain), for the presence and numbers 
of ‘DC-like’ cells, amongst all myeloid cells. As shown in Fig. 5.9, dramatically 
decreased numbers of peritoneal ‘DC-like’ cells (CD11bintMHCII+) were noted in naïve 
Ccr2‒/‒ mice, compared to wild type mice (Fig. 5.9A). Specifically, all three DC subsets 
decreased significantly in Ccr2‒/‒ mice, compared to Ccr2+/+ mice. There were no 
differences in ResMØ numbers between these two strains under homeostatic conditions.  
At 72 hours after SES challenge, the numbers of MHCII+ CD11c‒CD226‒ InfMØs as 
well as peritoneal ‘DC-like’ cells (CD11bintMHCII+) significantly decreased in Ccr2‒/‒ 
mice, compared to wild type mice (Fig. 5.10). Interestingly, the number of ResMØs in 
Ccr2‒/‒ mice is significantly greater than that in Ccr2+/+ mice, suggesting that altered 
expansion of ResMØs during the resolution phase of acute SES-induced peritonitis in 
Ccr2‒/‒ mice or increased recovery due to lower tissue adhesion, or emigration as a 
consequence of activation.   
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Figure 5.9  Myeloid cell compositions in the naïve peritoneal cavity of Ccr2‒/‒ 
mice, compared to wild-type Ccr2+/+ mice 
(A) Representative density plots showing peritoneal ResMØs (CD11bhighMHCII) and 
three ‘DC-like’ subsets (CD11bintMHCII+ with CD11clowCD226+, CD11c+CD226+ or 
CD11c+CD226low) from naïve C57BL/6 CD45.1 (Ccr2+/+) mice (left panels) and Ccr2‒
/‒ mice (right panels). Myelomonocytic cells (MØs + DCs) are pre-gated by 
CD19CD11b+F4/80high-to-low cells. In naïve Ccr2+/+ mice, three ‘DC-like’ subsets are 
CCR2high/+, while ResMØs are mostly CCR2‒. Dashed lines denote the level of isotype 
controls. In naïve Ccr2‒/‒ mice, the proportion of three ‘DC-like’ subsets within the 
MØ/DC pool is decreased and they are basically CCR2‒. Data are derived from one of 
two similar experiments. (B) Bar graphs depicting significantly decreased numbers of 
all three ‘DC-like’ subsets in Ccr2‒/‒ mice, compared to Ccr2+/+ mice. No gender 
difference was noted in this regard. Additionally, no differences in total cell number, 
eosinophils, ResMØ numbers were noted between Ccr2+/+ and Ccr2‒/‒ mice under 
naive status. Data is representative of two independent experiments (n = 5 per group, n 
= 20 in total). Data are shown as mean and error bars denote SEM. Data are analysed 
by two-way ANOVA tests (I: Interaction, S: mouse strain, G: Gender; the numbers 
denote P-value; F: female, M: male). 
  
144 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Figure legend in on the next page) 
B 
I: 0.4177 
S: <0.0001 
G: 0.1949 
I: 0.1256 
S: 0.1968 
G: 0.0365 
I: 0.5317 
S: 0.0001 
G: 0.0094 
I: 0.2907 
S: 0.0029 
G: 0.1087 
I: 0.2389 
S: 0.0002 
G: 0.2534 
I: 0.4004 
S: <0.0001 
G: 0.2615 
Fe
ma
le
Ma
le
0.0
0.5
1.0
1.5
2.0
BL/6 CD45.1
Ccr2-/-
N
eu
tro
ph
ils
 (x
10
4 )
Fe
ma
le
Ma
le
0.0
0.5
1.0
1.5
2.0
BL/6 CD45.1
Ccr2-/-
R
es
id
en
t M
) 
(x
10
6 )
Fe
ma
le
Ma
le
0.0
0.2
0.4
0.6
0.8
1.0
BL/6 CD45.1
Ccr2-/-
In
fla
m
m
at
or
y 
M
) 
(x
10
6 )
Fe
ma
le
Ma
le
0
2
4
6
8
BL/6 CD45.1
Ccr2-/-
C
D
22
6+
C
D
11
cl
ow
 D
C
 (x
10
4 )
Fe
ma
le
Ma
le
0
2
4
6
8
BL/6 CD45.1
Ccr2-/-
C
D
22
6l
ow
C
D
11
c+
 D
C
 (x
10
4 )
Fe
ma
le
Ma
le
0
2
4
6
8
BL/6 CD45.1
Ccr2-/-
C
D
22
6+
C
D
11
c+
 D
C
 (x
10
4 )
F   M F   M F   M 
F   M F   M F   M 
□ Ccr2+/+ mice 
■ Ccr2‒/‒ mice 
145 
 
Figure 5.10  Myeloid cell compositions in the peritoneal cavity from 72h post-
SES challenge Ccr2‒/‒ mice and wild-type Ccr2+/+ mice 
(A) Representative density plots showing peritoneal ResMØs (CD11bhighF4/80high), 
InfMØs (CD11bintF4/80intMHCII+/‒ with CD226low/‒CD11clow/‒) and three ‘DC-like’ 
subsets (CD11bintF4/80intMHCII+ with CD11clowCD226+, CD11c+CD226+ or 
CD11c+CD226 low) from 72 hours after SES challenge in C57BL/6 CD45.1 (Ccr2+/+) 
mice (upper panels) and Ccr2‒/‒ mice (lower panels). Myelomonocytic cells are gated 
as CD19‒Ly6GCD11b+F4/80high-to-low cells. In Ccr2‒/‒ mice, the proportion/number of 
CD11b+F4/80int-to-low InfMØ/DCs decreased, compared to Ccr2+/+ mice. Data are 
derived from one of two similar experiments. (B) Bar graphs depicting significantly 
decreased numbers of InfMØs and all three ‘DC-like’ subsets in Ccr2‒/‒ mice, compared 
to Ccr2+/+ mice. No gender difference was noted in this regard. The number of ResMØs 
in Ccr2‒/‒ mice is significantly higher than in Ccr2+/+ mice. Additionally, no differences 
in the number of total cells, neutrophils, or eosinophils were noted between Ccr2+/+ 
mice and Ccr2‒/‒ mice at 72 hours after SES challenge. Data represents one of two 
similar experiments (n = 3-4, per group, n = 13 in total). Data are shown as mean and 
error bars denote SEM. Statistical analysis was based on two-way ANOVA tests (I: 
Interaction, S: mouse strain, G: Gender; the numbers denote P-value; F: female, M: 
male). 
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5.2.7   Role of IL-10 on the inflammatory recruitment of peritoneal ‘DC-like’ 
subsets 
IL-10 has recently been reported to control the differentiation of peritoneal ‘DC-like’ 
cells during inflammation from peripheral monocytes (Nguyen et al, 2012), however, 
this study was unable to distinguish peritoneal ‘DC-like’ cells from concurrently 
infiltrating monocyte-derived InfMØs. To determine the differential influence of IL-10 
on peritoneal ‘DC-like’ cells and InfMØs, SES-induced peritonitis was undertaken 
using Il10–/–mice, compared to wild type controls (Il10+/+). Three days after SES 
administration, InfMØs (CD11bintF4/80intCD11c–CD226–) from Il10–/– mice exhibited 
more MHCII expression compared to the Il10+/+ mice (Fig. 5.11A). The numbers of 
neutrophils, InfMØs and ‘DC-like’ subsets were significantly increased in Il10–/– mice, 
compared to the controls (Fig. 5.11B). ResMØ numbers were similar between Il10+/+ 
and Il10–/– mice (Fig. 5.11B). To control for the exaggerated inflammatory response 
observed in the Il10–/– mice, we expressed the numbers of the DC subsets as a ratio to 
InfMØs. Whilst the numbers of DCs were higher in the IL-10-deficient mice compared 
to controls (Fig. 5.11B, lower row), relative to the InfMØs, the proportion of DCs was 
actually lower in the IL-10-deficient mice (Fig. 5.11C).  
Together, these data indicate that IL-10 plays an important role in limiting both the 
recruitment of InfMØs and ‘DC-like’ cells, although with a potentially greater impact 
on InfMØs recruitment and MHCII expression. Furthermore, there was no evidence of 
the proposed increase in ‘differentiation of APCs’ in the absence of IL-10, reported by 
Nguyen et al (2012).  
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Figure 5.11  IL-10 limits inflammatory response in acute SES-induced 
peritonitis model 
(A) Representative density plots showing the gating of monocyte-derived InfMØs 
(CD11bintF4/80int/lowTim4CD11cCD226) and the proportion of positive MHCII 
expression at 72 hours post-SES challenge in wild type (Il10+/+, upper panels) and IL-
10 knockout (Il10/, lower panels) C57BL/6 mice. Cells were pre-gated by the 
exclusion of doublets, Ly6G+ neutrophils and CD19+ B cells. Tim4 antibody was 
applied to assure the specific exclusion of the majority of Tim4+ ResMØs (Davies et al., 
2011). Comparison of high MHCII expression of InfMØs between Il10+/+ and Il10/ 
mice was shown in the bar graph (far right). Data shown is represented as mean ± SEM 
of 6-7 mice per group, combined from two independent experiments. Data are analysed 
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by Student’s t-test. (B) Graphs showing the comparisons of actual numbers of 
individual peritoneal population between Il10+/+ and Il10/ mice at 72 hours post-SES 
challenge. Data were derived from same animals shown in (A). Data are analysed by 
Student’s t-test. (C) Bar graphs showing the comparisons of the ratio of individual 
peritoneal ‘DC-like’ subset over InfMØs (expressed as percentage) between Il10+/+ and 
Il10/ mice. Data shown is represented as mean ± SEM of 6-7 mice per group, 
combined from two independent experiments. Data are analysed by Student’s t-test. 
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5.2.8   Differential cytokine responses among distinct peritoneal MØ/DC 
subsets upon ex vivo microbial product stimulation 
To explore the functional differences among these monocytic subsets, intracellular 
staining of peritoneal cells for TNF-α, IL-6 and IL-12p40 after 6 hours ex vivo 
stimulation with SES was undertaken to determine the pro-inflammatory cytokine 
production of individual monocytic subpopulations (Fig. 5.12A). The results showed 
that both ResMØs and three ‘DC-like’ subsets can generate significant amounts of 
TNF-α and IL-6 after SES stimulation (Fig. 5.12B). Notably, compared to ResMØs, 
‘DC-like’ cells have significantly greater potential for IL-12p40 production, 
particularly the CD11c+CD226 low subset (two-way ANOVA test with Bonferroni post-
tests, p <0.001). Similar results were revealed in cells either from naïve mice (Fig. 
5.12B, left panels) or and from mice 72 hours after SES injection, where MHCII+ and 
MHCII– InfMØs were also assessed (Fig. 5.12B, right panels). Similarly, these 
differential cytokine responses of the peritoneal MØ/DC subsets could be generated 
upon LPS stimulation (Fig. 5.12C). Additionally, the ability of these monocytic subsets 
to produce anti-inflammatory cytokine IL-10 was examined (Fig. 5.13A). Interestingly, 
ResMØs generated the highest amount of IL-10 upon ex vivo stimulation by SES or 
LPS for 6 hours, and the CD11c+CD226low subset exhibited very minimal IL-10 
production (Fig. 5.13B).  
Collectively, these data demonstrated that in response to microbial product stimulation, 
pro-inflammatory and anti-inflammatory cytokines can be differentially generated by 
distinct peritoneal MØ/DC subsets.  
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Figure 5.12  Peritoneal MØ/DC subsets exhibit differential pro-inflammatory 
cytokine production following SES or LPS exposure 
(A) Representative density plots depicting the flow-cytometric determination of 
intracellular cytokine production (TNF-α, IL-6, IL-12p40) by peritoneal MØ/DC 
subsets from naive C57BL/6 mice, after ex vivo stimulation with SES (1: 10 dilution) 
for 6 hours. (B) Bar graphs comparing the intracellular cytokine production (TNF-α, 
IL-6, IL-12p40) among individual subsets of peritoneal monocytic cells from C57BL/6 
mice, both naïve (left panels) and 72 hours post-intraperitoneal SES challenge (right 
panels). Positive intracellular cytokine production was determined by comparison with 
isotype controls. Data represent mean ± SEM and are derived from one of two similar 
experiments (n = 4-5 in each experiment). (C) Similar experiment was undertaken to 
detect differential cytokine production among the respective cells from C57BL/6 mice, 
both naïve (left panels) and 72 hours post-intraperitoneal SES challenge (right panels). 
Data represent mean ± SEM and are derived from one of two similar experiments (n = 
4-5 in each experiment). 
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Figure 5.13  Peritoneal MØ/DC subsets exhibit differential IL-10 production 
following SES or LPS exposure 
(A) Representative density plots depicting the flow-cytometric determination of 
intracellular IL-10 production by peritoneal MØ/DC subsets from naive C57BL/6 
mice, after ex vivo stimulation with SES (1: 10 dilution) or LPS for 6 h. (B) Bar 
graphs comparing the intracellular IL-10 production among individual subsets of 
peritoneal monocytic cells from C57BL/6 mice, both naïve (left panels) and 72 hours 
post-intraperitoneal SES challenge (right panels). Positive intracellular cytokine 
production was determined by comparison with isotype controls. Data represents the 
mean ± SEM of C57BL/6 female mice (n = 5) from one of two identical experiments 
giving similar results.  
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5.2.9   Differential capacity for in vivo apoptotic thymocyte clearance among 
distinct peritoneal MØ/DC subsets 
It has been recognised that mononuclear phagocytes play an important role in apoptotic 
and necrotic cell clearance. To determine the role of these peritoneal DC in apoptotic 
cell uptake during homeostasis and under inflammatory conditions, a previously 
established protocol was modified to assess the capability of apoptotic thymocyte 
clearance by each monocytic subset (Taylor et al., 2000; Uderhardt et al., 2012). Briefly, 
thymocytes from CD45.1+ 129 S6/SvEv mice were recovered then apoptosis was 
induced by ex vivo dexamethasone treatment for 4 hours. About one-third to one-half 
of treated thymocytes became apoptotic, which could be estimated by flow cytometry 
using NIM-DAPI solution (containing nuclear isolation medium, NIM-II and DAPI) to 
detect DNA degradation (Fig. 5.14). These CD45.1+ apoptotic thymocytes were 
intraperitoneally transferred to CD45.2+ cogenic mice, in either naïve mice or 3 days 
after SES injection. After 30 minutes retention (in vivo phagocytosis), the peritoneal 
cells were harvested and assessed by flow cytometry (Fig. 5.15A & B). To assure what 
we measure is genuine phagocytosis, only internalized apoptotic thymocytes within 
each MØ/DC subset were assessed, through the exclusion of surface CD45.1+ cells 
(adhered or partially digested apoptotic thymocytes) and exclusion of the doublets. 
Amongst myelomonocytic subpopulations in the naïve peritoneal cavity, ResMØs 
display the highest capability of apoptotic thymocyte clearance, while the 
CD11c+CD226low subset show the lowest ability (Fig. 5.15C). At 72 hours after SES 
challenge, ResMØs still have the highest phagocytic capacity among six defined 
subpopulations. InfMØs (MHCII+ or ‒) are less capable than ResMØs, but better than 
‘DC-like’ cells. CD11c+CD226low cells remain the least efficient cell type in terms of 
apoptotic cell clearance (Fig. 5.16).  
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Figure 5.14  Glucocorticoid-induced thymocyte apoptosis  
(A) The morphology of individual cytospun normal thymocytes (left) and apoptotic 
thymocytes after ex vivo glucocorticoid treatment for 4 hours (right) is shown (scale bar 
represents 30 μm). Data is representative of two independent experiments. (B) 
Representative histograms and density plots showing apoptotic thymocytes with DNA 
degradation (<2N DNA, also called ‘sub-G0’) after glucocorticoid treatment for 4 hours. 
Data represents one of four experiments.  
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Figure 5.15  Peritoneal MØ/DC subsets from naïve status exhibit differential 
capability of apoptotic thymocyte clearance 
(A) Representative plots depicting the flow-cytometric identification of peritoneal 
MØ/DC subsets from naive CD45.2+ 129S6/SvEv mice, after intraperitoneal injection 
of CD45.1+ apoptotic thymocytes for 30 minutes. Peritoneal MØ/DC subsets are gated 
on CD11b+F4/80high-low and surface-staining CD45.1 cells. (B) Histograms showing the 
proportion of phagocytosed CD45.1+ thymocytes within individual peritoneal MØ/DC 
subsets. (C) Graphs comparing the capability of apoptotic thymocyte clearance (% 
phagocytosis) among individual peritoneal monocytic subsets. Data represent the mean 
and are derived from one of two similar experiments (n = 5). 
)
Re
s M

CD
22
6+
CD
11
clo
w/
CD
22
6+
CD
11
c+
CD
11
c+

CD
22
6lo
w/
0
20
40
60
80
100
%
 P
ha
go
cy
to
si
s 
(C
D
45
.1
+ )
A 
CD11b 
F4
/8
0 
CD11b 
M
H
C
II 
FS Lin 
FS
 A
re
a 
FS Lin 
FS
 A
re
a 
CD11c 
C
D
22
6 
MØ/DC 
‘DC-like’ 
Doublets 
exclusion 
Doublets 
exclusion 
CD45.1 
Res MØ CD226+CD11clow 
CD226lowCD11c+ CD226+CD11c+ 
B C * *** *** 
Intracellular CD45.1/IgG2a 
C
D
45
.1
 
(in
tra
ce
llu
la
r) 
CD45.1 (surface) 
Adhered or 
partially digested 
apoptotic 
thymocytes 
ResMØ 
94% 
IgG2a 
156 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16  Peritoneal MØ/DC subsets from 72h after SES-induced peritonitis 
exhibit differential capability of apoptotic thymocyte clearance 
(A) Representative histograms showing the proportion of phagocytosed CD45.1+ 
thymocytes within individual peritoneal MØ/DC subsets from CD45.2+ 129S6/SvEv 
mice at 72 hours after SES-induced peritonitis (B) Graphs comparing the capability of 
apoptotic thymocyte clearance (% phagocytosis) among individual peritoneal 
monocytic subsets. Data represent the mean and are derived from one of two similar 
experiments (n = 3). 
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5.2.10   Fluorescence-activated cell sorting and morphological analysis of 
murine peritoneal MØ/DC subsets  
To understand the morphological appearance of individual peritoneal MØ/DC subsets, 
a flow-cytometric cell sorting approach for the purification of these cell typeswas 
performed, firstly from naïve C57BL/6 mice, was performed (Fig. 5.17A). After sorting, 
the isolated single cell populations were checked for the purity by flow cytometry (Fig. 
5.17A, 2nd panel from above).The following highest sort purities were achieved: 
ResMØ: 98.56%; MHCII+ InfMØ: 99.72%; CD11clowCD226+: 94.29%; 
CD11c+CD226+: 89.86%; CD11c+CD226low: 88.89%. In addition, cytospin 
preparations were made and the sorted cytospun cells were stained with Microscopy 
Hemacolour cell stain (Merck), visualized on a Leica DMLB microscope (Leica) and 
images were captured using a Leica DFC490 digital camera (Leica) and processed 
using QWin Software (Leica). The morphology of ResMØs and three ‘DC-like’ subsets 
stained with Microscopy Hemacolor (Merck) was as shown in Fig. 5.17A (3rd panel 
from abovetop). Compared to ResMØs, ‘DC-like’ cells have round or bean-shaped 
nuclei that are unilobar, (‘monocytic appearance’). Of note, CD11c+CD226low subset 
has the least cytoplasm among three ‘DC-like’ cells. Secondly, MHCII+ InfMØs was 
sorted from 72 hours post-SES challenged C57BL/6 mice (Fig. 5.17B, left panel). The 
purity of this cell type was generally > 98%. The morphology of MHCII+ InfMØs was 
as shown in Fig. 5.17B (right panel). They displayed an appearance consistent with 
more-likely mature ‘macrophage appearance’, similar to that of ResMØs. 
Additionally, these purified individual peritoneal MØ/DC subsets have been used for 
in vitro functional assay (undertaken by Dr. Marcela Rosas) to examine their ability of 
processing and presenting antigen to helper T cells (see Appendix 2). 
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Figure 5.17  Fluorescence-activated cell sorting and morphological analysis of 
individual peritoneal MØ/DC subset 
(A) Representative plots showing the flow-cytometric sorting strategies of ResMØs 
(1:CD19CD11bhighMHCII) and three ‘DC-like’ subsets (CD19CD11bintMHCII+ 
with 2:CD11clowCD226+, 3:CD11c+CD226+ and 4:CD11c+CD226 low) from cells 
pooled from 10 naïve C57BL/6 mice. The purity of each post-sorted cell subset is 
shown. The morphology of individual cytospun cells is shown (scale bar represents 30 
μm). (B) Dot plots showing the flow-cytometric sorting strategy of peritoneal MHCII+ 
InfMØs (CD19Tim4CD11b+MHCII+CD11cCD226) from 72 hours post-SES 
challenged C57BL/6 mice. The morphology of cytospun MHCII+ InfMØs is shown 
(scale bar represents 30 μm). Data is representative of two independent experiments.  
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5.3  Discussion 
 
In this chapter, a select surface marker panel has been successfully applied for defining 
‘DC-like’ subsets within the mouse peritoneal cavity. This decisive phenotyping has 
permitted for the first time a study of the origins and kinetics of these cells during 
inflammation, an assessment of their response to microbial products, stimuli and an 
evaluation of their specialised functions such as apoptotic cell clearance as well as 
antigen processing and presentation. Although tentatively classified into three ‘DC-like’ 
subsets, it appears to be two main subsets according to their morphology and 
immunophenotype, one which has a CD226lowCD11c+ phenotype with a slightly 
smaller size and less cytoplasm, to be more reminiscent of a conventional DC. The 
other subset is defined by high expression of CD226, but is notably heterogeneous in 
the expression of traditional DC-markers- CD209a (DC-SIGN) and CD11c. Importantly, 
the expression of CD226 and CD11c is largely restricted to these ‘DC-like’ subsets in 
both steady-state and inflamed peritoneum, allowing definitive discrimination of these 
cells from the large numbers of potentially MHCII+ InfMØs recruited during 
inflammation.  
The kinetic studies depicted found that resident peritoneal ‘DC-like’ cells disappeared 
after inflammatory insult (4 hours post-immune challenge), which could be possibly 
explained by leaving through lymphatic drainage to local lymph nodes, then followed 
by the accumulation of ‘DC-like’ cells during the early resolution phase (at 48-72 hours 
post-inflammatory challenge). The latter were primarily recruited from the periphery 
with limited local proliferation. This inflammatory recruitment process is consistent 
with their high expression of CCR2. Recent studies of assumed DC in the peritoneum, 
based on the use of a MHCIIhighCD11c+ phenotype, confirmed the importance of CCR2 
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for the recruitment of at least these cells (Goldszmid et al., 2012; Newson et al., 2014). 
Indeed, the results from CCR2-deficiency mice in this project also confirmed that 
CCR2 is critical for these ‘DC-like’ cells in both homing to the peritoneal cavity under 
the both steady state and during the inflammatory recruitment. Notably, this CCR2+ 
phenotype was conserved across species, with expression observed on human CD1c+ 
peritoneal DCs (Fig. 3.5). The observation of significant recruitment of these human 
peritoneal DCs (Fig. 4.10) in response to infectious peritonitis suggests that similar 
inflammatory kinetics upon during peritonitis may exist in both species.  
As a known regulatory of inflammatory responses, IL-10 is a keystone to limiting 
inflammation in the peritoneal cavity (Ajuebor et al., 1999). A recent study of an 
infectious peritonitis model assessed the regulatory role of IL-10 on the differentiation 
of peritoneal MHCII+ and MHCII– MØs (Nguyen et al., 2012). My data reproduces 
these observations, confirming that MHCII expression by InfMØs is an indicator of the 
inflammatory process and the state of InfMØ activation, which is regulated by IL-10. 
However, the presence of peritoneal ‘DC-like’ cells during an acute inflammatory 
response is seemingly less dependent of IL-10, than InfMØs (Fig. 5.11 C). Additionally, 
we found that MHCII+ InfMØs were actually quite poor at the processing and 
presentation of antigen to T cells when compared to ‘DC-like’ subsets (see Appendix 2, 
‘antigen processing and presentation assays’ were performed by Dr. Marcela Rosas), 
which contrasts with the conclusion of previous study (Nguyen et al., 2012). The reason 
for this discrepancy is unclear, but perhaps includes contamination of MHCII+ InfMØs 
with the previously unidentifiable peritoneal ‘DC-like’ cells, in the earlier study 
(Nguyen et al, 2012).  
Regarding the responsiveness ex vivo to microbial-derived stimuli (SES and LPS), all 
peritoneal ‘DC-like’ subsets from either naïve or inflamed mice were predisposed to 
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produce IL-12, but under inflamed conditions, MHCII+ InfMØs also represented a 
significant potential source of IL-12, especially given their relatively high numbers in 
an inflammatory context. Importantly, in a repeat-hit SES-induced chronic peritonitis 
model, the capability of pro-inflammatory cytokine production (TNF-α, IL-6, IL-12) 
from InfMØ/DCs may play a contributive role in the process of Th1-driven peritoneal 
fibrosis (Fielding et al., 2014). Conversely, InfMØs were less disposed to the 
production of IL-10 after LPS or SES stimulation than ResMØs, but least likely to 
produce IL-10 was the CD11c+CD226low DC subset.  
Previous study has shown that peritoneal ResMØs were effective at phagocytosing 
apoptotic cells in vivo (Taylor et al., 2000; Uderhardt et al., 2012). The results in this 
project, by comparisons of different MØ/DC subsets from either naïve or from inflamed 
mice, have demonstrated that on a single cell basis of all cell types, ResMØs are the 
most efficient for clearance of apoptotic cells and the CD11c+CD226low DC subset were 
the poorest in this regard. 
In summary, ‘DC-like’ subsets in the mouse peritoneal cavity have been characterized 
phenotypically and functionally. More importantly, their respective cellular kinetics 
during acute peritonitis has been investigated. Together with human data from PD 
patients, it is likely that these mouse peritoneal ‘DC-like’ subsets could be the 
homologues of newly identified human peritoneal CD1c+ DCs. However, it will need 
detailed transcriptional mapping between the two species to provide further evidence 
of their corresponding relationships.  
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Chapter Six 
 
General discussion 
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6.1  The identities of peritoneal macrophages and dendritic cells 
 
6.1.1  Peritoneal MØs: “resident” versus “recruited” 
In the murine peritoneal cavity, CD11bhighF4/80high MØs, have been recognized as the 
major tissue-resident MØ subset in the steady state (Rosas et al., 2007; Dioszeghy et 
al., 2008). These ResMØs are found to be mainly prenatal in origin (Yona et al., 2013), 
with the ability to maintain basal numbers by self-renewal, and display a unique 
proliferative capability for repopulation during the resolution phase of specific 
inflammatory responses (Davies et al., 2011 & 2013). By contrast, CD11b+F4/80int/low 
MØs, are known to accumulate in the peritoneal cavity during inflammation, denoted 
here as ‘InfMØs’. They are hematopoietic in origin, primarily recruited from the 
circulating Ly-6C+ monocytes in a CCR2-dependent manner (Yona et al., 2013). In 
this project, I attempted to identify the potential human analogous ResMØs within the 
PD effluents and discriminate them from InfMØs by examining a wide range of 
relevant myelomonocytic markers (Davies et al., 2011; Rosas et al., 2014). 
Nevertheless, the corresponding human ResMØs still could not be clearly recognised 
from the patients’ PD effluents under different clinical situations. One possible 
explanation is that the surface markers used in this project show lack of specificity to 
phenotypically discriminate ResMØs from InfMØs, and the markers found to be 
useful in mouse ResMØ phenotyping, including F4/80, Tim-4 and CD73, are not 
expressed in a similar pattern on their human counterparts. Another explanation could 
be related to the “disappearance reaction” of tissue ResMØs. This reaction has been 
noted in several murine models of experimental inflammation, and the proposed 
mechanisms include increased tissue adherence, migration through the draining 
lymphatic system, and cell death (Barth et al., 1995; Rosen et al., 1990). In the 
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context of PD, ResMØs could ‘disappear’ after catheter-related surgical insult or be 
depleted by the repetitive flushing and continuous dialysis exchange during the course 
of PD therapy. Indeed, one recent murine study investigated the effect of the catheter 
implantation-induced peritoneal inflammatory response, showing that decrease in 
number of ResMØs during the post-surgery period (Min et al., 2012). The fact that 
almost all CD14+ MØs harvested from PD fluids in this study are CCR2+, also 
suggests that these cells are mainly derived from the periphery (most likely from 
CD14+CD16– classical blood monocytes), and indirectly implies that recoverable 
ResMØs are lost under PD therapy. Finally, recent fate-mapping models revealed that 
in some murine tissues such as intestine, skin, heart, the prenatally-derived tissue 
ResMØs become substantially replaced by the circulating Ly-6C+(CCR2+) classical 
monocytes, from neonatal period to adulthood (Tamoutounour et al., 2013; Molawi et 
al., 2014; Bain et al., 2014). This tissue-specific replenishment over time could 
probably be explained by the diminished proliferative capability of prenatally-derived 
MØs during ageing process, thereby gradually insufficient to maintain normal tissue 
homeostasis. Accordingly, it is possible, given the age of the PD patients recruited for 
this study (mean age 55 years in the new-starters), that the identified peritoneal MØs 
may be monocyte-derived. In summary, CD14+ MØs harvested from PD effluent in 
this project are most likely monocyte-derived InfMØs, so the true phenotypic identity 
of human ResMØs remains elusive. However, the results shown in this study have 
provided three possibilities of ResMØ identity in humans: 1) In the normal human 
peritoneal cavity, prenatally-derived ResMØs do exist and self-renew, just like their 
murine counterparts, but inflammation and/or dialysis washout bias to a circulating 
precursor-derived cell type (‘monocyte-derived MØ’). In the future, maybe we can 
address this point by studying the peritoneal cells recovered at laparoscopic donor 
nephrectomy or cholecystectomy which will minimise the impact of surgery-induced 
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inflammation and dialysis 2) Human peritoneal ResMØs may start as self-renewing 
like in mice, but over the much longer human lifespan, there is a shift to 
monocyte-derived, with potential implications for tissue homeostasis during the 
ageing process. Perhaps future ageing experiments with longitudinal follow-up in 
mouse models may provide some clues in this regard. In humans, it will be interesting 
to investigate the peritoneal MØs from pediatric patients, to be able to compare the 
immunophenotypes with those from old patients. 3) It is also possible that over the 
much longer gestational period, the embryonic seeded (yolk sac/fetal liver-derived) 
peritoneal ResMØs in humans have been mostly replaced by the circulating 
precursor-derived MØs before birth, unlike what we found in mice. 
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6.1.2  Peritoneal DC population 
Since Steinman’s classical proposal describing DC’s in the 1970’s, several DC subsets 
in lymphoid and non-lymphoid tissues have been described with distinctive 
phenotypes and functions, both in mice and humans (Merad et al., 2013; Schlitzer and 
Ginhoux 2014). Although recent fate-mapping experiments in mice have delineated 
the ontogeny of DC, segregated from the monocyte-MØ lineage (Geissmann et al., 
2010; Merad et al., 2013; Schlitzer and Ginhoux 2014), the in vitro (Pickl et al., 1996) 
in vivo studies have demonstrated that monocytes can differentiate into DCs in 
inflammatory contexts (Serbina et al., 2006; León et al., 2007; Greter et al., 2012). To 
avoid confusion, it has been argued that bona-fide DCs should be restricted to 
“FLT3L/FLT3-dependent DC subsets, thereby all the non-FLT3L/FLT3-dependent 
DC-like subsets should be regarded as monocyte-derived (Jenkins and Hume 2014). 
However, in inflammatory scenarios, the term ‘inflammatory DC (InfDC)’ has been 
adopted for describing the DC pool in the inflamed tissues (Segura and Amigorena et 
al., 2014). These tissue infiltrating InfDCs are thought to be mainly derived from 
circulating monocytes (Osterholzer et al., 2009; Nakano et al., 2009; León et al., 2007; 
Zigmond et al., 2012; Goldszmid et al., 2012). So far, there is no clear evidence 
showing that blood DC precursors (FLT3/FLT3L-dependent DCs) contribute to 
InfDCs during inflammation (Plantinga et al., 2013).  
In humans, several tissue DC subsets have been defined, principally myeloid DCs 
(BDCA-1+/CD1c+ DCs and BDCA-3+/CD141+ DCs) and plasmacytoid DCs 
(CD123+CD303+ DCs) (Ziegler-Heitbrock et al., 2010). Each DC subset demonstrates 
a distinctive functional profile (Schlitzer et al., 2014). These DC subsets exist in a 
variety of human tissues/organs, including intestinal mucosa (Watchmaker et al., 
2014), intra-articular fluid (Moret et al., 2013), kidney (Kassianos et al., 2013), and 
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liver (Kelly et al., 2014). In this study, we identified, for the first time, CD1c+ DCs 
within the PD effluents from PD patients. A similar observation of this novel cell type 
has been reported by another group very recently, but from a very different clinical 
situation (tumor ascites) and using a different flow-cytometric gating approach 
(Segura et al., 2013). Both sets of data demonstrate that CD1c+ DCs are the 
predominant DC subtype within the “peritoneal DC pool”, at least under these 
inflamed conditions. Functionally, these DCs display a superior capability for antigen 
presentation and T cell stimulation (CD4 T cell stimulation in Segura et al., 2013; 
CD8 T cell stimulation in this study). The origin of these cells is difficult to address 
but could be directly from transmigration of blood CD1c+ DC precursors or from in 
situ differentiation of the recruited monocytes. The transcriptome analysis has shown 
that peritoneal CD1c+ DCs from tumour ascites are more close to blood CD14+ 
monocytes than CD1c+ DC precursors (Segura et al., 2013). However, this does not 
preclude the possibility of dual sources from the peripheral circulation.  
In mice, this study characterises two main ‘DC-like’ subsets (CD226+CD11c+/low and 
CD11c+CD226low) in the naïve or inflamed peritoneal cavity. The CD226+ cells are 
reminiscent of the previously described CD11b+F4/80+MHCII+ ‘small MØs’ (Rosas et 
al., 2007; Dioszeghy et al., 2008; Ghosn et al., 2010). Notably, CD226+ cells express 
some ‘MØ-associated’ surface markers such as MerTK and, when inflamed, CD64 
(Gautier et al., 2012), and share functional properties with both MØs and DCs. Hence, 
it could be argued that CD226+ cells are an ‘intermediate’ subtype between MØs and 
DCs. Intriguingly, one recent paper revealed that ‘small MØs’ could locally 
differentiate into ResMØs in a tissue-specific C/EBPβ-dependent pathway (Cain et al., 
2013), suggesting that at least in some instances, ‘small MØs’ or CD226+ cells can be 
immediate precursors of ResMØs. On the other hand, CD11c+CD226low cells are 
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morphologically, phenotypically and functionally more like bona-fide DCs despite 
their relatively low CD11c expression, compared to classical splenic DCs. The fact 
that CD226+ cells and CD11c+CD226low cells are CCR2high/+ and could be recruited 
into the peritoneal cavity in a similar way as InfMØs during experimental peritonitis, 
indicated that these ‘DC-like’ cells are likely Ly-6C+(CCR2+) monocyte-derived. 
Recent evidence using intravenous Ly-6C+ monocyte transfer experiments disclosed 
that after peritonitis is elicited, donor Ly-6C+ monocytes can migrate into the 
peritoneal cavity and differentiate into both InfMØs and CD11c+MHCII+ DCs 
(Goldszmid et al., 2012). However, our data from naïve Gata6 knockout mice showed 
a significant increase (4-5 fold) of CD226+ cells, but not CD11c+CD226low cells, 
accompanying the decrease of ResMØs, compared to the wild type littermates (Rosas 
et al., 2014 and unpublished data). These observations suggested that CD226+ cells 
and CD11c+CD226low cells have distinct developmental cues. Whether or not CD226+ 
cells could differentiate into CD11c+CD226low cells in situ under steady-state or 
inflamed conditions remains to be elucidated. 
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6.1.3  Comparisons between human and murine peritoneal MØ/DC subsets  
The phenotypic comparisons between mice and humans revealed characteristic 
surface marker expression conserved across both species. Specifically, peritoneal 
MØs (ResMØs/InfMØs in mice as well as CD14+ MØs in humans) express relatively 
high levels of CD36, CD64 and MerTK, while peritoneal DCs (CD226+ DCs and 
CD11c+ DCs in mice as well as CD1c+ DCs in humans) express relatively high levels 
of CD206, CD226 and CD301. These characteristic ‘MØ or DC-specific’ surface 
marker panels could be useful for future immunophenotyping. In both species, all 
peritoneal MØ/DC subsets could generate substantial amounts of pro-inflammatory 
cytokines such as TNF-α, IL-1β and IL-6 upon ex vivo LPS or SES stimulation. 
However, murine DC-like cells display significantly greater potential for IL-12p40 
production, compared to ResMØs or InfMØs. In PD patients, both CD14+ MØs and 
CD1c+ DCs generate similar extent of IL-12 upon stimulation. Functionally, Human 
CD14+ MØs have superior capability of phagocytosis (Staphylococcus epidermidis or 
zymosan particles) than CD1c+ DCs. Similarly, murine ResMØs or InfMØs are more 
efficient at phagocytosis of apoptotic thymocytes than DC-like subsets. On the other 
hand, human CD1c+ DCs have a superior ability to process and present antigen than 
CD14+ MØs, and the capability of antigen processing and presentation is mostly 
restricted to peritoneal ‘DC-like’ cells in mice. 
Taken together, murine CD11c+CD226low cells are phenotypically and functionally 
more likely analogous to subsets of human CD1c+ DCs, whereas CD226+ cells are 
phenotypically and functionally ‘intermediate’ between MØ and DC. To confirm the 
potential corresponding relationships between humans and mice, it will be necessary 
to perform cross-species mapping of gene expression profiles derived from the 
transcriptome analysis of multiple peritoneal MØ/DC subsets. 
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6.1.4  Future directions 
To identify bona fide human peritoneal ResMØs, further analysis of peritoneal cells 
from healthy individuals, possibly via laparoscopic surgery or perhaps from 
pediatric/young adult PD patients, will be needed. It should be kept in mind, however, 
that even minimally-invasive surgery can cause blood dissemination within the 
peritoneal cavity, and potentially induce inflammatory response and change the MØ 
phenotype. Because genetic lineage tracing is not feasible in humans, it would be 
difficult to prove that human peritoneal ResMØs (if identified) are prenatal in origin. 
However, recent studies on human skin from patients receiving sex-mismatched 
hematopietic stem cell transplantation have provided indirect evidence that at least 
some steady-state human skin ResMØs are long lived (possibly embryo-derived) and 
could persist more than one year post-transplantation independently of donor 
monocyte input. Conversely, steady-state human skin DCs are almost completely 
supplied from the donors’ circulating precursors within 40 days after transplantation 
(Haniffa et al., 2009; McGovern et al., 2014). Perhaps, this strategy will enable us to 
further clarify the developmental origins of human peritoneal MØ/DC subsets in the 
future. In addition, it will be of interest to perform transcriptome analysis of the 
isolated human peritoneal CD14+ MØs and CD1c+ DCs from PD effluent. Then we 
can compare the published data using tumour ascites as a different source of 
peritoneal cells (Segura et al., 2013) to tell how the two microarray datasets may have 
similarities or differences in terms of gene expression profiles from the respective MØ 
and DC subsets. 
In mice, there are some issues raised in this project. Firstly, it is unclear that for how 
long peritoneal ResMØs can maintain the required tissue cell number by self-renewal 
under steady state. It has been demonstrated that the proliferative capability of 
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peritoneal ResMØs gradually declines from newborns (2-week-old) to young adults 
(12-16-week-old) (Davies et al., 2011). However, it is still unclear to what extent the 
prenatally-derived tissue ResMØs can be replaced by monocyte-derived MØs during 
ageing. To address this issue, it would be necessary to conduct further experiments, 
for example using BM chimerism (Ccr2–/–/Ccr2+/+) with longer time point follow-up. 
Secondly, we still don’t know whether the recruited InfMØs can genuinely 
differentiate into ResMØs during the resolution phase of the elicited inflammation, 
and if so, how they can compare the prenatally-derived ResMØs. To decipher this 
point will probably need further BM chimerism experiments (CD45.1/CD45.2) and 
sorting of the respective ResMØs (CD45.1+ and CD45.2+) at the latter time points of 
the elicited peritonitis for transcriptomic comparisons. Finally, it remains obscure to 
what extent peritoneal DC-like subsets (CD226+ or CD11c+CD226low) are 
FLT3/FLT3L-dependent. Future lineage tracing studies, and the use of Flt3 and/or 
Flt3l knockout mice, may be helpful in clarifying this concern. 
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6.2   Alterations of peritoneal MØ/DC phenotypes and activation/ 
maturation status during PD therapy 
 
PD is a well-established renal replacement therapy for kidney failure patients, 
however its’ short-term and long-term influences on the peritoneal immune system 
have concerned the PD community. Mononuclear phagocytes are immune cells with 
high plasticity, which promptly respond to the microenvironmental changes in vitro or 
in vivo. In this study, one of the main objectives was to understand how the peritoneal 
mononuclear phagocytes are modified during the treatment course of PD, including 
PD-related peritonitis, and whether alterations observed correlated with clinical 
outcomes of PD patients.  
 
6.2.1  Altered distribution of peritoneal MØ/DC during PD therapy 
In this study, the longitudinal analysis of myelomonocytic subsets within the PD 
flushes/effluents from ‘new-starter’ patients revealed that peritoneal CD14+ MØs and 
CD1c+ DCs display distinct cellular kinetics along the PD course, implying that 
differential factors may control the recruitment or the differentiation process of the 
respective MØ/DC subsets. It was anticipated that CCR2 ligands (e.g. CCL2/MCP-1) 
would play a crucial role in the process of monocyte recruitment (predominantly 
inflammatory, but possibly also homeostatic) based on previous mouse work by our 
group and others (Goldszmid et al., 2012). On the other hand, GM-CSF might be 
essential for the (monocyte Æ DC) differentiation process, as GM-CSF is an 
important growth factor for DC differentiation in vitro. FLT3 ligand, another growth 
factor critical for DC development, may also be involved in this process. Although 
these chemokines/growth factors could be diluted by the instilled PD fluids, it is 
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possible that local concentrations remain high enough within the peritoneum 
(particular in the interstitial layer), leading to continuous leukocyte transmigration 
and/or in situ differentiation. Interestingly, the ratio of CD14+ MØ to CD1c+ DC may 
be a good indicator of the status of intra-peritoneal inflammation, as shown by the 
decline of the ratio from one week after catheter insertion (20-25:1) to 3-6 month 
maintenance dialysis (5-10:1) and which dramatically increases during acute 
peritonitis (up to nearly 100:1). During acute bacterial peritonitis, CD14+ monocytes 
are rapidly recruited into the peritoneal cavity, presumably depending on the 
chemotactic gradient generated by the inflamed peritoneum, including for example 
CCL2/MCP-1 secreted from peritoneal mesothelial cells (Li et al., 1998). Intriguingly, 
the increase in CD1c+ DC number is very limited during peritonitis. One possible 
explanation is that the local chemokine and cytokine microenvironment during 
peritonitis may favour monocyte transmigration, rather than DC migration and/or in 
situ monocyte-to-DC differentiation. Hence, the ratio of MØ to DC drastically 
increases during inflammation. Importantly, preliminary observation showed that 
patients with adverse outcomes (catheter failure or peritonitis failure) had higher 
ratios of MØ to DC than those with good prognosis, suggesting that higher ratios are 
associated with more severe intra-peritoneal inflammation. Notably, there is a trend 
towards a higher number of peritoneal MØs and also a higher ratio of MØ to DC in 
stable dialysis patients with a history of multiple peritonitis episodes, compared to 
those without any history of peritonitis. These observations could be a consequence of 
chronic peritoneal inflammation with increased infiltration of monocyte-MØs after 
repeated peritonitis, and possibly would lead to to accumulating membrane fibrosis 
and technique failure in the longer term, similar to the results found in the repeat-hit 
SES-induced peritoneal fibrosis mouse model (Fielding et al., 2014). 
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6.2.2  Altered activation/maturation status of peritoneal MØ during PD therapy 
Another impact of PD therapy on peritoneal MØ biology is altered MØ 
activation/maturation status. We observed heterogeneous surface marker expression in 
peritoneal CD14+ MØs from serial PD effluents of ‘new-starter’ patients,, probably 
reflecting different stages of MØ activation and maturation. Notably, the number and 
the proportion of CD206+ MØs (also with higher expression of HLA-DR, CD86 and 
CD163, denoted as ‘mature MØ’ phenotype) declined after dialysis intervention, 
indicating that continuous dialysis exchanges may hinder the maturation process of 
recruited monocytes turning into tissue MØs, perhaps owing to the diluted cytokines, 
insufficient for the maturation requirement.  
Previously, two studies have shown that peritoneal MØs from uninfected PD effluent 
samples display a M2-like phenotype (CD163+ or CD206+) with ‘anti-inflammatory’ 
IL-10 production after ex vivo LPS stimulation (Xu et al., 2007) or with increased 
mRNA expression of ‘pro-fibrotic’ genes such as TGF-β1, MMP-9, CCL18 (Bellon et 
al., 2009). Our results demonstrate that peritoneal MØs from uninfected PD effluent 
samples differentially expressed CD16 and CD206, and could generate significant 
amounts of ‘pro-inflammatory’ cytokines such as TNF-α, IL-1β, IL-6 as well as IL-12 
upon ex vivo LPS or SES stimulation. Altogether, these findings suggest that 
peritoneal MØs are highly heterogeneous in vivo and retain phenotypic plasticity in 
response to micro-environmental changes, and that the classical M1/M2 paradigm 
may be inadequate in this context. This contrasts with the presence of ‘M1-MØs’ or 
‘classically activated MØs’ during acute bacterial peritonitis. In the context of the 
post-surgery period, the catheter-related sterile inflammatory response, either from 
surgical injury or from catheter-induced foreign body reaction, enriches the cavity 
with both CD206+ and CD206– MØs. Hence, it is difficult to fit this scenario into 
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either the M1 or the M2 category. Moreover, the fact that the proportion of CD206+ 
cells within CD14+ MØs is significantly reduced after the commencement of dialysis 
implies that CD206 may be more appropriately used here as a “maturation marker” 
for MØs, rather than a definitive “M2-specific marker”. Perhaps the genuine 
‘M2-MØs’ in vivo, based on the rigorous definition, can only be found in extremes of 
clinical scenario, similar to the conditioned in vitro polarised microenvironment 
(Murray et al., 2014).   
As for the relationship between MØ activation and clinical outcomes, peritonitis 
patients with treatment failure displayed a trend of lower proportion of CD16+ cells 
within CD14+ MØs and a significantly higher number of the CD14+CD16–(CD206+ or 
–) subtype, compared to those who were successfully treated. As described, this 
CD14+CD16– subtype may represent newly recruited classical monocyte/MØs within 
the peritoneal cavity. Therefore, the high amplitude of inflammatory recruitment of 
this cell type may be associated with adverse outcomes. In new-starter patients, those 
suffering from catheter failure had a higher percentage of CD16+ cells within CD14+ 
MØs and a significantly higher number of CD14+CD16+CD206– subtype at the time 
of the 1st flush (one week after surgery), compared to those with good catheter 
outcomes. Similarly, stable dialysis patients with a history of multiple peritonitis 
episodes had a higher percentage of CD16+ within CD14+ MØs and a significantly 
higher number of the CD14+CD16+CD206– subtype, than those without any history of 
peritonitis. These CD14+CD16+CD206– cells are possibly derived from transmigration 
of CD14+CD16+ blood monocytes or from up-regulated CD16 expression of 
CD14+CD16– blood monocytes after recruitment. Nevertheless, the increase in this 
subtype may reflect a unique inflammatory status, i.e., catheter-related sterile 
inflammation or chronic (non-infectious) inflammation.  
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6.2.3  Future directions 
These studies have demonstrated the impact of PD therapy on the peritoneal MØ/DC 
phenotype, and activation/maturation within the peritoneal cavity. However, there are 
some issues that need to be addressed. Firstly, PD patients have a complex uraemic 
background which has been suggested to influence the MØ/DC biology. For example, 
a recent study showed that the uraemic toxin, indoxyl sulphate, alone could stimulate 
MØ function, e.g. inducing ROS and nitric oxide release; and also enhance peritoneal 
MØ activation in response to LPS challenge with increased TNF-α/IL-6 production 
(Adesso et al., 2013). Additionally, it has been shown that advanced glycation end 
product (AGE)-modified beta-2 microglobulin, which is frequently accumulated in 
uraemic dialysis patients, could activate peritoneal MØs by increasing TNF-α/IL-1β 
secretion (Rashid et al, 2006). In the future, it would be interesting to measure PD 
effluent levels of these “uraemic factors”, and investigate their associations with the 
altered MØ/DC activation/differentiation, pro-inflammatory cytokines changes and 
peritoneal membrane dysfunction in long-term PD patients. With regard to the 
potential effects of dialysis fluids on peritoneal MØ/DC biology, a series of studies 
have revealed that conventional acidic lactate-buffered PD solutions would 
compromise MØ function, compared to new biocompatible PD fluids such as neutral 
pH solutions buffered with bicarbonate/lactate (Mackenzie et al., 1998 & 2000, Jones 
et al., 2002). Furthermore, a study has suggested that conventional PD solutions 
would impair monocyte-to-DC differentiation and also inhibit the LPS-induced 
maturation of monocyte-derived DCs. The evaluation of PD fluids revealed that 
sodium acetate and glucose degradation products are the key components which 
would inhibit the acquisition of DC marker expression (CD1a, CD209) and impair 
LPS-stimulated NF-kB activation (Puiq-Kroger et al., 2003). Because the PD effluent 
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cells analysed in this project are generally derived from conventional PD fluids, 
which means the MØ/DC biology data shown in this project would possibly be 
influenced by those PD fluid components. Nonetheless it would need to compare 
different types of dialysis fluids in the future, to clarify to what extent the altered 
MØ/DC biology due to different PD fluids is correlated to PD patient outcomes, 
particularly long-term membrane function.  
In this project, I stratified peritoneal MØs into multiple subtypes based on the CD16 
and CD206 expression, representing different stages of MØ activation and maturation. 
However, it is unclear whether the distinct activation/maturation status is committed 
to different functional properties. For example, it has been shown that blood 
CD14+CD16+ monocytes produce more inflammatory cytokines upon LPS challenge 
but exhibit less capability to generate ROS, compared to blood CD14+CD16– 
monocytes (Cros et al., 2010). It will be of interest to know whether such functional 
distinction exists in the context of PD between CD16+ MØs and CD16– MØs. 
Similarly, whether CD206+ MØs are functionally different from CD206– MØs 
remains to be determined. Finally, understanding the factors by which MØ 
activation/maturation is controlled could be important for developing novel 
therapeutic strategies to modify disease outcomes in the future.   
  
178 
 
6.3  From peritonitis to peritoneal fibrosis: defining the roles of 
peritoneal MØ and DC in PD patients 
 
Peritonitis remains one of the major reasons for technique failure or death in PD 
patients, despite advances in connective technology and antimicrobial treatment. One 
of the key determinants is that renal failure patients are relatively 
immunocompromised and vulnerable to microbial attack. Hence, the study of PD 
patients’ peritoneal immune system is pertinent to understand the host-pathogen 
interaction and further delineate possible links to clinical outcomes. In the context of 
MØ and DC, our human and mouse studies have provided a broad insight as to how 
these cell types contribute to peritoneal immunity upon infectious challenge. In 
general, peritoneal MØ/DC serve as the frontline cell types to sense invading 
pathogens though their abundant PRRs on their cell surface, triggering chemokine and 
cytokine production, and attracting massive numbers of neutrophils and 
monocyte/MØs into the peritoneal cavity. The recruited neutrophils and InfMØs 
substantially participate in phagocytosis and microbial killing. MØs also play a 
predominant role in the clearance of apoptotic cells, and in the resolution of acute 
inflammation. In fact, the term “resolution-phase MØs” has been used in mouse 
experimental peritonitis models to describe this type of MØs, to distinguish from 
“pro-inflammatory MØs” (Stables et al., 2011). Although the transcriptome analysis 
of these two cell types shows differentially expressed gene signatures (Stables et al., 
2011), these data should be interpreted with caution as both these classes of MØs 
comprise a mixed population when sorted. Hence, the phenotype of MØ (and/or DC) 
actually involved in the resolution process remains elusive. In PD patients, we only 
studied peritoneal MØs from day 1 peritonitis patients, which are recognized as 
‘pro-inflammatory’ type MØs. In the future, it will be of interest to know how the MØ 
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phenotype changes during the course of PD-related peritonitis by serial follow-up of 
PD effluent from the same patient until the episode has resolved or the treatment 
failed. Then we can possibly identify ‘high risk’ patients who may have defects in the 
transition from ‘inflammation’ to ‘resolution’, thereby suffering from adverse 
outcomes. Similarly, it could also be important to identify patients with impaired 
monocyte/MØ function, who may be at high risk for developing peritonitis and are 
potentially associated with poor prognosis.  
Peritoneal DCs, despite overlapping phenotypically with MØs, display distinctive 
functional properties. For instance, they are less capable of phagocytosis, but 
significantly more efficient at processing and presenting antigen. The latter provides 
for superior T cell stimulation, presumably leading to the development of effective 
protective immunity against infections. However, like MØs, peritoneal DCs can 
generate significant amounts of pro-inflammatory cytokines in response to external 
microbial stimuli, potentially contributing to tissue damage in persistent or recurrent 
inflammation.  
What are the roles of peritoneal MØs and DCs in the development of peritoneal 
fibrosis in PD patients? This is a complex issue as peritoneal fibrosis is contributed to 
by many factors, including genetic predisposition, uraemic background, pre-existing 
comorbidities, and most importantly, exposure to non-physiologic PD fluids and 
infectious events. Although the ‘multi-hit’ SES mouse model has provided a novel 
insight into how the immune cells and related cytokines play their roles in the 
development of repeated infection-related peritoneal fibrosis (Fielding et al., 2014), 
whether or not MØ and DC participate in ‘non-infectious type’ peritoneal fibrosis as 
well as fulminant encapsulating peritoneal sclerosis (EPS) remains to be determined. 
In a recent global transcriptome analysis of peritoneal tissues from patients with 
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encapsulating peritoneal sclerosis (EPS), compared to PD patients without EPS or 
uraemic patients without history of PD, the canonical pathway analysis of 
differentially expressed genes has revealed enrichment in several pathways relating to 
MØ/DC function and activation/maturation, highlighting the critical role of these 
immune cell types in the process of peritoneal fibrosis (Reimold et al., 2013). Hence, 
exploring the underlying mechanisms controlling peritoneal MØ/DC biology and the 
potential crosstalk between MØ/DC and other cell types such as mesothelial cells and 
fibroblasts will pave the way for the development of novel therapeutic strategies to 
retard this devastating complication of PD in the future. 
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Appendix 1. Clinical characteristics of the study patients 
 
(A) Clinical characteristics of new-starter PD patients (n = 50) in this study 
Age at PD start (year-old) 55.18 ± 15.87 
Gender (F/M) 18/32 
Primary renal disease  
     Diabetic kidney disease 15 
     Glomerulonephritis 12 
     Hypertensive renovascular disease 5 
     Cystic kidney disease 3 
     Myeloma kidney 2 
     Pyelonephritis 1 
     Interstitial nephritis 1 
     Congenital renal dysplasia 1 
     Nephrectomy 1 
     Unknown 9 
 
(B) Clinical characteristics of stable patients and peritonitis patients in the study 
 Stable patients 
(n = 37) 
Peritonitis patients 
(n = 37) 
Age at PD start (year-old) 63.81 ± 14.50 63.95 ± 15.00 
Gender (F/M) 6/31 13/24 
Primary renal disease   
     Diabetic kidney disease 11 8 
     Glomerulonephritis  7 6 
     Hypertensive renovascular disease 4 5 
     Pyelonephritis 2 2 
     Interstitial nephritis 1 0 
     Obstructive uropathy 1 0 
     Nephrectomy 1 3 
     Cystic kidney disease 0 3 
     Unknown 10 10 
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Appendix 2. Antigen processing and presentation assay in mice 
  
Note: This extract from a manuscript in preparation was written by Dr. Marcela Rosas and Prof. Philip 
Taylor. The experiments and data analysis were performed by Dr. Marcela Rosas. 
 
Materials & Methods 
Antigen processing and presentation assay 
Bone marrow-derived dendritic cells (BMDC) from 129S6SvEv mice were differentiated in 20 
ng/ml GM-CSF for seven days. B3Z, a CD8 + T-cell hybridoma specific for the ovalbumim257-
264 peptide (SIINFEKL) in the context of Kb, was provided by Nilabh Shastri (University of 
California, Berkeley, CA) (Karttunen et al., 1992). BO-97.11, a CD4+ T-cell hybridoma that 
responds to the peptide ovalbumin323-339 (ISQAVHAAHAEINEAGR) presented by I-Ab, was 
a gift from Philippa Marrack (National Jewish Center for Respiratory Medicine, Denver, CO) 
(Hugo et al., 1992). Purified APCs (104 cells per well) were co-cultured with BO97.11 cells at 
a 1:1 ratio in a 96-well flat-bottom plate in 40μl complete RPMI with or without 5 mg/ml EWE 
(see below). In control experiments 5x104 BMDC, were used in a 1:1 ratio with either B3Z or 
BO97.11 cells with EWE or ovalbumin. To ensure antigen internalization and processing was 
occurring, BMDC were fixed with 1% paraformaldehyde for 10 minutes, which was then 
quenched with an equal volume of 0.1M glycine in PBS (pH 7.0) for 10 minutes (all at room 
temperature). APC were washed three times with medium before coculture with the T-cell 
hybridomas. The ovalbumin peptides indicated above (2μM) were used as controls. After 24 
hours of culture at 37oC, IL-2 in the supernatants was measured by ELISA on triplicate samples 
(R&D systems).  
Preparation of EWE 
To prepare EWE (Boes et, al., 2003), egg white was recovered through a small hole in the end 
of a fresh chicken egg and diluted to 50 ml with PBS. The egg white was repeatedly passed 
through decreasing needle sizes (21G to 25G) and then a 0.2 µm filter before storage at -80oC. 
 
Results 
To determine if the peritoneal ‘DC-like’ cells were competent APCs we established a specific 
assay. To ensure that we directly measured antigen processing and not presentation of 
unprocessed ‘low quality’ antigen preparations, we prepared a fresh egg white extract (EWE) 
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as a source of ovalbumin (Boes et, al., 2003) (Supplementary Fig. 1A). BMDC were used live 
or fixed in antigen presentation assays with EWE and commercial ovalbumin to specific T cell 
hybridomas B3Z (MHCI-restricted (Karttunen et al., 1992)) and BO-97.11 (MHCII-restricted 
(Hugo et al., 1992). Commercial ovalbumin, but not EWE, could be presented by fixed BMDC 
(Supplementary Fig. 1B), so we used EWE to assess antigen processing and presentation.  
Three ‘DC-like’ subsets and ResMØs were purified (See section 5.2.10). All putative APCs 
could process EWE and present to BO-97.11 CD4+ T cells, as determined by IL-2 production. 
(Supplementary Fig. 1C). As previously noted (Dioszeghy et al., 2008), the MHCIIlow/– 
ResMØs had no significant activity in this assay. Compared to putative APCs, MHCII+ InfMØs 
had only a minimal capacity to present ovalbumin to the BO-97.11 hybridoma 
(Supplementary Fig. 1D).  
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Supplementary Figure 1 All ‘DC-like’ subsets are effective at antigen processing and 
presentation. A) Coomassie stained SDS PAGE gel showing the protein content of EWE (5 
µg resolved on a 12% SDS PAGE gel). Ovalbumin (OVA) (~45 KDa) is the major constituent 
of egg white. B) EWE was compared to a commercial preparation of OVA in antigen 
processing and presentation assays. The ability of BMDC (both live and paraformaldehyde 
fixed) to process and present both sources of OVA to BO-97.11 and B3Z cells as a measure of 
presentation on MHCII and MHCI, respectively. The fixed BMDC were able to present 
commercial OVA, particularly to the B3Z cells, indicating the presence of degraded protein 
and peptides and hence not an effective measure of antigen processing. The EWE, however, 
was only presented to either reporter cell when the BMDC were live, indicating that antigen 
processing was required. C) The ability of the purified cellular subsets from naïve C57BL/6 
mice to process and present EWE on MHCII to BO-97.11 cells was assessed and compared to 
BMDC and BMDC pulsed with specific peptide. All three subsets of APCs were found to be 
competent at antigen processing and presentation. Data shows mean±SEM of IL-2 production 
by the BO-97.11 T cell hybridoma from two independent experiments, which were pooled after 
normalization of the data to the peptide pulsed BMDC control. D) Similar APC assay was 
performed using purified three ‘DC-like’ subsets as well as MHCII+ InfMØs from 72 hours 
post-SES challenged C57BL/6 mice. Bar graph depicting the IL-2 production of BO-97.11 
cells after culture with the indicated cell subsets and EWE. Data represents the mean±SEM of 
one of two identical experiments. 
 
